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Summary 
 
Drug discovery is undertaken to discover new candidate medicines. Identifying new therapeutics is 
of critical medical, social and economic importance. In recent years the rising cost associated with 
drug discovery and development has necessitated the more frequent use of in silico approaches. The 
prediction of protein-ligand interactions using in silico approaches has become widely used to study 
biomolecular interactions and mechanisms. These approaches allow for high throughput virtual 
screening of thousands of potential drug candidates at specific protein drug targets. While the data 
generated provides ample opportunity for scientific and clinical exploitation, challenges are 
presented concerning the vast quantity of information generated and the ability to utilise this 
information fruitfully.  
In this study in silico approaches are used to “virtually screen” the entire human proteome against 
the 20 most valuable sold drugs in the UK. Homology and protein threading approaches were used 
for protein structure modelling; AutoDock Vina and DOCK 6.0 were used for protein-ligand docking 
with the use of High-Performance Computing (HPC).  
The large-scale application of these approaches was evaluated, and methods iteratively refined to 
improve predictive accuracy. A novel combinational forecasting method was developed to increase 
the accuracy of the predictions of the docking programs. The method produced a docking an overall 
accuracy of 77.05% for identifying known protein interactions and known protein misses correctly. A 
platform system was developed to allow the vast amount of data to be efficiently reported and 
visualised within a Graphical User Interface (GUI).  
The developed database and system prototype have the potential to change the way drugs are 
developed in the drug discovery sector. This system is a powerful tool which can be used for the 
advancement of personalised medicine with incorporation of further knowledge of protein 
interactions as well as the effects of protein variation.  
The work carried out in this project has contributed towards the development of a comprehensive in 
silico platform, Human3DProteome (human3dproteome.com), that utilises the system architecture, 
methodologies, data and methods of data analysis advanced in this project. Human3DProteome is 
the first public platform which aims to catalogue structural models for every protein in the human 
body alongside a comprehensive database of predicted small molecule interactions of interest. 
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1 Introduction 
1.1 Overview 
The aim of this project is to develop a comprehensive 3D structural database of human proteomic 
variation and pan-proteomic interaction with the most widely sold drugs. The work is part of a more 
comprehensive project focused on the implementation and scaling of ligand (drug) docking 
algorithms on High-Performance Computing (HPC) Wales and Supercomputing Wales. These 
algorithms will be used in conjunction with pre-computed 3D-structures of the whole human 
proteome, with potential future application to the investigation of the impacts of genetic mutations 
which have been computed as part of the wider project but are not featured in this thesis, as the 
structural database also contains hundreds of thousands of variants as detailed in the UniProt 
protein database (UniProt Consortium, 2018). The results will be stored in a publicly accessible 
database for future work.  
The interaction between proteins and chemical compounds is an inherently complex issue, bearing 
vital importance due to its relevance to the pharmaceutical, healthcare and medical research 
sectors. Recent advances in bioinformatics and molecular modelling have enabled in silico structural 
prediction approaches which have the potential for scaling to the whole- or multi-genome analysis. 
In particular, new technologies such as High-Performance Computing support rapid development in 
the bioinformatics field, enabling the generation of vast amounts of data relating to medically critical 
molecular interactions. While the data generated provides ample opportunity for scientific and 
clinical exploitation; challenges are presented concerning the vast quantity of information generated 
and the ability to access this information fruitfully.  
Screening approaches for candidate drugs or chemical agents will continue to provide an incomplete 
picture unless tested against all possible variants in each organism. Furthermore, the scope for 
identifying potential adverse drug reactions by in silico approaches will not be realised unless a 
whole proteome approach is adopted.  
Additionally, the knowledge and understanding of the molecular interactions of drug targets are of a 
significant commercial interest with direct relevance to the following processes;  
a). Assist the lead discovery process  
b). Re-purpose existing drugs to maximise revenue and  
c). Reduce the risk (both financial and medical) of drug development by improving efficacy and 
reducing adverse reactions. 
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The prevailing approach to drug discovery in recent decades is that of rational drug design, which 
involves the development of new drugs with a specific target in mind (usually a specific site in a 
single or small number of protein targets which bind with the ligand). Adverse drug events due to 
off-target interactions are not currently assessed by in silico approaches. There are in vitro 
approaches that are increasingly employed, typically involving pharmacological profiling or 
toxicology panels comprising binding assays, such as for around 44 protein receptors (Bowes et al., 
2012). Such in vitro toxicology panel data provide valuable validation information for our in silico 
approaches. There are, however, no panel data for most drugs in use today. Data for known toxins 
are given in the literature reviewed in Bowes et al., (2012), and prolifically in the NIH TOXNET 
database (Fowler and Schnall, 2014) and this data will be used to test and validate the proposed 
database platform. 
1.2 The Human Genome Project 
The Human Genome Project was an international collaboration, the objective of which was to fully 
map and sequence every gene within the human body and to make it freely available for research. 
Twenty different research groups from the United Kingdom, France, Germany, the United States, 
China, and Japan have helped to produce a draft of the genome sequences that cover around 94% of 
the human genome (Lander et al., 2001). The idea of sequencing the entire human genome began in 
the early 1980s and was discussed in a scientific meeting which was organised by the US Department 
of Energy. From this meeting, it was agreed that there was a need for a broader research objective. 
This included: 
• The creation of genetic, physical and sequence maps of the human genome. 
• The parallel efforts in key model organisms such as bacteria, yeast, worms, flies and mice. 
• The development of technologies that would aid the process of reaching the objectives. 
• Research into the ethical, legal and social issues raised by human genome research.  
The project was initially launched by in the United States by the National Institute of Health and the 
Department of Energy. This began the international collaboration, which led to the Human Genome 
Organization (HUGO) being founded.  
The Human Genome Project reached it's objective and was completed in 2003, which was two years 
ahead of their original deadline and successfully sequenced 20,000-25,000 genes. The work that has 
been carried out by the Human Genome Project has allowed researchers to delve deeper into the 
working of the human body and learn how it functions.  
3 
 
An essential component of this project is the structural modelling of a large variety of human 
proteins, and this work would not have been possible without the gene sequences provided by the 
Human Genome Project. 
1.3 Next-Generation Sequencing (NGS) 
Next-Generation Sequencing, which is also known as high-throughput sequencing is a collection of 
new modern sequencing technologies used for DNA sequencing. NGS has made it possible to 
sequence thousands to millions of DNA molecules simultaneously which increases the speed of 
research. These new methods of sequencing have and continue to be very beneficial to fields such as 
personalised medicine, genetic diseases and clinical diagnostics.  
NGS platforms were built upon Sanger sequencing (Heather and Chain, 2016), which is still classed 
today as the leading method for sequencing DNA molecules and is used to validate the data 
generated by the NGS. Four different NGS platforms are currently in use, these being Illumina 
(Solexa) sequencing, Roche 454 sequencing, Ion torrent: Proton / PGM sequencing, and SOLiD 
sequencing.  
The four different systems have common features to each other, these being the sample 
preparation, the sequencing machines, and the data outputted by them. Each of the NGS platforms 
requires a library of samples that have been obtained by either amplification or elongation with 
custom adaptor sequences (Head et al., 2014). The libraries used for the sequencing process. The 
common features of the sequencing machines used are that they all amplify library fragments onto 
solid surfaces with covalently attached DNA linkers which hybridise the library adaptors. This 
method is called bridge PCR which is mainly used by Illumina sequencing (Heather and Chain, 2016). 
The other method used is called emulsion PCR which involves amplification which creates clusters on 
DNA which each are generated by a single library fragment. With the emulsion PCR method, each of 
the clusters is classified as a single sequence reaction. All four of the NGS platform uses the emulsion 
PCR method (Kanagal-Shamanna, 2016). The final common feature is that all the NGS platforms 
provide the same raw data output at the end of the sequencing run. The raw data is a collection of 
DNA sequences that had been generated by each cluster in the sequencing process.  
The differences between the four NGS platforms are based on the method used to carry out and 
record the sequencing reactions. There are four different methods which are pyrosequencing, 
sequencing by synthesis, sequencing by ligation, and ION semiconductor sequencing. 
Pyrosequencing is the basis of the Roche 454 NGS platform and uses pyrophosphate during the 
nucleotide incorporation process (Harrington et al., 2013). The phosphate is used in a series of 
chemical reactions which causes the generation of light which is captured by a camera that then 
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records the appropriate sequence for that cluster. A single base is added at a time to the solution, 
and the light is measured which if detected degrades the other unincorporated bases. The method is 
then repeated with the next base and continues until the sequencing process is complete.  
Sequencing by synthesis is the second method that is used by Illumina and is the most popular of the 
four methods available. The following method utilises the step by step incorporation of reversible 
florescent and terminated nucleotides for DNA sequencing. Instead of one base added at a time like 
in the pyrosequencing method, sequencing by synthesis adds all four nucleotides to the same 
sequencing chip. When one of the bases have been incorporated, the other three are washed away. 
The fluorescent signal from the incorporated base is then read and recorded for each cluster. The 
fluorescent and terminator group of the base is then cleaved and washed away; then the process is 
repeated until the sequencing reactions are complete. (Guo et al., 2010) 
The SOLiD NGS platform uses sequencing by Ligation. The following method, instead of using DNA 
polymerase like Pyrosequencing and Sequencing by synthesis, which were discussed previously, 
sequencing by ligation, relies on 16 octamer oligonucleotide probes. Each of the oligonucleotide 
probes has one of the four fluorescent dyes attached there five prime ends which have been ligated. 
Each of the octamers has two probe specific bases with six degenerated bases. This means that each 
fluorescent light represents two bindings of two nucleotides. For the sequence reaction, this first 
step is to bind the primer to the adaptor, which is then hybridised with the appropriate probe. When 
one of the probes have been annealed, it is then ligated to the primer sequence through a DNA 
ligase. The probes which have not annealed are then washed away. The signal from the fluorescent 
dye is then detected and recorded. The last three bases of the octamer are cleaved, and the process 
is repeated for 7-cycles of the ligation. After this step, the primer is then removed, and a new primer 
is added but offset by one base compared to the previous primer. The process is then repeated with 
the new primer. This step is only repeated five times. (Garrido-Cardenas et al., 2017) 
The final sequencing method, which is used is ION semiconductor sequencing that is used by the Ion 
torrent: Proton / PGM sequencing NGS platform. The method uses a similar step to pyrosequencing, 
but instead of using pyrophosphate, ION semiconductor sequencing measures the release of 
hydrogen ions during the sequence reaction to detect the sequence of a cluster. The clusters are all 
located above a semiconductor transistor that can detect pH changes within the solution. During the 
nucleotide incorporation, a single hydrogen ion is released into the solution which is then detected 
by the semiconductor. The Ion semiconductor method is a faster method of sequencing compared 
to pyrosequencing.  (Alekseyev et al., 2018) 
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With the development of these NGS technologies, it has made it possible to look at genome-wide 
interactions and brought the possibility of personalised medicine even closer with personal whole 
genome sequencing.  
1.4 An Introduction to Protein Structure 
The human body has up to 20,000 different types of proteins within it, each with its own job to do 
(Ponomarenko et al., 2016). Proteins consist of a long chain of amino acids, the details of which 
provide their structure and function. It is possible to extract the amino acid sequences of these 
proteins from protein sequence databases such as UniProt (UniProt Consortium, 2018) and Swiss-
Prot (Bairoch, 2000). But with only these amino acid sequences, there is limited information that can 
be derived about the precise function and mode of action of the protein. This is where the 
importance of knowing the protein structure comes to the fore. The three-dimensional structure is 
determined by the way the amino acids in the polypeptide chains interact with each other which 
cause folds to be generated from linear chains. The folded domains can be part of large assemblies 
like virus particles or muscle fibres. The three-dimensional structure of the protein ultimately defines 
its function, such as which molecules an enzyme will bind and process, or which atoms a transporter 
will carry, or how a protein might regulate the expression of DNA (Brändén and Tooze, 2009) 
1.4.1  Amino Acids 
Shown in table 1.1 are all 20 amino acids, their 3-letter and 1-letter symbols. All amino acids have a 
central carbon atom. A Hydrogen atom, amino group, and a carboxyl group are attached to this 
central carbon atom. An example is shown in figure 1.1. What distinguishes one amino acid from the 
other are that they have different side chains which are attached to the central carbon atom.  
Figure 1.1: Example of the formula for a general amino acid – shown is the general formula for an amino acid. Each amino 
acid has a hydrogen atom (H), amino group (NH2), a carboxyl group (COOH), and R-group (R) that is attached to a central 
carbon atom (C).  
Shown in figure 1.2 is a Venn diagram showing the different types of amino acid property groups and 
which amino acid is a part of each group. There are amino acids that are classified in more than one 
group. Shown in table 1.2 is a list of each group and an explanation about the type of amino acid 
that is in that category. 
C 
NH2 
COOH R 
H 
6 
 
Table 1.1:Amino acid names and abbreviations – shown are the 20 amino acids, and there 3 lettered and single lettered 
abbreviations. 
 
Table 1.2: Different type of amino groups – shown are 6 different amino acid groups. Amino acids can cross into more than 
one of these groups, which are shown in figure 1.3. 
 
Amino Acid Group Definition 
Aliphatic the R-groups are nonpolar and hydrophobic 
Aromatic mostly nonpolar but all amino acids in this 
group can absorb ultraviolet light 
Hydrophobic Side-chains are mostly composed of carbon and 
hydrogen and tend to repel water. 
Polar side chains that can either be charged or can 
participate in hydrogen bonding. 
Positively Charged can be charged at pH=7 (basic side chain). 
Negatively charged can be negatively charged at pH=7 (acidic side 
chain). 
Amino Acid Name Amino Acid 3-letter 
symbol 
Amino Acid 1-letter 
symbol 
arginine arg R 
Asparagine asn N 
aspartic acid asp D 
cysteine cys C 
glutamine gln Q 
glutamic acid glu E 
glycine gly G 
histidine his H 
isoleucine ile I 
leucine leu L 
lysine lys K 
methionine met M 
phenylalanine phe F 
proline pro P 
serine ser S 
threonine thr T 
tryptophan trp W 
tyrosine tyr Y 
valine val V 
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Figure 1.2: Venn diagram showing the different types of amino acid property groups – shown are the different types of 
amino acid groups that exist and displays the type of each amino acid. 
For these amino acids to join to create a protein, the central carbon atom of one amino acid 
connects to the nitrogen atom of another amino acid via a polypeptide bond. Proteins can consist of 
very long polypeptide chains ranging from 100s of amino acids residues to thousands of them.  Four 
levels of protein structure exist which are shown in figure 1.3. These are the Primary Structure, 
Secondary Structure, Tertiary Structure, and Quaternary Structure.  
Figure 1.3:Four Levels of protein structure – shown is an image of the 4 levels of a protein's structure. The four levels consist 
of the primary structure, Secondary structure, Tertiary structure, and Quaternary Structure. 
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1.4.2 Primary structure  
The Primary Structure of a protein is defined as a linear sequence of amino acids. The linear 
sequence is referred to as a polypeptide chain. These amino acids within the chain are held together 
with covalent bonds which are created during the process of protein synthesis/translation. These are 
the building blocks of a protein structure (Nelson and Cox, 2017). The primary structure of a protein 
is determined by the gene, which corresponds to that particular protein. A specific sequence of 
nucleotides is extracted from DNA and is transcribed into mRNA. The mRNA sequence is then read 
by ribosomes which are called translation. It was discovered that proteins have defining amino acid 
sequences by Frederick Sanger who sequenced the amino acids in insulin (Sanger, 1959). This 
discovery showed that an amino acid sequence determines the structure and function of a protein.  
1.4.3  Secondary Structure 
The Secondary Structure is the stable arrangements of amino acid residues which result in a 
structural pattern (Nelson and Cox, 2017). These relate to parts which are seen a lot in proteins 
being the α-helices and β turns. Coils in a protein structure are known as an α-helix (shown in figure 
1.4), and folds in a protein structure are known as β turns or β-pleated sheets (shown in figure 1.5). 
An α-helix is formed by hydrogen bonding between every fourth amino acid. For a β turns to be 
formed two different regions of a polypeptide chains lay next to each other and are bound by a 
hydrogen bond. There are two different types of β turns that can occur these being a parallel β turn 
and an antiparallel β turn. The stability of the sheets is mainly determined by how the hydrogen 
bonds form. These bonds can form between a partially negative oxygen atom and a partially positive 
nitrogen atom (Rehman and Botelho, 2019). The secondary structure can be defined as consecutive 
fragments of protein sequences that corresponds to a region of protein structure that shows a 
distinctive geometrical feature (Pirovano and Heringa, 2009).  
Figure 1.4:Example of an α-helix – shown is an example of a modelled α-helix. 
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Figure 1.5:Example of a β turn/sheet – shown is an example of a modelled β turn/sheet. 
1.4.4 Tertiary Structure 
The Tertiary structure is all the aspects of the three-dimensional folding of a polypeptide (Nelson 
and Cox, 2017). This is the final arrangement of all the residues which are formed by the interactions 
of the side chains and create a 3D structure of the protein. The properties of the amino acid 
sequence determine the overall shape of the tertiary structure. (Rehman and Botelho, 2018) The 
tertiary structure is held together by the interactions between the R-group and the side-chain, which 
is created by hydrogen bonding, hydrophobic interaction, ionic bonding and disulphide bonding 
(Medarametla, 2014).  
There are two different types of tertiary structure which are fibrous and globular. The fibrous 
tertiary structure is usually just having structural roles in the body whereas, for globular tertiary 
structures, these have a more complicated structure which has multiple types of secondary structure 
within one polypeptide chain (Nelson and Cox, 2017).  
1.4.5 Quaternary Structure 
Sometimes proteins contain different polypeptide chains (or subunits) that join to form a complex, 
and this is referred to as a Quaternary Structure (Nelson and Cox, 2017). These subunits can operate 
as a single functional multimer. There are different terms used depending on the number of subunits 
within the multimer. If there are 2 subunits within the multimer, these are called dimers, if there are 
3 subunits these would be called a trimer, if there are 4 subunits these would be called tetramers, 
and finally, if there are 5 subunits within a multimer these would be called pentamers. Usually the 
subunits within a multimer are related to each other through symmetry operations. If a multimer 
contains identical subunits within the word “homo” is added to the start of the word for example if 
there was a tetramer within identical subunits this would be called a homotetramer. Multimers with 
different subunits would have the word “hetero” added to the front for example heterotetramer. 
10 
 
1.5 Genetic Variants/Mutations 
Human DNA is not identical between individuals, so there may be 20,000 proteins in the human 
body, but no two people have the same sequenced proteins. Four different types of mutations 
occur, these being a missense mutation, Nonsense mutation, “silent” mutation, and a frameshift 
mutation. A missense mutation is when a single amino acid within a sequence changes to a different 
amino acid. These mutations can be classified as a polymorphism if the mutation has been observed 
in a fraction of the population or it could be a rare mutation which has been found in an individual or 
a small group of people (Zhang et al., 2012). A nonsense mutation is when a stop codon replaces an 
amino acid which causes premature termination of the translation (Lodish et al., 2000). This 
mutation leads to major changes to the sequence of a protein which in turn changes that proteins 
assembly and function (Ruwald et al., 2016). A “silent” mutation does not affect the amino acid 
sequence but can still cause phenotypic effects such as speeding up or slowing down protein 
synthesis. These mutations are classified as passenger events (Zheng, Kim and Verhaak, 2014). A 
frameshift mutation is when several nucleotides get deleted or inserted into the DNA of a gene 
which leads to a sequence being transitioned in an unnatural frame from the position of that 
mutation until the end of the gene (Old, 2013).  
1.6 Structural modelling 
Protein modelling is an approach used to convert a 1-Dimensional string amino acid sequence into a 
3-Dimensional structural model that can be computationally displayed and processed further. There 
are many different methods used to determine protein structure, including experimental and 
computational methods. These methods are X-Ray Crystallography (Experimental), NMR 
Spectroscopy (Experimental), Cryo-EM (Experimental), Homology Modelling (Computational), Fold 
Recognition (Computational), and Ab Initio Modelling (Computational). The results of the 
experimental methods inform the computational methods in further prediction of the 3-D structure.  
1.6.1 X-Ray Crystallography 
X-ray crystallography is the most commonly used method for the determination of the 3D structure 
of a protein (Zheng et al., 2015). With the availability of a protein structure, it is possible to obtain a 
more in-depth understanding of its function.  
The purpose of this method is to try and gather knowledge of a 3D structure from a crystal. A high 
concentration sample is taken then crystallized. This crystal is then exposed to an X-ray beam which 
generates a diffraction pattern. A diffraction pattern is an array of reflections of the diffracted x-ray 
beam that are collected by x-ray crystallography. These patterns are processed to gather yield 
information about the packing symmetry of the crystal and then the size of the repeating unit which 
forms that crystal. This information is gathered from the diffraction spot patterns that are created by 
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the X-rays. Using the intensity of the spots, the structural characteristics can be determined and help 
generate an electron density map. If the electron density map is of sufficient quality, it is then 
possible to allow a molecular structure to be built. There are many different methods that can be 
used to enhance the quality of the electron density map at this stage. The structure that is then 
created is then refined so that it fits the electron density map to form a more thermodynamically 
favoured conformation (Smyth and Martin, 2000). Figure 1.6 summarises the process of X-ray 
crystallography and shows the protein sample is subjected to an X-ray beam. The X-ray beam is then 
diffracted into a pattern that is determined by the regular crystal lattice structure of the protein.  
The diffraction data that is collected is then inputted into a computer which can determine the 3D 
coordinates of all the residues present based on the electron densities that diffract the X-Ray beam. 
All this data is used to assemble the full 3D structure of the protein. Figure 1.7 shows a graph of how 
X-ray crystallography has increased its influence in the bioinformatics field.  
Figure 1.6: X-Ray Crystallography process – shown is an Image of the process undertaken by X-Ray Crystallography 
(Available at: http://www.chem.ucla.edu/~harding/ec_tutorials/tutorial73.pdf [Accessed 4 May. 2018]) 
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Figure 1.7: Graph shown the increasing number of structures being uploaded to the Protein Data Bank through X-Ray 
Crystallography. (Available at: https://www.rcsb.org/pdb/statistics/contentGrowthChart.do?content=explMethod-
xray&seqid=100 [Accessed 15 Jun. 2019]) 
1.6.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Nuclear magnetic resonance (NMR) was first developed by physicists Felix Bloch and Edward Purcell 
in 1946. Nuclear magnetic resonance is another experimental approach to determine a protein 
structure from a solution of a protein. NMR spectroscopy has become an essential technique in 
helping with structure-based drug design (Pellecchia, Sem and Wüthrich, 2002). Unlike X-ray 
crystallography, this process does not use crystals. Instead, NMR is applied to a solution of the 
molecule. NMR uses the magnetic properties of specific atomic nuclei to gather information such as 
structure, dynamics, reaction state, and chemical environment of the molecule. The intramolecular 
magnetic field of an atom changes its resonance frequency. Due to this, it is possible to determine 
the electronic structure of a molecule and its functional groups. 
NMR is also known for how it can be used as a valuable screening tool for ligand-protein interactions 
(Maity, Gundampati and Suresh Kumar, 2019). This process can detect and quantify interactions with 
high accuracy without the need for protein function information. It can also be used to collect 
information about the structure of a protein or ligand, which helps determine whether the binding is 
weak or strong. Within a magnetic field, this can cause some magnetic nuclei to accept a state of 
nuclear spin of different energies and radio-frequency radiation can cause the nuclei to go between 
these states. The chemical environment of specific magnetic nuclei provides its NMR properties (Fan 
and Lane, 2016). These include properties such as its resonance frequency. Due to this, NMR is now 
an essential tool for chemistry, the life sciences and medical diagnostics. This has also become a 
fundamental method in determining the 3-Dimensional structures of macromolecules. (Pellecchia, 
Sem and Wüthrich, 2002). NMR has contributed to the increasing accuracy of homology protein 
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modelling and fold recognition modelling. There are currently 12675 NMR structures that have been 
deposited in the Protein Data Bank (PDB) (rcsb.org, 2019). Figure 1.8 shows a graph of how NMR has 
increased its influence in the bioinformatics field by the number of structures deposited since its 
invention. But NMR is now on a relative decline due to the higher costs of the approach. 
 
Figure 1.8: Graph shown the increasing number of structures being uploaded to the Protein Data Bank through NMR 
(Available at: https://www.rcsb.org/pdb/statistics/contentGrowthChart.do?content=explMethod-nmr&seqid=100 
[Accessed 15 Jun. 2019]) 
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1.6.3 Cryo-electron Microscopy (Cryo-EM) 
Cryo-electron microscopy (Cryo-EM) is now one of the most widely used tools in structural biology 
(Merk et al., 2016). The basis of the Cryo-EM methodology is to create images of radiation-sensitive 
specimens in an electron microscope under cryogenic conditions. Cryo-EM is now used to image a 
wide range of biological structures, such as intact tissue sections, all the way down to individual 
bacteria and protein molecules. The methodologies all use parts of Cryo-EM to help analyse 
biological structures in different ways such as Cryo-electron tomography, Single-particle cryo-
electron microscopy, and Electron crystallography. Cryo-EM’s method involves taking multiple 2D 
projection images and combining them to determine the 3D structure. Shown in figure 1.9 is the 
process undertaken for Cryo-electron Microscopy. A purified sample of a macromolecule complex is 
frozen to the same temperature as liquid nitrogen. This helps protect and preserve the sample from 
the electrons. Cryo-EM uses a low number of electrons so that it does not cause any damage to the  
Figure 1.9: Cryo-electron Microscopy process - Shown is the process undertaken for Cryo-electron Microscopy. (Available at: 
http://www.eicn.ucla.edu/cryoem [Accessed 10 Jun 2018]) 
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sample. The electrons are then directed at the sample and will either pass through small gaps in the 
sample or be refracted from denser areas. Magnetic coils are used to magnify and focus the electrons. 
A 2D image is then produced. These 2D images are then used to create a 3D model of the 
macromolecule. Computers are used to data merge the 2D images to create this. (Carroni and Saibil, 
2016) These images, as with structures from NMR and X-Ray crystallography, are uploaded to the 
Protein Data Bank (PDB) (Berman, 2000). Cryo-EM is increasing its influence in the bioinformatics field 
by leading to the deposition of more significant numbers of structures to the PDB. Shown in figure 
1.10 is the amount of structures Cryo-EM has added to the Protein Data Bank. 
Figure 1.10: Graph shown the increasing number of structures being uploaded to the Protein Data Bank through Cryo-
electron Microscopy (Available at: https://www.rcsb.org/pdb/statistics/contentGrowthChart.do?content=explMethod-em&seqid=100 
[Accessed 15 Jun. 2019]) 
1.6.4 Homology Modelling 
Homology modelling, which is also known as comparative modelling, is a computational method for 
modelling proteins from their amino acid sequence. Of all the computational methods used to 
generate 3D models of proteins from sequences, homology modelling is currently the most accurate 
(Muhammed and Aki-Yalcin, 2018) but protein threading is catching up quickly.  
Homology modelling can predict the 3D structure of a protein from its amino acid sequence. This 
predicted structure is based on known structures of homologous proteins (templates). These 
determined structures have been produced by using X-Ray crystallography and NMR spectroscopy as 
discussed previously in the chapter, following their conversion to Protein Data Bank (PDB) format. 
The PDB file format is a computer-based archival file for macromolecular structures (Bernstein et al., 
1978). This file contains atomic coordinates and partial bonds between atoms that have been 
gathered from the output of X-Ray crystallography/NMR. Figure 1.11 shows an example of the types 
of data contained and how it is formatted within the PDB file. Shown in table 1.3 is the stored data  
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Figure 1.11: Example of a Protein Data Bank File (PDB file) – shown is an example of how a protein PDB file looks and how 
the data is represented within it. 
Table 1.3: Data which is stored in a PDB file – shown are all the data tags which are used within a PDB file and the definition 
of those tags 
Tag Data 
(HEADER, TITLE, AUTHOR) holds data such as the name of the protein, the 
file creator’s name. 
REMARK this tag is for information about the experiment 
that was conducted to create the data, for 
example, the resolution of the camera used for 
the X-ray crystallography experiments. Also, if 
the file has been run through any programs, for 
example, DSSP, OBABEL. 
SEQRES This tag is used to input the amino acid 
sequence corresponding to the protein 
structure. 
ATOM Used to store the atom coordinates of the 
structure. 
HETATM This is used to store coordinates of solvents, 
ligands, and cofactors. 
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within the PDB file. These files can be visualized by molecular visualization software such as UCSF 
Chimera (Pettersen et al., 2004). All these files that have been generated from X-Ray 
Crystallography/NMR are all stored in the RCSB Protein Data Bank (Burley et al., 2018), which is 
accessible online. Currently (September 2018) there are approximately 153601 biological 
macromolecular structures stored on the database. This has increased over the last decade, and 
when this project first started (2014), there were 104866 biological macromolecular structures in the 
database. With homology modelling, a protein sequence with 30% identity or more is now able to be 
reliably modelled to a known structure and can often be predicted with an accuracy equivalent to a 
low-resolution X-ray structure (Lam et al., 2017). The pipeline that is used consists of four stages 
these being Identify the homologue of known structure, Align the query sequence to template 
structure (BLAST) (Altschul et al., 1990), Build the model based on the alignment (T-COFFEE) 
(Notredame, Higgins and Heringa, 2000), and Assess and refine the model. 
For a protein that has 40% or more sequence identity, the alignment process is straightforward. In 
the model, there will be hardly any gaps, and 90% of main-chain atoms can be modelled with an 
RMSD (root-mean-square distance) error of about 1 Å (Mohammadi et al., 2016) . About 57% of all 
known sequences have at least one domain that is related to at least one PDB protein template, and 
this is continuously improving year by year. Figure 1.12 shows a flowchart for the Homology 
Modelling pipeline. It all begins with an amino acid sequence. The first stage of the process is to use 
the sequence to detect and select homologues that have known 3D structures (templates) that are 
similar to it. Developments of the alignment program BLAST (Basic Local Alignment Search Tool) 
(Altschul et al., 1990) are used to search for these templates.  
1.6.4.1 Basic Local Alignment Search Tool (BLAST) 
BLAST first takes the sequence that has been inputted and starts comparing it to all the sequences 
that are stored within the non-redundant database, which is provided by NCBI (National Centre for 
Biotechnology Information). This database contains non-redundant sequences from GenBank 
(Benson et al., 2012) translations and other databases such as RefSeq (Pruitt, Tatusova and Maglott, 
2007), PDB (Burley et al., 2018), SwissProt (Bairoch, 2000), PIR (Protein Information Resource) 
(Barker, 2000).  
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Figure 1.12: Homology modelling flowchart – shown is a flowchart of the process used for homology modelling. Homology 
modelling consists of 7 steps: entering a query sequence, Detection and selection of homologs, Alignment of the query 
sequence with templates, construction of the 3D model, and quality assessment. 
The BLAST process is shown in a flowchart in figure 1.13. BLAST considers the input sequence and 
searches the Non-Redundant (NR) database for matching sequences. It does this by listing “words” 
which are short sections of the amino acid sequence. This is called the k-letter. For example, if the k-
letter = 4 BLAST will list every 4 amino acid sequence from the beginning of the input sequence until 
it reaches the end of the sequence. For each “word” BLAST creates every possible 3 letter “words” 
combination and compares them. BLAST then gives a score for each “word”. It does this by using a 
scoring matrix to score each residue pairing. The scoring matrix used is the BLOSUM62 weighting 
scheme (Styczynski et al., 2008) which is shown in figure 1-14. For example, if GEF is compared to 
GEQ and GAF, the respective scores would be 8 and 11. BLAST is then only concerned with the high 
scoring comparisons. This is all decided by the threshold T. For example if threshold T = 10 then the 
“word” GAF would be added to the list but GEQ would be discarded. The remaining words are then 
organised into an efficient search tree. This helps the program to be able to search the database  
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Figure 1.13: BLAST process flowchart – shown is a flowchart describing the BLAST process. BLAST consists of 5 steps: enter a 
query sequence, compare the query sequence with the Non-redundant database, calculate a weight score for all identified 
sequences, align top-scoring sequences with the query sequence, and output a result. 
quickly with the high scoring “words”. These two stages are repeated for all the k-letters in the input 
sequence. When the list has been compiled of all the high scoring “words”, BLAST then searches the 
NR database for exact matches. When a match is found, the two matching “words” are then aligned 
and seeded for a potential un-gapped alignment between the input sequence and the database 
sequence. This means that the two sequences are aligned at the point of the matching “word” and 
one amino at a time BLAST looks at each amino every side to see if there is a match for more than 
the 3-amino acid “word”. This is shown in figure 1.15.  To determine when the seeding should stop 
on the sequence, high-scoring segment pairs (HSP) are used. By using the BLOSUM62 weighting 
scheme matrix, scores are used to compare each amino either side of the exact match.  The seeding 
completes when the score turns negative. The new HSP’s with a higher score than the empirically 
determined cut off score are then listed. With the new list of HSP’s, BLAST then analyses the  
Figure 1.14: BLOSUM62 Matrix – shown is the BLOSUM matrix used to calculate a weight score for every similar sequence 
identified by the database search. 
ala 4
arg -1 5
asn -2 0 6
asp -2 -2 1 6
cys 0 -3 -3 -3 9
gln -1 1 0 0 -3 5
glu -1 0 0 2 -4 2 5
gly 0 -2 0 -1 -3 -2 -2 6
his -2 0 1 -1 -3 0 0 -2 8
ile -1 -3 -3 -3 -1 -3 -3 -4 -3 4
leu -1 -2 -3 -4 -1 -2 -3 -4 -3 2 4
lys -1 2 0 -1 -3 1 1 -2 -1 -3 -2 5
met -1 -1 -2 -3 -1 0 -2 -3 -2 1 2 -1 5
phe -2 -3 -3 -3 -2 -3 -3 -3 -1 0 0 -3 0 6
pro -1 -2 -2 -1 -3 -1 -1 -2 -2 -3 -3 -1 -2 -4 7
ser 1 -1 1 0 -1 0 0 0 -1 -2 -2 0 -1 -2 -1 4
thr 0 -1 0 -1 -1 -1 -1 -2 -2 -1 -1 -1 -1 -2 -1 1 5
trp -3 -3 -4 -4 -2 -2 -3 -2 -2 -3 -2 -3 -1 1 -4 -3 -2 11
tyr -2 -2 -2 -3 -2 -1 -2 -3 2 -1 -1 -2 -1 3 -3 -2 -2 2 7
val 0 -3 -3 -3 -1 -2 -2 -3 -3 3 1 -2 1 -1 -2 -2 0 -3 -1 4
ala arg asn asp cys gln glu gly his ile leu lys met phe pro ser thr trp tyr val
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statistical significance of each by using the Gumbel extreme value distribution (EVD). Multiple 
functions are used to determine this. This is to assess and produce a score that represents the un-
gapped local alignment of the HSP. This is usually called the E score, E-value, or e-value, which is 
reported in the BLAST output.  
Sometimes there is a need to join two or more HSPs together to create a more extended alignment. 
This can help provide more information on the relationship between the query sequence and the 
sequences within the database and increase the accuracy of the alignment. There are two scoring 
methods that are used, the Poisson method and the sum-of-scores method.  The Poisson score is 
mostly used due to it giving a more significant result compared to the sum-of-score method. the 
sum-of-scores method is when the scores of the two or more HSPs that have been joined are added 
together. The sum-of-scores method prefers choosing the HSPs that have the highest score, whereas  
the Poisson method uses equations to work out, which is the best HSP. BLAST creates a file that 
contains all the highest scoring HSP alignments with the respective scores. The results of BLAST are 
then forwarded to an alignment program called T-Coffee. 
Figure 1.15 : Example of aligned seeding – shown is an example of how aligned seeding works. 
Tree-based Consistency Objective Function for Alignment Evaluation (T-Coffee) 
T-Coffee is a multiple sequence alignment (MSA) program that is used to generate multiple 
alignments of sequences using heterogeneous data sources (Notredame, Higgins and Heringa, 2000). 
MSA is a method used in protein structural analysis. MSA is a tool that is used to compare three or 
more sequences together to see if there is any relationship between them, such as a shared 
function, structural or evolutionary. For the homology modelling process, this is a pivotal step to pick 
the best-aligned templates of the BLAST results to be used in the modelling stage. 
T-COFFEE’s process is shown in figure 1.16. The input query of multiple sequences into T-COFFEE is 
run through two different pairwise alignment tools called ClustalW (Larkin et al., 2007) and Lalign 
(ebi.ac.uk, 2017). Lalign is used to do a local pairwise alignment, whereas ClustalW is responsible for 
the global pairwise alignment. Local and global pairwise alignments are two different techniques of 
aligning sequences. Local pairwise alignments compare a small portion of the query sequence 
against the other sequences within the file provided by BLAST, whereas for the global pairwise 
alignment, the entire query sequence is compared to the sequences in the BLAST file. This means 
that global pairwise alignments will produce more gaps between the query and the subject 
sequences than the local pairwise alignment. The results of ClustalW and Lalign are then put through 
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a weighting process which will assign a weighted score to each pair of aligned sequences. The best 
weighted pair-wise alignments of each method are added to a primary library for each method.  
The primary library of the best ClustalW weight scores and the primary library for the Lalign 
weighted scores are then combined. To do this efficiently, if the same pair of aligned sequences 
appear in both the ClustalW and Lalign primary libraries, these are then combined into one single 
record. The weighted scores for each are then also combined using addition. If there is no duplicate, 
a new record is created for the single pair-wise alignment which is being considered, using the 
weighted score that was calculated. Pairs that do not occur at all are not used. By doing this, the 
value of the information is increased due to examining the consistency of each of the pair of 
residues against every pair of residues alignment in the library (Notredame, Higgins and Heringa, 
2000). This process is called library extension. 
The next stage is progressive alignment where firstly the pair-wise alignments are used to create a 
distance matrix which is then used to create a phylogenetic guide tree. The phylogenetic guide tree 
is used to help group the sequences for the multiple sequence alignment. Dynamic programming is 
applied to the two closest sequences, which are in the tree matrix to align them. This uses the 
extended library weight scores to do the alignment. These sequences are then fixed, then the next 
two sequences are aligned, or the next sequence is aligned with the first two sequences depending 
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on what the phylogenetic guide tree suggests. This continues until all sequences have been aligned. 
These groups of aligned sequences are then aligned against each other where the average of the 
extensive library weighted scores are used.  
For the homology modelling pipeline, there is a mode within T-COFFEE called Expresso that is used. 
With the program Expresso (Armougom et al., 2006), it takes the sequences that BLAST has collected 
of the templates that are like the query sequence and reruns BLAST to download the 3D structures 
of the PDB templates like those in the BLAST results. These are then assigned to their corresponding 
sequence. 3DCOFFEE (Poirot et al., 2004) within Expresso uses computational methods like standard 
T-COFFEE it either a sequence-based alignment using Lalign, or a structural alignment using SAP. 
Structural based alignment is used for the Swansea Bioinformatics groups homology modelling 
pipeline. Firstly, a structure-based alignment is done using the templates; then the sequences are 
aligned with their corresponding structure. These are then all added to the library. Figure 1.17 shows 
a flowchart of this process. When the library has been completed, the standard T-COFFEE multiple 
sequence alignment algorithms are run.  
Figure 1.16: T-Coffee flowchart (adapted from Notredame, 
Higgins and Heringa, 2000) 
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Modeller 
Modeller (Webb and Sali, 2016) is the final stage of the homology modelling process. This stage is 
where the 3D models for the query sequences are generated. Modeller takes the T-COFFEE results 
file with all the aligned sequences and begins to go through the file in “chunks”. Modeller works 
through the file in vertical slices and considers only a few amino acids at a time. For each “chunk” of 
the T-COFFEE results that Modeller looks at, it assigns a slice of each template that is associated with 
the aligned sequences. It then looks at these segments of structure and searches these for 
consistency. Modeller then “wraps” the segments around the 3D structure and compares them to 
each other. Where MODELLER ((Mohammadi et al., 2016; Webb and Sali, 2016) finds similarities 
between the structures, it takes the similar segment 3D coordinates and stores them for the 
modelling stage along with the associated part of the sequence. It does this until the whole T-
COFFEE file has been read.  
For the modelling stage, when this file is complete MODELLER creates a 3D models automatically 
using a class called automodel. Modeller will produce 5 models that are based on the file that was 
produced with the 3D coordinates. Due to multiple models being created, MODELLER produces 
scores to provide information for which model is the best. There are many different scores that 
MODELLER can use so that the user can pick the best model according to the particular scoring that 
they want. MODELLER produces its own assessment score called the modeller objective function. 
Figure 1.17: Flowchart of 3D COFFEE process. (Adapted from 
Armougom et al., 2006) 
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This also includes the DOPE (Shen and Sali, 2006) and SOAP assessment scores. These scores are 
ranked based on the alignments provided and is only an approximate measure.  
1.6.5 Protein Threading 
Protein threading is another method of modelling a 3D protein structure. Also known as fold 
recognition, protein threading models amino acid sequences by identifying proteins that have 
same/similar folds to that of proteins with known structure. This method is used for proteins that 
cannot be modelled by homology modelling due to having low or no homologous coverage within 
the Protein Data Bank (PDB) (Burley et al., 2018) . Homology modelling has always been classed as 
the best modelling method between it and protein threading, but threading has continually 
improved over the last decade or so. With its ability to be able to model proteins with low homology 
and the steadily increasing quality of the structures it produces, threading is helping to narrow the 
gap between proteins that have known structure to those that have experimentally characterized 
structures. There are many protein threading suites available to model protein sequences in this 
way. A few examples are I-TASSER (Iterative Threading ASSEmbly Refinement) (Roy, Kucukural and 
Zhang, 2010), HHpred (Soding, Biegert and Lupas, 2005), and RAPTOR (XU et al., 2003) 
For this project, I-Tasser was used. The reason why this program has been chosen is explained in the 
methods chapter. The following description of the threading method is based on I-TASSER. There are 
four components to protein threading approaches being Threading, Structural Assembly, Model 
selection and refinement, and Structure-based functional annotation. The flowchart shown in figure 
1.18 summarises the method that I-TASSER uses. 
Threading 
“Threading refers to a bioinformatics procedure for identifying template proteins from solved 
structure databases that have a similar structure or similar structural motif as the query protein 
sequence.” (Roy, Kucukural and Zhang, 2010) I-TASSER uses BLAST to identify evolutionary relatives. 
This is used to create a sequence profile that is then used to predict a secondary structure (using 
PSIPRED (Buchan et al., 2013)). When the profile of the secondary structure has been predicted, the 
secondary structure is threaded using LOMETS (Wu and Zhang, 2007) through a PDB structure 
library. LOMETS is a meta-threading server which uses multiple state-of-the-art threading programs 
which then find suitable templates. The threading programs used in LOMETS are FFAS-3D (Xu et al., 
2013), HHsearch (Fidler et al., 2016), MUSTER (Wu and Zhang, 2008), pGenTHREADER (Lobley, 
Sadowski and Jones, 2009), PROSPECT2 (Kim et al., 2003), SP3 (Zhou and Skolnick, 2009), and 
SPARKS-X (Yang et al., 2011). 
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LOMETS then takes the templates and alignment generated by the 9 threading programs and assigns 
a Z-score. The Z-score is used to evaluate the significance of the alignments for a given template 
compared to the other templates (Yang et al., 2015). To determine if the templates are good or bad, 
each program has its own “cut-off point” Z-score. LOMETS stores the top 20 templates of each 
threading program, listed in order of how good the alignments are.  I-TASSER uses this list to create 
spatial restraints and to help construct initial conformations that the modelling simulations will 
begin with. 
Structural assembly 
In the structural assembly stage, fragments within the threading alignments are used to build a 
structural conformation of all the sections that aligned well, combined with the unaligned regions 
that were generated by ab initio modelling. Ab initio modelling is a method which uses designed 
energy functions to conduct a conformational search and leads to a number of possible 
conformations being generated. I-TASSER uses a reduced model for the protein's chain. These 
models have residues which are represented by their Cα and side-chain centre of mass. The regions 
that are not aligned during the threading process are due to having a low modelling accuracy, in 
these regions the structure modelling is confined to a lattice system of grid 0.87 Å, which means that 
the entropy of conformation search can be reduced (Roy, Kucukural and Zhang, 2010). 
Monte Carlo Simulation is used to assemble the fragments. The Monte Carlo simulation reassembles 
the PDB fragments that have been collected for the aligned regions. For proteins that do not have 
any template associated with it, the models are entirely created by ab initio modelling. The 
Figure 1.18: the I-Tasser process flowchart.  (Roy, Kucukural, and Zhang 2010) 
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simulation is guided by “composite knowledge-based force field” (Roy, Kucukural and Zhang, 2010). 
This contains statistical terms that are stored within the PDB, spatial restraints from threading 
templates, and sequence-based contact predictions from SVMSEQ (Wu and Zhang, 2008). The 
conformations that have been generated in the refinement simulation are then clustered by a 
program called SPICKER. This is done so that the low-energy states can be identified. These are then 
put into a cluster centroid which stores the average 3D coordinates of all the structural decoys. 
Model selection and refinement 
The first part of this stage is the fragment assembly simulation stage and is performed by again using 
the selected cluster centroids. The second run of this stage is that steric clashes are removed and 
refines the global topology. Template Model align (TM-align) is used to pick out threading 
alignments and structures that are the closest to the cluster centroids. These results are then 
clustered. The structures that have produced the lowest energy scores are inputted into a program 
called REMO. REMO creates the final structures of the proteins which are built by using all atoms. 
These all-atom models are built using Cα traces through the optimization of hydrogen bonding 
networks. 
Structure-based functional annotation 
This last stage is where the final models are generated. The 3D models are structurally compared to 
protein templates from information within their PDB files. These protein templates that they are 
being compared are annotated by 3 structure/function databases and are represented as: 
• 5,798 non-redundant entries with known EC numbers 
• 26,045 non-redundant entries with known GO terms 
• 19,658 non-redundant entries with known ligand binding sites 
The global structural search is used to see if there are similar folds, while the local similarity search 
allows it to compare functions and active/binding sites.  The functional analogues are ranked by 
using the Template Model Score (TM-score), RMSD, and sequence identity, coverage of structural 
alignment. The results are then ranked on how accurate each model is with a C-score. I-TASSER 
produces 5 PDB models for the user to choose from. 
1.7 Virtual Drug Screening 
In the pharmaceutical industry, the method that has widely been adopted to help the early stages of 
drug discovery is in vitro high-throughput screening (HTS) (Cronk, 2013). This method has been used 
to discover new targets and to test newly designed drugs on specific targets. Computational or in 
silico methods are being developed to reduce the vast chemical search space to increase the 
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probability of identifying active ligands without prior knowledge of receptor structure (Cheng et al., 
2012) One of these methods that have been developed is virtual drug screening. Due to the increase 
of knowledge of protein structure and being able to model/predict the structure of a protein target 
due to the advances of X-ray crystallography and NMR, it is possible to compute how a drug might 
interact with a specific target protein. This method is a cheaper and faster method than HTS.  
All docking-based virtual screening approaches employ the same broad workflow, this being shown 
in figure 1.19. The first step is acquiring the protein or target of interest, and then to compile a 
library of the compounds/ligands that are relevant to the research being conducted. The structure 
files for these are then prepared and then docked. The docking algorithms used then produce a 
score that will represent the interaction between the protein of interest and the ligand that has 
been docked. It also produces a conformation file so that it is possible to view these predicted 
dockings in 3D. Then these conformations and scores are analysed to see if the predicted dockings 
will be classified as predicted interactions or Hits.  Many different docking algorithms are being used 
for virtual screening. Shown in figure 1.20 are all known docking programs available and their 
percentages of publications they have been involved in. If all the docking programs, the most 
Target Structure 
Preperation
Compound Library 
Preperation
Docking
Ligand Scoring
Post Processing
Hits to assay
Figure 1.19: Docking-based virtual screening workflow – shown is the basic workflow to perform a virtual 
screening docking.  
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popular are AutoDock, Gold, and Glide. These programs make it possible to predict whether there is 
a possible interaction between the protein of interest and any of the compounds/ligands in the 
compiled list. This is also more cost-effective than X-Ray Crystallography and NMR. These are both 
expensive and lengthy processes which can only be done one at a time whereas, for virtual docking, 
hundreds of protein-ligand dockings can take place within the same timeframe and for a fraction of 
the cost. However, docking predictions are only just that – predictive simulations. X-ray 
crystallography and NMR provide details of known actual structures. This means there is a pay-off 
between cost and convenience on the one hand and the introduction of error on the other. In this 
project, the chosen docking programs to use for the docking process are AutoDock Vina and DOCK 
6.0 due to them being freely available and are deemed to be accurate. 
1.7.1 AutoDock Vina 
AutoDock Vina (Trott and Olson, 2009) is an open-source ligand-receptor docking program. It is 
possible for the program to predict how a ligand would interact/bind to a receptor/protein. This 
program is a docking algorithm that has been improved on its predecessor, AutoDock 4 (Morris et 
al., 2009). AutoDock Vina has increased the speed of docking, and the accuracy of binding 
predictions compared with AutoDock 4 (Trott and Olson, 2009). With the ability to now parallelise 
docking jobs it has been made possible to dock multiple protein-ligand pairs at the same time. 
AutoDock Vina then produces an affinity score which is associated with the calculated conformation 
and represents the global strength of an interaction.  
Figure 1.20 : All docking publications from 1990 to 2013 (Chen, 2015) – shown is a pie chart of all known virtual docking 
programs and the percentage of papers which have referenced these programs between 1990 to 2013. 
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Figure 1.21 shows a flowchart of the process needed to perform an AutoDock Vina’s docking. The 
file format for structural models used in AutoDock Vina is PDBQT. These can be based on structures 
that are stored in the Protein Data Bank database or models that have been created using homology 
modelling or protein threading methods. AutoDock Vina uses a box search space for the receptor. 
The search space box can be set as the entire surface of the inputted receptor, or the box size and 
location can be determined by the user. The ligands that are required for docking have their PDB 
files downloaded and converted to PDBQT file format. These can be ligand files that have been 
downloaded or ligand PDB files that have been generated. Once the files for both the receptor and 
the ligands have been acquired, they are then docked using the AutoDock Vina’s algorithm. 
AutoDock then outputs a top conformation accompanied by an affinity score which can give an idea 
of whether interaction has occurred. These conformation files can then be visualised using programs 
such as Chimera which can be used to analyse the docking and examine it in more depth, 
investigating such as the closest atoms between the ligand and the receptor. 
1.7.2 UCSF DOCK 6.0 
UCSF DOCK 6.0 (Allen et al., 2015) is another open-source ligand-receptor docking program which is 
the latest development from the original DOCK program. The original DOCK program was created in 
the 1980s by Irwin Kunt’s Group from the University of California, San Francisco. DOCK 6.0 was built 
as an extension to DOCK 5, which has improved sampling and scoring capabilities and has also 
improved the optimisation and testing for compatibility with RNA (Allen et al., 2015). DOCK 6.0 has 
Figure 1.21: Protein-Ligand docking process for AutoDock Vina (Adapted from Chen, 2015) 
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several more scoring functions compared to AutoDock Vina such as Electrostatics Scoring, Hawkins-
Cramer-Truhlar GB/SA solvation scoring with optional salt screening, B/SA solvation scoring, AMBER 
Binding energy scoring, AMBER Receptor Flexibility Scoring, AMBER Scoring, Contact Scoring, and 
Grid-Based Scoring. There are many more different parameters generated in the predicted docking 
that can be investigated by using DOCK 6.0 compared with other docking algorithms such as 
AutoDock Vina. The DOCK 6.0 process is shown in figure 1.22 where firstly the protein file is 
acquired. DOCK 6.0 uses MOL2 files of the protein and ligand to compute a docking, this being 
different to AutoDock Vina which mainly uses the PDBQT format. DOCK has two different methods 
of specifying a search space, these being Sphgen and Grid. For docking, Sphgen is used as the 
preferred method. This is an inbuilt program in the DOCK 6.0 suite. To determine the search space of 
the protein, spheres are used which are then used to attempt to dock a ligand within. Sphgen scans 
the entire 3D structure of the protein and uses multiple spheres to mark possible cavity locations 
where a ligand can potentially bind. There are three different options in Sphgen that can be used to 
determine the search space. The first option is to select the largest cluster of spheres that Sphgen 
has generated for the search space. The second option is to specify a radius from the protein and 
only use the spheres within it that Sphgen had generated. The final option is for the user to specify 
the spheres manually in the desired locations. An example of the output produced by Sphgen is 
shown in figure 1.23. DOCK will then use this as the search area for the docking algorithms, which is 
different from the box search area AutoDock Vina uses. After the search space has been specified 
the docking can then take place. The list of ligands that are under investigation is acquired with their 
Receptor 
Coordinates
Sphgen Grid
for 
complementarity 
with receptor
Ligand coordinates
Figure 1.22: DOCK 6.0 process (Adapted from Dock.compbio.ucsf.edu, 2018) 
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corresponding MOL2 files which are then used for the docking process. DOCK 6.0 will then attempt 
to dock this list of ligands into the spheres that have been selected for the receptor using its docking 
algorithm. DOCK 6.0 outputs the top 10 conformations calculated for a docking pair accompanied by 
scores such as affinity and electrostatics. Like AutoDock Vina, these conformations can be visualised 
in programs such as Chimera for further analysis.  
1.8 Protein Structure in Drug Discovery 
Predominantly proteins are the machines that drive the biochemical life processes in the human 
body. If one of these processes is going wrong, that can be the cause of an illness or a disease. 
Protein structures have helped the pharmaceutical industry massively as it makes it possible to 
create new drugs that can target specific proteins associated with particular diseases or symptoms. 
The ability to be able to visualise a protein of interest and its predicted structure of that helped 
make it possible to be able to design drugs that can either stop a protein from working or modulate 
its function within the body. Methods such as Cryo-EM, X-ray crystallography, and NMR has made it 
possible to isolate a single protein and define its structure. When these methods are performed, a 
drug is often co-purified to see whether and how it binds or has an effect of the protein at all. This 
gives drug designers a clearer understanding of how proteins of interest work. Applying these 
methods is very expensive, which is the reason that only a small fraction of proteins have been 
structurally determined which means there is a need for alternative solutions to bridge the 
“structure gap” to be able to study the le the entire human proteome. This is where computational 
power is used. As it is not currently possible to crystallise all the proteins in the body, computational 
modelling is used to predict structures based on templates of homologous proteins that are within a 
Figure 1.23: Example of Sphgen output which indicates 
possible locations for drugs to be docked. 
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database. This makes it possible for drug designers to identify drug targets with strongly predicted 
interactions with specific ligands on a large scale.  
1.9 Adverse drug events 
Adverse drug events are classed as an injury which occurs from a medical intervention-related drug. 
(Health.gov, 2018) These can be caused by Medication errors, Adverse drug reactions, Allergic 
reactions, and Overdoses. Adverse drug reactions can cause many problems for patients and put a 
lot of pressure on health services due to additional appointments and extended hospital stays. The 
following figures show how much of an issue adverse drug event is (Health.gov, 2018). Data for 
inpatient Adverse drug events account for an estimated 1 in 3 of all hospital adverse events, Affect 
about 2 million hospital stays a year, and Prolong hospital stays by 1.7 to 4.6 days. Outpatient 
adverse drug events account for each year over 3.5 million physician office visits, An estimated 1 
million emergency department visits, and approximately 125,000 hospital admissions. Due to 
adverse drug events, more patients are staying longer in the hospital than they need to be. Physician 
time is being wasted due to them needing to deal with adverse drug events.  
An example of a drug that is known for its off-target interaction is Tamoxifen. Tamoxifen is an 
estrogen modulator that acts to inhibit the binding of endogenous estrogens competitively. This is a 
drug that is widely used to treat breast cancer but can cause a number of adverse drug reactions. 
There have been 22 off-target interactions identified for Tamoxifen which include receptors such as 
histamine H1 and H3, and muscarinic M1, M4, and M5 subtypes, and dopamine D2 receptor (Flynn, 
Heale and Alisaraie, 2017).  
1.10 High-Performance Computing (HPC) Wales / Supercomputing Wales 
High-Performance Computing Wales (https://www.hpcwales.co.uk) was a £44 million project which 
began in 2009. The project was funded by a number of partners such as the Welsh European 
Funding Office, Department for Business, Innovation and Skills, and the Welsh Assembly 
Government. HPC Wales was the UK’s largest distributed supercomputing network with an available 
17,000 computing cores with a capacity of 320 teraflops. The purpose of the project was to provide 
high-performance computing easily accessible for businesses, researchers. The HPC Wales project 
ended in 2015 but since a new £15 million project has been launched called Supercomputing Wales 
(https://www.supercomputing.wales). This project was funded by the European Regional 
Development Fund through the Welsh Government. The aim of this project was slightly different to 
HPC Wales as it is aiming to give access to high-performance computing to university research teams 
within a consortium of universities, Cardiff University, Swansea University, Bangor University, and 
Aberystwyth University. The project is not able to be accessible for commercial use. The number of 
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cores available are 13,080 cores which are less than the HPC project, but they use a more up to date, 
and faster type of CPU as the capacity of the system is 1 petaflop. With the amount of computing 
power available, HPC Wales and Supercomputing Wales have made the project possible which 
involves a large amount of modelling and computer calculations to generate the vast amount of data 
required. 
1.11 Drugs 
The Association of the British Pharmaceutical Industry (ABPI) produced a list of the top 30 most 
valuable sold drugs in the United Kingdom for the year of 2013. Within the top 30 list, there are 9 
drugs that are proteins. As the docking algorithms that are being used do not support protein-
protein interactions, these will be excluded from the study. Shown in table 1.4 is a list of the drugs 
that will not be used. The Drug Clexane (Enoxaparin) will also be excluded due to there not being an 
available structure. The remaining non-peptide drugs that are used in this study to test against the 
entire human proteome. Shown in table 1.5 are the drugs that will be included in the study. The 
table contains information such as drug name, Drugbank ID, PubChem ID, a brief description of the 
drug, it’s known targets, and finally, the amount spent on the drugs in the United Kingdom. 
Table 1.4:Drugs excluded from the thesis – shown are the drugs that have been excluded from the thesis due to them 
needing protein-protein interaction software which will not be used. 
 
 
 
 
 
 
Drug Name Drugbank ID 
Enbrel (Etanercept) DB00005 
Herceptin (Trastuzumab) DB00072 
Humia (Adalimumab) DB00051 
Lantus (Insulin Glargine) DB00047 
Lucentis (Ranibizumab) DB01270 
Mabthera (Rituximab) DB00073 
Novarapid (Aspart) DB01306 
Privigen DB00028 
Remicade (Infliximab) DB00065 
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Table 1.5 (A): Table of the top 19 most valuable sold drugs – shown are the 19 drugs that will be included in the study. The 
table contains the name of the drug, Drugbank ID, PubChem ID, a brief description of the drug, known targets of that drug, 
and the cost of the amount sold in the UK in 2013. Some of the drugs within this study have more than one ligand 
associated with them. 
Drug 
Name 
Drugbank 
ID 
Pubchem 
ID 
Description Known 
Targets 
(Uniprot ID) 
Sales 
(2013) 
(000s) 
Seretide DB00588 444036 Seretide also was 
known as Fluticasone 
Propionate is a drug 
which is used to 
relieve inflammatory 
and pruritic symptoms 
of dermatoses and 
psoriasis. It is also 
used for respiratory 
problems such as 
asthma (Andersson et 
al., 1999). 
P04150, 
P06401, 
P47712, 
P08235 
£472,444 
Abilify DB01238 60795 Abilify, also known as 
Aripiprazole, is an 
FDA-approved drug, 
which is an 
antipsychotic 
medication for the 
treatment of 
schizophrenia (Stip 
and Tourjman, 2010). 
It is also a treatment 
for acute manic and 
mixed episodes 
associated with 
bipolar disorder. 
P28223, 
P14416, 
P08908, 
P28222, 
P28221, 
P28566, 
P28335, 
P46098, 
P50406, 
P34969, 
P21728, 
P21918, 
P35462, 
P21917, 
P35367, 
P35348, 
P35368, 
P08913, 
P18089,  
P18825, 
P11229, 
P08172, 
P20309,  
P08173, 
P08912 
£86,455 
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Table 1.5 (B): continuation of table 1.4 
Drug 
Name 
Drugbank 
ID 
Pubchem 
ID 
Description Known 
Targets 
(Uniprot 
ID) 
Sales 
(2013) 
(000s) 
Atripla DB00300 
DB00879  
464205 
60877 
Atripla, a combination of two drugs 
being Tenofovir and Emtricitabine, 
is a member of the group of 
antiretroviral drugs which are 
known as analogue reverse 
transcriptase inhibitors (nRTIs). 
This drug has been designed to 
block reverse transcriptase, which 
is an essential enzyme which helps 
viral production in HIV infected 
patients (Fung, Stone and Piacenti, 
2002). Both Tenofovir’s and 
Emtricitabine’s known target is 
Reverse transcriptase/RNaseH  
Q72547 £137,663 
Ezetrol DB00973 150311 Ezetrol, also known as Ezetimibe, is 
a drug that is an anti-
hyperlipidemic medication which is 
used to treat low cholesterol levels 
(Nutescu and Shapiro, 2003). 
P35610, 
Q9UHC9
, P15144 
£70,194 
Glivec DB00619 5291 Glivec, also known as Imatinib, is a 
drug that is a kinase inhibitor which 
is used to treat certain types of 
cancer such as chronic 
myelogenous leukaemia (Sacha, 
2013) and gastrointestinal stromal 
tumours (Lopes and Bacchi, 2009). 
A9UF02, 
P10721, 
O43519, 
P04629, 
P07333, 
P16234, 
Q08345, 
P00519, 
P09619,  
£102,058,
000 
Januvia DB01261 4369359 Januvia also was known as 
Sitagliptin, is an anti-diabetic drug 
which can be used with or without 
metformin to help control type 2 
diabetes mellitus (Plosker, 2014). It 
has been developed specifically to 
target the dipeptidyl peptidase 4 
(DPP-4) protein. 
P27487 £84,011,0
00 
 
 
 
 
 
36 
 
Table 1.5 (C): continuation of table 1.4 
Drug Name Drugbank 
ID 
Pubchem 
ID 
Description Known 
Targets 
(Uniprot ID) 
Sales 
(2013) 
(000s) 
Keppra DB01202 441341 Keppra also was known 
as Levetiracetam, is a 
drug that has been 
developed as an 
anticonvulsant 
medication which is 
used to treat epilepsy 
(Abou-Khalil, 2008). 
Q7L0J3, 
Q00975 
£67,716 
Levothyroxine DB00451 5819 Levothyroxine is a 
primary hormone 
derived from the 
thyroid gland, which is 
used to treat 
hypothyroidism (Javed 
and Sathyapalan, 2015). 
P10827, 
P10828 
£97,688 
Lipitor DB01076 60823 Lipitor also was known 
as Atorvastatin, is 
classed as a statin drug 
which is used to lower 
cholesterol. 
P04035, 
P27487, 
P35869 
£124,830 
Lyrica DB00230 5486971 Lyrica also was known 
as Pregabalin, is an 
anticonvulsant drug 
which is used to treat 
neuropathic pain 
(Verma, Singh and Jaggi, 
2014), epilepsy (Ryvlin, 
Perucca and Rheims, 
2008), and generalised 
anxiety disorder 
(Baldwin and Ajel, 
2007). 
O00555 £282,497 
Neurontin DB00996 3446 Neurontin also was 
known as Gabapentin, is 
a drug that has been 
created to treat 
epilepsy (McLean and 
Gidal, 2003). It is also 
used to treat pain, such 
as neuropathic pain 
(Backonja and 
Glanzman, 2003). 
P54289, 
Q9NY47, 
Q00975, 
P30542, 
Q9UBS5, 
O75899 
£76,448 
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Table 1.5 (D): continuation of table 1.4 
 
 
Drug 
Name 
Drugbank 
ID 
Pubchem 
ID 
Description Known 
Targets 
(Uniprot 
ID) 
Sales 
(2013) 
(000s) 
Revlimid DB00480 216326 Revlimid also was known as 
Lenalidomide is a drug that 
has been created to treat 
multiple myeloma (Chen et al., 
2013) and has also been used 
for myelodysplastic 
syndromes (Giagounidis et al., 
2007). 
Q96SW2, 
O14788, 
P33151, 
P35354 
£115,703 
Spiriva DB01409 3086655 Spiriva also was known as 
Tiotropium has been designed 
as a long-active anticholinergic 
bronchodilator drug which is 
used to manage chronic 
obstructive pulmonary disease 
(COPD) (McIvor, 2010). 
P20309, 
P11229, 
P08172, 
P08173, 
P08912,  
£246,624 
Symbicort DB01222, 
DB00983 
5281004, 
3410 
Symbicort also was known as a 
combination of two drugs, 
Budesonide and Formoterol. 
Budesonide is a glucocorticoid 
which is used to manage 
asthma (Hodgson, Mortimer 
and Harrison, 2010). This is 
also used to treat different 
types of skin conditions and 
allergic rhinitis. 
P04150, 
P07550, 
P08588, 
P13945 
£224,851 
Truvada DB00300, 
DB00879 
464205, 
60877 
Truvada is also known as a 
combination of two drugs, 
Tenofovir and Emtricitabine. 
Tenofovir and Emtricitabine 
are both a class of HIV drugs 
that are called nucleoside 
reverse transcriptase 
inhibitors (NRTIs). This drug 
helps block the critical enzyme 
that increases viral production 
(Masho, Wang and Nixon, 
2007). 
Q72547,  £108,071 
Vesicare DB01591 154059 Vesicare is also known as 
Solifenacin is a drug created to 
treat overactive bladder with 
urge incontinence (Basra and 
Kelleher, 2008). 
P20309, 
P11229, 
P08172, 
P08173, 
P08912 
£90,203 
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Table 1.5 (E): continuation of table 1.4 
Drug Name Drugbank 
ID 
Pubchem 
ID 
Description Known 
Targets 
(Uniprot ID) 
Sales 
(2013) 
(000s) 
Zytiga DB05812 132971 Zytiga also was known as 
Abiraterone is hormonal 
therapy drug which is 
used to treat advanced 
prostate cancer (de Bono 
et al., 2011). 
P05093 £96,684 
 
1.12 Whole proteome-scale screening 
An extensive literature search for publications or documentation relating to whole proteome-scale 
screening revealed no record of it ever having been achieved before. There have been large docking 
programmes performed using supercomputing but not to this scale. Large docking projects that have 
taken place are mostly based on one target receptor (Protein) being docked against hundreds to 
thousands of drugs. An example of this is the work of Capuccini et al., 2017 where they have docked 
single receptors against around 2.2 million compounds using publicly available cloud 
supercomputing supplied by Amazon and the use of Googles MapReduce. Capuccini’s project was 
more focused on the parallelization of the docking method and its performance rather than the 
biological data generated by the experiment.  
A similar project has been carried out using high-performance computing for drug-protein docking. 
An experiment conducted by LaBute et al., 2014 looked at a computational method of predicting 
Adverse Drug Reactions (ADRs) combined with known information about ADRs collected from 
Drugbank and SIDER databases. The AutoDock Vina program was used to perform the dockings. 
These dockings were run for a virtual panel of 409 protein targets that were created from the data 
stored on the Drugbank database against a set of 906 small molecule drugs. The protein target 3D 
structures were all crystal structures extracted from the Protein Data Bank database. In total, this 
resulted in 370,554 calculated docking scores. This combined with the annotated targets of the 
compounds stored on the Drugbank database were used to train different groups of logistic 
regression models which in turn produced promising results. When comparing the AutoDock Vina 
off-target binding models with the Drugbank on-target models, they produced comparable AUCs 
(area-under-the-receiver-operating-characteristic-curves) during 10-fold cross-validation. There 
were PubMed entries that have supported several putative ADR proteins that the analysis had 
produced.  
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These docking projects though impressive, do not extend to the proteome-wide screening 
undertaken in this project. This project results in a system that allows the prediction of interactions 
with 20,386 wildtype proteins against the top 20 most valuable sold drugs in the UK, with the 
possibility of extending to dockings of known variants and Isoforms. The work of LaBute et al., 2014 
looked explicitly at adverse drug reactions. The developed system has the potential to identify off-
target interactions which may lead to adverse drug reactions and also repurpose drugs.   
1.13 Aims 
The aims of this project are as follows: 
1. Develop a system which will help assist the lead discovery process, Re-purpose existing 
drugs, and Reduce the risk (both financial and medical) of drug development by improving 
efficacy and reducing adverse reactions. 
1.14 Objectives 
The objectives of this project are as follows: 
1. Generate and evaluate 3D structural models the 20,386 wild-type amino acid sequences of 
the Human Proteome. 
2. Undertake the molecular docking of the proteins of the human proteome against the 20 
most valuable sold drugs. 
3. Implement a versatile system architecture that will facilitate the display and analysis of 
molecular interactions. 
4. Test and validate the accuracy of the docking process in the prediction of known receptor-
drug interactions with target proteins and known non-interactions and identify the potential 
for further improvements if applicable. 
5. Evaluate the performance of the system in terms of the scope for the use of the system in 
reliably predicting new drug leads, repurposing opportunities and adverse drug reactions. 
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2 Methodology 
The core approach of the project that was undertaken is shown in figure 2.1. The study consists of 6  
Figure 2.1: Methodology Flowchart – shown are the different stages that had to be undertaken to complete this study. 
There are 6 stages, which consist of Data Collection, Protein Modelling, Protein-Ligand Docking, Docking Score Analysis, 
Development of the system architecture, and the development of the graphical user interface 
stages that had to be undertaken to complete it. Stage 1 was the collection of data for the proteins 
and ligands and the extraction of structures. The methods used are discussed in section 2.1. Stage 2 
was the modelling of the protein sequences of the entire human proteome. The methods used for 
stage 2 are discussed in section 2.2. Stage 3 is the docking of the top 20 drugs against the entire 
human proteome. Methods used for this stage are discussed in section 2.3. The analysis of the 
docking scores produced by the docking algorithms is stage 4, for which the methods used in the 
development of an accurate prediction of dockings are discussed in section 2.4. Stage 5 is the 
development of the system architecture, for which the methods and technologies used are 
discussed in section 2.5. Finally, stage 6 is the development of the Graphical User Interface which 
will display all of the docking data generated. The technologies used in the development of the 
graphical user interface are discussed in section 2.6. 
 
Stage 1:
Data Collection
Stage 2:
Protein 
Modelling
Stage 3:
Protein-Ligand 
Docking
Stage 4:
Docking Score 
Analysis
Stage 5:
Develop System 
Architecture
Stage 6:
Develop 
Graphical User 
Interface (GUI)
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2.1 Data Collection 
2.1.1 Human Proteome Amino Acid Sequences 
the collection of all the amino acid sequence of the human proteome so that they could be 
modelled. The sequences are stored in a file format called FASTA. This file format is used in the 
bioinformatics field for storing nucleotide and peptide sequences. An example of a FASTA file is 
shown in figure 2.2. The FASTA file format contains the name or names of the protein to which the 
sequence relates which is placed above the amino acid sequence with the line starting with a “>” 
symbol. The source from which all of the Human proteome sequences were taken was UniProt 
(UniProt Consortium, 2018). UniProt is an extensive database of proteins which stores data such as 
sequence, protein function, known variants, known active sites etc. UniProt facilitates the download 
of the entire human proteome amino acid sequence in one large FASTA file. Only the Swiss-Prot 
(Bairoch, 2000) reviewed human proteome sequences were used for this project. This is because 
these proteins have been manually annotated and reviewed. These were downloaded so that the 
protein structures corresponding to the amino acid sequences could be modelled. The amount of 
amino acid sequences obtained from UniProt was 20,160. 
2.1.2 Top 20 Most Valuable Sold Drugs 
The 3D structural models of the top 20 most valuable sold drug ligands that are listed in section 1.11 
were extracted from the PubChem database (https://pubchem.ncbi.nlm.nih.gov) (Kim et al., 2018). 
PubChem is a database which stores chemical molecules and details of their activities in biological 
assays. This database stores 3D coordinate SDF files of the ligands. An SDF (Structure-data File) is a 
file format used in drug discovery which stores structural information and associated data items for 
a single or multiple ligands (Dalby et al., 1992). Not all the names used within the list provided by the 
ABPI were the same as the drug chemical names which were used in the PubChem database. To get 
the appropriate names of the top 20 drugs, a search was carried out on each drug to find their true 
chemical name. Once the names were gathered the next stage of the process was to download all 
the SDF file for those top 20 drugs from the PubChem database. 
Figure 2.2: Example of an amino acid sequence in FASTA format – shown is an example of a 
protein amino acid sequence in a FASTA file format. The first line starting with “>” contain 
the name of the protein and relevant information. The amino acid sequence then follows. 
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2.2 Protein Modelling 
2.2.1 Homology Modelling 
To model the amino acid sequences gathered for the proteins of the human proteome, two different 
methods were used, homology modelling and protein threading. Homology modelling is used as it is 
widely accepted as generally the most efficient way to compute protein structures. Many papers 
have been published that prove homology modelling can be very accurate, with models closely 
resembling how proteins look and function in real life. An example of this is the work of 
Abdelmonsef and colleagues whereby using a model of Rab38 generated by homology modelling 
researchers were able to identify an active site then using virtual screening were able to identify 
novel antagonists (Abdelmonsef et al., 2016). In this project, an in-house homology modelling 
pipeline was used for the initial modelling stage. The homology modelling pipeline was installed on a 
High-Performance Computer (HPC), increasing the throughput of the number of sequences that can 
be modelled in a day. By using HPC, it is possible to compute the structures of multiple protein 
sequences simultaneously, in parallel. All the sequences were stored in one FASTA file and inputted 
into the pipeline by uploading to HPC as one. Multiple scripts are subsequently run to prepare the 
sequences for modelling. When these scripts have completed, a submission script is sent which runs 
through each sequence and models them. 
2.2.2 Protein Threading 
Protein threading is used in this project to model those proteins that fail to generate a model using 
the homology modelling pipeline. Like homology modelling, threading aligns sequences to structure 
templates, but considers and uses many more templates and iteratively evaluates the resulting 
models by a score or quasi-energy function, and so is much more computationally intensive, which is 
why it is used as the second option after attempted homology modelling. 
It is not possible to attain structural models for all proteins using homology modelling, due to the 
limits of homologue template coverage encountered by the approach, which samples relatively long 
sections of query sequence – template identity in selection of structural templates for homology 
modelling pipeline to produce a model of any meaningful quality for a sequence, that sequence has 
to have at least 20% global identity. Therefore, where this is not the case, protein threading is used. 
Sequences that do not produce a model using homology modelling were modelled by protein 
threading because protein threading can model sequences that only have about 10% of homologue 
identity. This is due to the method of how protein threading predicts a structure. In contrast to 
homology modelling, protein threading models by fold recognition. By modelling the sequences that 
could not be modelled by homology modelling, it was possible to have greater coverage of the 
human proteome for docking against the top 20 drugs. 
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The threading program that was used in this project is I-TASSER (Yang et al., 2015). I-Tasser is a suite 
of multiple programs that work together to predict the structure and function of a protein. I-TASSER 
was selected for this project due to how it compares to other similar programs. I-TASSER was ranked 
number one by the Critical Assessment of Techniques for Protein Structure Prediction (CASP) 
(http://www.predictioncenter.org). I-TASSER competed in CASP7 (2006), CASP8 (2008), CASP9 
(2010), and CASP10 (2012), CASP11 (2014), CASP12 (2016) and came first in all six competitions, 
making it widely accepted as the best protein threading program available. 
In this study, all the sequences that do not produce a model with homology modelling were run 
using I-TASSER to get more viable and higher quality structures to dock against the top 20 drugs. I-
TASSER was also installed on HPC, which increased the output of sequences that can be modelled 
per day. 
Compared to homology modelling, I-TASSER takes a lot more CPU time to model a given amino acid 
sequence for a protein. There is a stage in I-TASSER called the Monte Carlo simulation stage which 
runs up to 15 separate modelling simulations for each sequence. These can take up to 50 hours for 
each of the 15 or so simulations. By using HPC and multiple cores, it only takes up to a one 50-hour 
stint to complete all the simulations in parallel, much faster than having to carry out one simulation 
at a time. The completion time also depends on sequence length, the longer the sequence, the 
closer it gets to hitting the 50-hour limit for a simulation. Due to this time run issue, the sequences 
that did not model using homology modelling were split into different FASTA files depending on 
sequence length. The shortest sequences were modelled first, and when completed, the routine 
moved on to the next sequence length until the modelling of all sequences had been attempted. 
When these models were completed, they were prepared for docking with the two docking 
algorithms being used. 
2.3 Protein-Ligand Docking 
Protein-ligand docking algorithms are applied to try to predict the interactions between a predicted 
3D protein structure and the 3D representation of a ligand. Protein-ligand docking incorporates 
molecular docking, which tries to predict the structure of the intermolecular complex formed 
between two or more constituent molecules. This has become a tool used widely for drug discovery. 
This field has been growing because of its application to medicine (Sousa et al., 2013).There are 
many challenges for drug discovery, for example a lack of characterised targets, so in silico 
predictions of absorption, distribution, metabolism, elimination and toxicity (ADMET) are being 
increasingly used to help focus medicinal chemistry into more ideal areas of biological and chemical 
property space, minimizing the number of ligands needed to be synthesized (White and Modi 2018). 
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The basis of ADMET predictions lies in the understanding of molecular interactions between given 
receptors and ligands, predicted by molecular docking. There were several docking programs 
available to perform this task, but only two were chosen for this project. These are AutoDock Vina 
(Trott and Olson, 2009) and UCSF DOCK6 (Allen et al., 2015). AutoDock Vina and USCF DOCK6 were 
the chosen as they are freely available and that they could easily be implemented on HPC. AutoDock 
Vina and DOCK6.0 were the chosen algorithms to be used to predict the dockings against the top 20 
most prescribed drugs with the proteins of the human proteome. 
2.3.1 AutoDock Vina 
In the case of AutoDock Vina, the PDB files need to convert into a PDBQT format. A PDBQT file is 
very similar to a PDB file format, but it can store data such as atomic coordinates, partial charges and 
AutoDock atom types for both the receptor and the ligand used for the docking. Section 1.7.1 
discusses in more detail the process that AutoDock Vina uses. In the development of more accurate 
protein-ligand docking predictions, Shipyard 1.5 incorporated AutoDock Vina into it is docking 
pipeline which section 2.3.4 discusses.  
2.3.2 DOCK6 
In the case of DOCK6.0, the PDB files must be converted into a MOL2 file format. A MOL2 file format 
is the file format for DOCK input and output. Compared to the PDB file format, MOL2 can store extra 
information which is essential for DOCK6.0 to compute a docking such as atom features, position, 
and connectivity. Discussed in section 1.7.2 is the DOCK6 process in more detail. In the development 
of a more accurate protein-ligand docking prediction, DOCK6 was also incorporated into a docking 
pipeline called Shipyard 1.5 which is discussed in section 2.3.4. 
2.3.3 DoGSiteScorer 
DoGSiteScorer is a program that can detect potential binding pockets and subpockets of a protein by 
analysing a PDB file (Volkamer et al., 2012). The program analyses geometric and physiochemical 
properties of the protein pockets and gives a prediction of the druggability of those pockets using a 
support vector machine (SVM). An SVM is a supervised machine learning model which is used for 
analysing data for classification and regression. Shown in figure 2.3 is a flowchart for the 
DoGSiteScorer process. Firstly, by analysing the surface of the protein to identify potential pockets 
by only using the  
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coordinates of the heavy atoms. A grid is placed around the protein and points are labelled, which is 
dependent on whether there is any spatial overlap with any of the protein’s atoms. A Gaussian filter 
is then applied to the grid which helps identify locations on the protein surface where a sphere-like 
object is favourable. The program then clusters all the identified positions into sub-pockets using a 
density threshold. Many geometric and physicochemical properties are calculated for all the 
identified pockets and sub-pockets automatically. Then the volume of each pocket is calculated by 
using the volume of the grid boxes which had been applied previously. The depth of the pockets is 
then calculated, and atoms that are within 4 angstroms of any of the pocket points is classified as a 
pocket atom. This leads to the composition of the pockets being determined, which describes the 
physicochemical features of those pockets. 
The final stage of the DoGSiteScorer process is to calculate the drugability of each of the potential 
pockets. This stage is when an SVM is used to analyse and estimate the attractiveness of a pocket for 
a drug. The SVM model used has been trained and tested against a non-redundant version of a 
drugable dataset (Schmidtke and Barril, 2010). The SVM was trained by half of the drugable set, and 
the other half was used as test data with an outcome of a mean accuracy of 90% (Volkamer et al., 
2012). The program then gives a score to each of the identified pockets between 0 and 1 with the 
higher score meaning, the more druggable an identified pocket is.  
In this study, the DoGSiteScorer program is used to identify potential pockets that a drug could bind 
to for every 3D modelled protein either via homology modelling or protein threading. The generated 
information is then used personalised search areas for each unique protein for AutoDock Vina and 
DOCK6. Using this method gives the advantage of the processing speed for each docking increasing 
significantly. The processing speed increases due to AutoDock Vina and DOCK6 not needing to 
search the entire protein surface area but instead only to use a search area which contains the 
potential docking pockets.  
 
 
Figure 2.3: DoGSiteScorer flowchart – shown is the flowchart of the DoGSiteScorer 
process. 
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2.3.4 Shipyard 1.5 
Shipyard is a docking pipeline that was developed by Karl Austin-Muttitt, a colleague of the author at 
Swansea University Medical School as part of a more extensive Research Group project which 
became applicable to this study. The pipeline executes the process of docking the same group of 
proteins and ligands together using the two different docking algorithms, AutoDock Vina and 
DOCK6.0. A diagram of the Shipyard 1.5 workflow is shown in figure 2.4. Shipyard takes a folder 
containing all the proteins that want to be used and a folder containing all the ligands that are going 
to docked against them. The protein models would initially be in PDB format, and the Ligands would 
be in SDF format. The first stage carried out by the Shipyard pipeline is to prepare the Protein and 
Ligand files. On each of the protein PDB files, a program called “reduce” is run. This program adds  
Figure 2.4: Workflow of the docking process for Shipyard 1.5 – shown is the process shipyard 1.5 undertakes when 
performing a docking. Firstly, the protein PDB’s and ligand SDF goes through a preparation stage which validates that the 
files are correct. An extra step is carried out for the protein PDB to calculate the electrostatics of the protein. The second 
stage is to dock the ligand and protein together using AutoDock Vina and DOCK6. The third stage is that the conformations 
generated by both docking programs are rescored using different scoring functions with DrugScoreX, DOCK, DOCK GBSA, 
and AutoDock Vina. The fourth stage is that all of the rescored conformations are ranked from best to worse, and the top 
10 conformations are selected. The final stage is that all scoring results and conformations are inputted into a zip file. 
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hydrogen atoms to the PDB file which are not computed during the modelling process in either 
homology modelling or threading pipelines. These hydrogens need to be added before the docking 
process as they affect the ‘partial charge’ of atoms that they bond to. Hydrogens can affect and 
determine if an atom is negatively or positively charged. It is essential that these are added as this 
property determines the general of each protein. After all the hydrogen atoms have been added, a 
program called UCSF Chimera (Pettersen et al., 2004) is used to calculate the electrostatics of each 
protein PDB. UCSF Chimera is a program that can visualise and analyse molecular structures and 
related data such as protein structure and protein-ligand dockings. After adding the hydrogens, it is 
known which parts of a protein are positively or negatively charged, and by also knowing which 
ligands are positively or negatively charged, it is possible to know which regions of the protein are 
likely to possess a strong electrostatic attraction for a particular ligand.  
The next stage involves the use of a program called DMS (Distributed molecular surface) to be used 
to define the surface area of the protein. It is essential for the docking process that the protein 
surface is defined as it will help determine where there are potential pockets for ligands can fit into. 
Finally, a program called Sphgen, which is an accessory program within DOCK6, is run on each 
protein PDB file. Sphgen processes a protein structure and calculates every possible space a ligand 
could be docked in. It does this by generating sets of overlapping spheres around the surfaces of the 
protein. These are then considered by AutoDock Vina and DOCK6.0 as areas where the algorithms 
should attempt to dock a ligand. 
For the preparation of the ligands, a program called OBABEL (O'Boyle et al., 2011) is used to add 
hydrogen atoms onto them like the “reduce” program for the protein PDB files. Chimera is then used 
to calculate the charges of each atom in the ligand. When all the protein and ligand coordinate files 
have been prepared, they are docked together using the AutoDock Vina and DOCK6.0 algorithms 
which were discussed in section 1.7.1 and 1.7.2. Both docking algorithms will use the Sphgen 
spheres calculated for the proteins and attempt to dock them in each determined pocket. Both 
AutoDock Vina and DOCK6 algorithms produce up to 10 conformations for each docking pair and 
score them using their in-built scoring functions. When all docking has completed, all the calculated 
conformations are then run through a variety of different scoring functions. Shown in table 2.1 are 
the different scoring functions that Shipyard 1.5 can apply to every docking conformation generated.  
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Table 2.1 (A): Scoring functions calculated in Shipyard 1.5 – shown are all of the scoring functions that the Shipyard 1.5 
pipeline calculates on every protein-ligand docking pair and the definition of what each scoring function calculates. 
Scoring Function Definition 
DOCK Affinity These are the components of DOCK’s physics-
based scoring function, which are 
linked by the relationship: 
DOCK_Affinity = DOCK_van_der_Waals + 
DOCK_Electrostatics. 
DOCK van der Waals A scoring function within DOCK which calculates 
the force between atom caused by induced 
polarity; necessary for neutral atoms 
DOCK Electrostatics Calculates the force between electrical charges 
DOCK Internal energy Calculates the energy needed to rotate the 
bonds of the ligand to a final conformation 
GBSA (Generalised Born with solvent-
accessible Surface Area) affinity 
These are the components of the GBSA 
(generalised Born with solvent-accessible 
surface area) scoring function. This is a more in-
depth physics-based function that 
attempts to account for solvation effects. The 
scores are related by: 
GBSA_Affinity = GBSA_van_der_Waals + 
GBSA_Screened_electrostatics + 
GBSA_Born_solvation + GBSA_Solvent-
accessible_surface_area. 
GBSA (Generalised Born with solvent-
accessible Surface Area) van der Waals 
A GBSA scoring function which calculates the 
force between atom caused by induced polarity; 
important for neutral atoms 
GBSA (Generalised Born with solvent-
accessible Surface Area) screened 
electrostatics 
A GBSA calculation the force between atom 
caused by induced polarity but modified to take 
into account that the solvent has its own 
electrical properties 
GBSA (Generalised Born with solvent-
accessible Surface Area) Born solvation 
Calculates the energy needed to displace water 
GBSA (Generalised Born with solvent-
accessible Surface Area) Solvent-accessible 
surface area 
Calculates the energy of the interaction of the 
ligand and the water that surrounds it  
Vina Affinity These are the heuristic parameters used by 
AutoDock Vina’s empirical scoring 
function, linked by: 
Vina_Affinity = Vina_Gauss_1 + Vina_Gauss_2 + 
Vina_Repulsion + 
Vina_Hydrophobic + Vina_H-bond + 
Vina_Rotatable_bond_entropy. 
Vina Gauss 1 Gauss scoring functions model attractive atom-
atom forces (and, 
correspondingly, the repulsion function models 
repulsive atom-atom forces). 
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Table 2.1 (B): Continuation of table 2.1. 
 
Each conformation is uploaded and scored using the scoring functions above. This is so that 
conformations from AutoDock Vina and DOCK6.0 can be compared with each other using a 
standardised scoring function. Shipyard then ranks each of the docking pair conformations from 
each docking algorithm and selects the top 10 scoring conformations. The scores of the top 10 
conformations for each docking pair are then inputted into a large CSV file, in a format that it can be 
inputted into the database scores relate to, DOCK score, AutoDock Vina score, DOCK GBSA score, 
and DrugScoreX score.  
2.4 Docking Score Analysis 
2.4.1 Mean and Standard Deviation Outlier Method 
The mean and standard deviation outlier method is a known mathematical calculation which is used 
to identify outlier within a mass amount of data. In this study, the mean and standard deviation 
outlier method is used on the docking data generated on each individual drug column. Firstly, the 
mean and standard deviation is calculated for each drug column within a docking data file. Using 
Scoring Function Definition 
Vina Gauss 2 Gauss scoring functions model attractive atom-
atom forces (and, 
correspondingly, the repulsion function models 
repulsive atom-atom forces). 
Vina Repulsion Vinas equivalent to calculating the van der 
Waals repulsion 
Vina Hydrophobic Calculates the effect that hydrophobic groups 
would prefer to be in contact 
Vina H-bond calculates the hydrogen bonds between the 
ligand and the protein 
Vina Rotatable bond entropy Energy term that calculates the effect of the 
flexible bonds within the ligand on the overall 
binding energy 
DSX (Drug Score X) atom distances These are the machine learning outputs used by 
DSX (Drug Score X) in its 
knowledge-based scoring system. The columns 
are related: 
DSX_Atom_distances = DSX_Contact_count × 
DSX_Per_contact 
DSX (Drug Score X) Contact count DSX_Per_contact models the strength of the 
interactions individual ligand atoms make with 
atoms in binding residues they are 
in contact with (in a ligand size-independent 
way). 
DSX (Drug Score X) per contact DSX_Atom_distances attempt to model the 
overall binding energy (which 
can depend on ligand size) 
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each individual docking pair score, the following formula is applied to calculate the number of 
standard deviations away from the drug column mean: 
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With the results of this equation, the rules shown in table 2.2 are applied to identify outliers within 
each drug column. 
Table 2.2: Rules applied to Standard Deviation Outlier Method results – shown are the scores and rules that are applied to 
determine if a docking is an interaction or a possible interaction. 
Standard Deviations away from the Mean Rule 
Between -1 and -2 Docking classified as a potential interaction 
-2 or less Docking classified as interaction 
 
The Mean and Standard Deviation Outlier Method is used throughout the docking analysis, which is 
discussed in section 4. 
2.4.2 Combinational Forecasting 
Combinational Forecasting is a method where many different parameters can be considered and 
combined into a single result which can increase the accuracy of predictions (Jiang, Zhang and Song, 
2014). Within this study, combinational forecasting is used to increase the accuracy of identifying 
the known interaction of the top 20 drugs. As there were many docking scoring functions generated, 
combinational forecasting was used to help improve baseline results as individually, they were not 
very accurate, which is discussed in section 4.  
2.4.3 Area Under the Curve (AUC) and Receiver Operating Characteristics (ROC) Curve 
AUC – ROC curve is a measurement that can determine the performance or the quality of a 
diagnostic test. Within this study, this method is used to determine the accuracy of each docking 
scoring function used within shipyard 1.5 for correctly predicting known targets of drugs and known 
misses of drugs correctly. This is calculated by plotting the true positive rate against the True 
Negative rate. The true positive rate is the proportion of actual positives that have been correctly 
identified, and the True Negative rate is the proportion of actual negatives that have been correctly 
identified. When these have been determined, they are then plotted on a graph like the one shown 
in figure 2.5. When the graph has been plotted, the ROC curve can be drawn. The max number on 
either axis is 1. With the ROC curve determined, the AUC can be calculated. To calculate the AUC, 
the area underneath the curve must be split up into sections which are shown in figure 2.6. Area A, 
which is shown in figure 2.6 will have its area calculated using the following formula due to it being a 
rectangle: 
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For example, if the height of section B was 0.7, and the width of section B was 0.8, the area of 
section A would be 0.56. To calculate section B and C, the following equation is used due to both 
shapes being a triangle: 
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For example, section B has a height of 0.7 and a width of 0.2 which gives the area 0.07 by using the 
equation, and for section C which has a height of 0.3 and a width of 0.8 would give an area of 0.12. 
Now with all of the areas calculated, the final stage is to add all of them together for which in the 
example would be an area under the curve of 0.75. For the scores given for the AUC, the closer the 
score is to 1, the higher the accuracy. 
It was possible to determine the most accurate scoring functions that shipyard 1.5 produced an is 
explained further in section 4.7.  
Figure 2.5:Example of an Area Under the Curve (AUC) and Receiver Operating 
Characteristics (ROC) Curve – shown is an example of how a ROC curve is plotted and the 
area that is used to calculate the AUC  
True 
Positive 
Rate 
False Negative 
Rate 
ROC 
AUC 
1 
1 
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2.5 System Architecture 
2.5.1 Structured Query Language (MySQL) 
MySQL is an open-source relational database management system which was created and 
maintained by the Oracle Corporation. MySQL is a server-side system which allows the ability to 
structure data into tables and create relationships between those different tables. With it being 
possible to create relationships with different tables, it avoids having to put all data within one table 
which would cause an array of problems such as database querying speed and the possibility of the 
data becoming too complicated to read. MySQL gives the ability to add, access, and process the data 
stored within that database and can work with web languages such as PHP which allows a web-
based system the ability to query a database. 
MySQL is used to create the core database of the study which will store all data such as protein and 
ligand information, docking scoring function results, and file locations for the protein, ligands, and 
generated conformations.  
2.5.2 Ubuntu Server 
Ubuntu server is an open-source Linux operating system (OS). The operating system was developed 
by Canonical Ltd, which maintains and releases security updates the Operating system. The version 
of the Ubuntu operating system used in this study is Ubuntu 16.04 LTS. The system is being used as it 
True 
Positive 
Rate 
False Negative 
Rate 
ROC 
A 
C 
B 
1 
1 
Figure 2.6:Example graph of how to calculate the area under the curve (AUC) – shown is 
an example of how the AUC is calculated by splitting the area into sections and calculating 
the area by using calculations explained in section 2.4.3. 
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is a free server OS which is also being used on the server which will be storing and running the final 
database and graphical user interface for the created protein-ligand docking database system. 
2.6 Graphical User Interface (GUI) 
2.6.1 HyperText Markup Language (HTML) 
Hypertext Markup Language is an open-source language, which is used for the structuring and 
inputting the content of a website page. HTML is the basis of a website, but it is not a programming 
language. The language uses “tags” to structure a website. These “tags” tell the web browser how a 
website should be displayed. For example, if there is a heading for the page, this would be put in-
between a “<h1>” tag. This tells the browser that this is a heading so that the text will be more 
prominent. These “tags” are used mainly for the basic structure. For more advanced visual layouts, a 
language called Cascading Style Sheets is used. 
2.6.2 Personal Home Page (PHP) 
Personal Home Page or PHP: Hypertext Pre-processor, as it is known, was initially used to create 
dynamic web pages and is a server-side scripting language. PHP’s primary use is to interact with 
MySQL databases which are stored on a server. Example code of how PHP connects to a MySQL 
database is shown in figure 2.7. 
It has many other uses; for example, it can be used to run programs on a server’s command line and 
generate XML Documents. PHP can be embedded within an HTML website, but different from HTML, 
PHP is a programming language. An HTML page which has PHP embedded within it has a file name 
ending in “.php” instead of “.html”. 
For this interface, PHP will be used to interact with the MySQL database stored on the local server. It 
will also be used to run some scripts on the Linux command line in some stages of the 
interface/server interactions. 
<?php 
$con=mysqli_connect("localhost","username","password","database_name"); 
// Check connection 
if (mysqli_connect_errno()) 
   { 
   echo "Failed to connect to MySQL: " . mysqli_connect_error(); 
   } 
?> 
Figure 2.7: PHP code which allows a connection to a MySQL database – shown is an example of code that can be 
used to connect the client to a MySQL database stored on a server. The information needed within the code are the 
IP address of the server (localhost), the username and password for the database (username, password), and the 
name of the database (database_name). 
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2.6.3 Cascading Style Sheets (CSS) 
Cascading Style Sheets is used to design the style and layout for displaying the content of the 
website. This links with the HTML “tags” within the website file and tells the web browser how the 
website should look and where components of the website should be placed. A CSS is usually a 
separate file in which only styling code is placed. This is linked to the HTML files using the code, as 
shown in the example below: 
<link rel="stylesheet" href="(style sheet file name and location)"> 
When the website is loaded within a web browser, the browser loads the CSS file followed by the 
HTML code within the “<body>” tag as directed by the CSS file. For parts of the CSS design, a CSS 
framework called Bootstrap (http://getbootstrap.com/)  is used.  
2.6.4 JavaScript 
JavaScript is used to code how a website behaves and is presented in the web browser. JavaScript is 
a client-side language that can work with the Document Object Model (DOM) of a web browser. It is 
mostly used to create interactive websites. The most common use for JavaScript is the creation of 
pop-up windows within a browser. This is used in this project to create an interactive table with data 
from the proteins, ligand and dockings tables. 
2.6.5 AJAX 
Asynchronous JavaScript and XML (AJAX) is a language that is used to communicate with a database 
or server to update parts of a webpage, without the need for refreshing the entire page. This is used 
to make the webpage more interactive and speed it up. Without using AJAX, there would be a need 
for the user to refresh a page every time the content needed to be changed. Shown in figure 2.8 is a 
diagram showing how AJAX works. AJAX language is based on internet standards and uses HTTP 
requests to exchange data with the database/server in the background. AJAX can then link with 
JavaScript/DOM to display the data and enhance user interaction with that data. This will be used to 
work with the database of this system, in the background, so that the interface table will be 
Figure 2.8: Diagram showing how AJAX works within a web page 
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continuously updated depending on the user’s choices. This language also works well with JavaScript 
and PHP, which are also being used in the interface.  
2.6.6 PV – Javascript Protein Viewer 
PV is a protein visualiser which has been developed in Javascript which can represent PDB files in 3D. 
The Viewer is used as the default protein viewer for SWISS-MODEL (Waterhouse et al., 2018). The PV 
protein viewer has featured such as support for different styles of rendering a protein, for example, 
Spheres (to chow protein surface) and ribbon (to show alpha-helix’s and beta sheets). Allows 
residues to be selected and distances to be measured between them and also the ability to label 
within the viewer. This viewer will be used to display proteins and ligands on their selected 
individual pages but also to display conformations for selected protein-ligand docking pairs on the 
graphical user interface.  
2.6.7 DataTables 
For designing the tables, a JQuery plug-in is used called DataTables (http://datatables.net). 
DataTables is a library of CSS and JavaScript files that have been created explicitly for displaying and 
giving enhanced functions to any HTML table. This plug-in is used to give search functions to the 
table window, and due to there being a considerable amount of data to display within the table it 
creates pages so that the user is able for example, views ten results at a time extending up to 25 
results at a time. The DataTables plug-in is used on all data tables that are generated on the 
graphical user interface to give the user more flexibility for how they would like to search and 
interact with the data. 
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3 System Architecture 
This chapter will describe the architecture of the system that has been developed to handle all of the 
data from protein and ligand information and generated conformations produced by the docking 
methodologies. 
3.1 System Overview 
The objective for this system is to provide an easy way for biomedical researchers and 
pharmaceutical companies to be able to view specific receptor-ligand interactions for re-purposing 
drugs and to investigate the potential molecular causes of adverse reactions for some users with 
particular medicines. The system needs to be able to store a large amount of data, including 3D 
Protein/Ligand models, Protein and ligand data, Docking results, and Structural conformation files. 
This large store of data allows the user to view all relevant data about the receptor and ligand 
interactions that have been computed using the docking algorithms. 
The process of creating the system design is completed by using a Virtual machine (VM) with Ubuntu 
Server Operating system (OS). The next step is installing the Apache HTTP server software is installed 
with MySQL and PHP with a PhpMyAdmin control panel interface on this system, allowing ease of 
data manipulation between the MySQL database and the web interface. Storing the system on a 
local server which has internet access allows access by the end-user from any location.   
Figure 3.1 shows the system flow chart. Each box represents a particular stage in the information 
workflow, moving from first obtaining the protein sequences and ligand structures through to the 
user viewing the vast amounts of data produced. 
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3.1.1 Homology modelling 
The processing of data begins with structural modelling.  The sequences are collected and submitted 
to the homology modelling pipeline for modelling. An explanation of the homology modelling 
pipeline in more depth in section 1.6.4. All sequences that fail to produce a model are modelled 
using protein threading.  
3.1.2 Protein Threading 
Protein sequences that cannot be modelled using the homology modelling pipeline are sent to be 
modelled by protein threading. This process uses I-TASSER, refer to section 1.6.5 in the introduction. 
I-TASSER is a suite that incorporates eight different threading algorithms to determine the best 
templates that can be used to model a sequence. A more in-depth description of the process is in 
Chapter 4. 
3.1.3 Ligand Structures 
Collecting the Ligand structures from PubChem by using PubChem ids of gives the top 20 drug 
ligands used in the UK. The list is available from ABPI for the year 2013. The list of ligands is within 
the introduction. 
Figure 3.1: System Flowchart – this workflow shows the created system architecture.  
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3.1.4 Molecular Docking 
The ligand models and protein models are gathered or generated before sending for docking against 
each other. The docking of each ligand with each protein is investigated to find possible interactions. 
The docking algorithms used are AutoDock Vina and DOCK6.0. The docking process is described 
further in chapter 4. 
3.2 Database Prototype 1 
All data for the proteins, ligands, and conformations are stored within a database. The database will 
be developed using MySQL language. Figure 3.2 shows the broad structure of the first database 
designed for the system. 
 
The first database designed was very simple with only three tables, one for proteins, one for ligands 
and an (AutoDock) Vina runs the table. These tables contained unprocessed information about the 
proteins and ligands, and the basic Vina runs output. This first design of the database created before 
the completion of the docking results.  
3.2.1 Protein Table 
The Protein table holds relevant information about the proteins stored within the system. Within the 
Protein table, there are six columns. The primary key column “ProteinID” is for the unique ID of each 
protein. The system autoincrements the ID. The primary key is identified by queries searching to 
gather information about each protein. The column “ProteinName” is for the full name of the 
protein. The column “Variant” is so that if this protein is not the wild-type and has a mutation within 
it, then the logging of the mutation is done within this column. For example, “S235T” which stands 
for Serine has mutated at position 235 into Threonine. For the user, this is essential information for 
when investigating differences between wild-type and variant conformations. The column 
“Homology_run” is for storing the 3D protein models if modelled via homology modelling. This is so 
when selecting a protein; the user will know whether the modelling of the protein is via homology 
Figure 3.2: First Database Design showing 3 tables (Protein Table, Vina_run Table, Ligands Table). The Protein Table is 
linked to the Vina_Run Table with the common field “ProteinID”. The Ligand Table is linked to the Vina_run Table with 
the common field “LigID”. 
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modelling or not. The “UNI_PROT_ID” column stores the UniProt code associated with the protein. 
The user can access more information about the protein if needed from the UniProt website and be 
able to search the database directly by UniProt accession code. The” Date created” column stores 
the date of the 3D model's generation. The PDB database is updated continuously, which means it 
would allow the sequences to be routinely re-modelled with an automated system to see if there are 
new templates that could improve the quality of the model structure. The system can, therefore, 
contain multiple models of the same protein, date referenced. 
3.2.2 Ligands Table 
The ligands table consists of 5 columns which store data about the ligands used in the dockings. The 
primary key is the “LigID”, which as the primary key in the proteins table, is the unique ID for the 
ligand. The “Chebi_ID” column is where the CHEBI ID number of the ligand is stored. On the 
interface, the user can link to the CHEBI database to find more information about the ligand. The 
“Chebi_Name” column is the name used in the CHEBI database for the given ligand. Therefore 
enabling the user to search the database for a specific ligand by name. Like the “Date_Created” 
column within the proteins database, storing the ligand downloaded date is similarly stored. Finally, 
the “Metabolism Target” stores known targets of the ligand, enabling the user to examine these 
directly through the interface. 
3.2.3 Vina_run Table 
This table holds all the data of the dockings and their results produced by AutoDock Vina and 
DOCK6.0. This table also links with the Protein and ligand tables. The table consists of 8 columns. The 
primary key for this table is the “RunID”, The unique ID number given to each separate docking.  
The “LigID” contains the ID of the ligand used in the docking. This ID links with the “LigID” column 
within the ligand table. The “ProteinID” contains the ID of the protein used in the docking. This links 
to the “ProteinID” column in the protein table. With these tables linked together by these ID’s, the 
database is queried to obtain specific information about the protein and ligand used in each record 
of this table. 
The “Results_file” column stores the location of the results files produced by AutoDock Vina and 
DOCK6.0. The “Log_file” column is for the location of the log file of the docking produced. The 
“Headline_Results” column is the best conformation score produced by DOCK6.0 and AutoDock 
Vina. The process of extracting from the conformation file produces the score. Like the 
“Date_Created” columns within the protein and ligand tables, the “Date_Run” column stores the 
date the docking had taken place. It is necessary due to the generation of multiple dockings of 
different models of the same protein and ligand. Finally, the “ProjectID” gives the name of the 
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particular research project that those dockings are related to, for example, who or which research 
group or collaborator wants to have these proteins and ligands docked. This broad structure is 
adapted to future proof the system - currently, the system only holds data for the top 20 drugs 
against the entire human proteome, but this can be expanded to include many further ligands in the 
future. 
3.3 Database Prototype 2 
The preliminary version 1 database design development assumed that all that was needed were the 
docking scores and conformations and information about the proteins and ligands involved. After 
discussing with potential users, it was clear that this design needed to be expanded to include more 
information. It was clear that there was a need to connect the proteins and ligands with a broader 
range of databases used in the field, includes databases such as KEGG (Kyoto Encyclopaedia of 
Genes and Genomes) (Kanehisa et al., 2018)(https:// https://www.genome.jp/kegg/pathway.html) 
and the Reactome Pathway Database (Fabregat et al., 2017) (https:// https://reactome.org) which is 
an open-source pathway database. New tables and links had to be added to accommodate the new 
data. Figure 3.3 shows the updated database structure.  
Adding two new data tables providing links to the protein table. Compared to the previous design, 
this database structure is more comprehensive and can store a more considerable amount of data. 
One table called KEGG has been added to store KEGG related data about the proteins within the 
system, linking to the existing protein information by using the “ProteinID” column in both. The 
purpose is to create a query for a particular protein that can gather all the relevant information 
about the protein with the single selected ID. The other new data table is “Reactome” as shown in 
figure 3.3. This table stores all the Reactome ID’s related to a selected protein using the “ProteinID” 
column. It is a many-to-many relationship as many 
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Figure 3.3: Entity Relationship Diagram (ERD) of second database design – Shown is the design for the prototype 2 database structure which includes two new tables for 
the Reactome and KEGG data. 
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Reactome and KEGG numbers with links to multiple proteins within the “Proteins Table”. The 
“Proteins Table” has also been modified to include three new columns compared to the original 
design. The new columns are “GENE_NAME”, “Threading_run”, and “PDB location”. The 
“GENE_NAME” column has been added to store the gene name associated with the protein. The 
information is helpful for the user to have, and this is another way for the user to search for a 
protein of interest instead of searching the UniProt accession code or the name of the protein. The 
inclusion of the “Threading_run” column is necessary as not all the structures would be modelled 
using homology modelling, meaning that on the interface, it will show the method used to model 
the protein. If there is a yes in the “Homology_run” column, it shows that the protein modelling is by 
homology modelling. If there is a yes in the “Threading_run” column, it shows that the protein 
modelling is via protein threading. Finally, the” PDB_location” is to store the location of the PDB file 
of the modelled protein, enabling the interface architecture to locate the 3D model so that it can be 
accessed and displayed. 
The way of storing the docking scores are stored on the system involved modification in this version. 
Because of the use of two different docking algorithms, there are two different scores for every 
docking produced. To store all this data in one table is somewhat confusing, so in this version, two 
different tables are being used to store the scores, a “Vina_run Table” and a “DOCK_run Table”. Now 
the respective score is stored in the corresponding table, and the interface can display both 
algorithm scores to the user when a specific selection docking is selected. 
3.4 Database Prototype 3 
Following modifications to the molecular docking approaches, there were more scores that the 
docking algorithms produced which could be potentially beneficial to the users for their research. 
Previously the database contained only affinity scores produced by both algorithms. Following the 
modifications, other parameters generated by the docking algorithms have been included, which 
allows the calculation of multiple different scores and measurements about each molecular docking, 
the explanation in more detail is in section 4.5. Also, the algorithms produce up to 10 conformations 
for each docking calculated, meaning that there was a need to update the way scores are stored on 
the system so that it can hold multiple scores for multiple conformations for a single docking pair. 
Version 2 of the database also needed to be made more efficient in how it stored its data and in 
having the database set up for the inclusion of further sets of proteins, ligands, and dockings that 
may require adding to it. The database was substantially re-constructed compared to version 2 and 
that the necessary information and structure would be present within the database to prepare it for 
future protein, ligand, and docking data. 
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3.4.1 Prototype 3 Database re-structure 
The first thing studied was the core information which concerns the method of storing the protein 
and ligand information on the database.  
Protein and Ligand Tables re-structure 
In the previous version, all the information about proteins is stored in the Proteins table and 
similarly the ligand information in the Ligands table. The database design is adapted to cope with the 
problem of duplication within the same table, resulting in unduly increasing the amount of storage 
used and affecting database querying time. The solution is displayed in figure 3.8 with all key 
information about proteins in a single table and similarly, all key information about ligands in a single 
table. The two tables are linked via one-to-many relationships using the “UniProt” column, used in 
both tables. Many records within the “Proteins” table linked to one record within the “Protein_Info” 
table. Ensuring that there is no duplication of protein or ligand information within the proteins table, 
which will save storage space and speed up queries. Shown in table 3.1 are the columns and data 
that are within the “Protein_Info” table. 
By developing the database in this way, it was also possible to add more information about the 
protein that was previously stored. The previous architecture will have led to substantial duplication 
of information if all the information above contained in a single proteins table which would have 
seen the required storage for the database increase massively. Data stored within the “Proteins” 
table relates to the UniProt code of the protein and information about the 3D model stored on the 
system. Shown in table 3.2 is the information stored within the “Proteins” table. 
The “Ligands” table had the same structure as in prototype 2, as shown in figure 3.8. There had been 
some modification to the data stored and how it is stored. The “Ligands” table has a table called 
“Ligand_Info” associated with it. This table holds the PubChem ID which is how the tables link in a 
query, and the name linked with that ID. The format of the “KEGG” and “Reactome” tables did not 
change from the previous implementation. The data within the “Ligands” table has changed. Shown 
in table 3.3 are the columns and information now stored within the “Ligands” table. 
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Table 3.1: Columns set within the Protein_Info table – shown are the columns that have been set within the Protein_Info 
table and what type of data that is stored within them. 
 
 
 
 
 
 
Column Name Data Stored 
UniProt The column stores the UniProt code of the 
protein which information is stored in each 
record and is how the table links to the 
“Proteins” table. 
Gene_Name The column stores the gene name of the 
protein within the record. 
Protein_Name The column contains the long, human-readable 
name of the protein, for example, the name for 
a protein with UniProt code P36575 is Arrestin-
C. 
Other_gene_Names Stores other known gene names associated 
with a single protein. 
Organism The protein’s organism type is stored in this 
column. This prototype will only contain Homo 
sapiens (Human) proteins, but in the future, the 
evolving system could contain a wider variety 
of organisms such as mouse and rat. 
seq_length the column stores the length of the sequence 
of the protein. 
Proteomes this column stores the species name (for 
example homo sapien) 
Sequence The column contains the full sequence of the 
protein in FASTA form. 
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Table 3.2: Data columns for the Proteins table – shown are all the data columns that will be stored within the Proteins table 
with the type of data that will be stored within them. 
 
 
Column Name Data Stored 
Protein_Index The column stores the unique ID of each record 
within the table. 
genename The column contains the gene name of the 
protein; this is used for linking to other tables. 
pdb_file The column stores the location of the PDB file 
of each protein stored. 
uniprot The column stores the uniprot code of the 
protein within the record and is used to link to 
the “Protein_Info” table. 
Variant The column stores details of variants of the 
wild-type protein which have been modelled. 
For the wild type, this contains the word 
“Wildtype”. If an isoform it contains the word 
“Isoform, or if it is a mutation it stores for 
example “S235T” which stands for a Serine 
residue that has undergone a mutation at 
position 235 into Threonine. 
md5 The column stores the md5 checksum is stored 
for the protein and its model; this will be 
explained in more detail in the data import 
system in section 3.5. A checksum is a value 
used to verify the integrity of a file or a data 
transfer. It is a sum that’s used to check the 
validity of data. 
model_type The column stores details of whether the 
model has been created using the homology 
modelling method or by protein threading. 
Homologue_coverage The column stores the percentage of the 
homologue coverage of the model produced. 
Procheck_res The column stores the Procheck percentage 
quality score given to the 3D model. 
Date_created The column stores the date that the 3D model 
was uploaded to the system. 
66 
 
Table 3.3: Data columns for the Ligands table – shown are all the data columns that will be stored within the Ligands table 
with the type of data that will be stored within them. 
  
Docking table re-structure 
The next stage was to re-design the storage of docking results in the database. Due to the multiple 
different scores being produced by the two docking algorithms and more than one conformation 
produced for each docking pair, there was too much information for it to store in one dockings table.  
The amount of data could confuse and make it difficult to query. The change made was to create 
two tables for docking results. One to store the information about the docking pairs and the location 
of the conformation files; the other to store all scores that are associated with those docking pairs 
and link the two tables together using a one-to-many relationship. The “Docking_Table” stores all 
the data about the protein and ligand pairs used for each docking. Shown in table 3.4 are the 
columns and data stored within the Docking table. 
 
 
Column Name Data Stored 
Lig_Index this is the unique identifier for each record 
within the table 
pdb_file this is the location of the PDB model of the 
ligand 
pubchem this is for the PubChem ID for the ligand, and 
this column is linked to the attached 
information tables “KEGG”, “Reactome” and 
“Ligand_Info”. 
drugbank_id this is the drugbank ID for the ligand as a 
second identifier as not all ligands will have a 
PubChem ID. 
md5 this is where the md5 code is stored for the 
protein and its model. 
Date_created This is the date that the 3D model was 
uploaded to the system. 
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Table 3.4: Data columns for the Docking table – shown are all the data columns that will be stored within the Docking table 
with the type of data that will be stored within them. 
 
 
Column Name Data Stored 
Docking_ID The column stores the unique identifier for 
each docking pair. 
Protein_Index The column stores the unique identifier for the 
protein used in the docking. This links with the 
protein table’s Protein_Index column, which 
when queried gives the details of the protein 
used. 
Lig_Index The column stores the unique identifier for the 
ligand used in the docking. This links with the 
ligands table’s Lig_Index column which when 
queried gives the details of the ligand used. 
prot_md5 The column stores the md5 checksum for the 
protein files, which is used to link the docking 
table records with the correct protein record 
within the Proteins table.  A checksum is a 
value used to verify the integrity of a file or a 
data transfer. It is a sum that’s used to check 
the validity of data 
lig_md5 The column stores md5 checksum for the ligand 
files which is used to link the docking table 
records with the correct ligand record within 
the Ligands table.  A checksum is a value used 
to verify the integrity of a file or a data transfer. 
It is a sum that’s used to check the validity of 
data 
results_file The column stores the location of the 
conformation file produced by the algorithms. 
Date_Created The column stores the date the conformation 
was added to the database. 
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This table is the main link to the interface, and all information is attained through it using a query. 
The “Score” table stores all the known scores for each of the pairs within the “Docking_Table”. 
Shown in table 3.5 are the columns and data stored within the “Scores” table. With this structure, it 
is possible to store a large amount of data without over-complicating or duplicating the data. The 
structure makes it very efficient to query and get all the appropriate data that is needed. Figure 3.4 
shows the full database scheme in an entity-relationship diagram (ERD). This database structure is 
designed to hold a large amount of data, which is easy to query within the interface to access the 
correct data. 
Table 3.5: Data columns for the Scores table – shown are all the data columns that will be stored within the Scores table 
with the type of data that will be stored within them. 
Column Name Data Stored 
Score_Index The column stores the unique identifier for 
each score record stored within the table. 
Docking_ID the column links to the Docking_ID within the 
Dockings table. This is the identifier for all the 
scores that are related to a docking pair. 
Conformation the docking algorithms produce multiple 
conformations of the same docking within the 
docking process. This column stores the 
conformation associated with that score for a 
specific docking pair. 
Enumeration the column stores the name of the attribute or 
parameter that the score is associated with. 
The docking algorithms that are used produce 
multiple types of scoring functions relating to a 
single docking pair. These include docking 
affinity, electrostatics, internal energy etc. 
These are discussed in more detail in section 
2.3.4. So, for example, if the score was the 
docking affinity of the conformation, the 
column would have “Docking Affinity” within its 
field. 
Score The column scores contain the score associated 
with the particular conformation and 
enumeration within the record. 
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Figure 3.4: Entity-relationship diagram (ERD) of the 3rd and final system database design – shown is the final scheme for the protein-ligand docking database. The 
database contains 8 tables which are the Protein_Info, Proteins, Ligand_Info, Ligands, Reactome, KEGG, Docking_Table, and the Scores Tables. 
genename 
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3.5 Data import system 
With a large amount of data stored in the database, there needs to be a method of importing large 
amounts of docking data automatically. The method used will split the data and import the correct 
data into the correct tables and link the correct data together with the appropriate ID numbers. To 
make this automated process and to correctly upload the data to the correct tables requires the 
creation of multiple shell scripts and SQL files. Automating the uploading process lowers the risk of 
human error and corrupting data. With the developed scripts it has made it possible to upload a 
large amount of generated protein-ligand docking data and conformations by only launching a single 
upload script. Shown in figure 3.5 is a flowchart of the process for launching using a single parent 
script called Import_archive_dockings.sh, which is discussed further in section 3.5.2.5. On launching 
the parent script, the first script runs the Import_archive_protein.sh script which uploads all protein 
data and files. This import script is discussed further in section 3.5.2.1. Within the 
Import_archive_protein.sh script an SQL script called Create_proteins.sql is launched which uploads 
the formatted data to the database. Section 5.5.2.2 describes the script in more detail. After 
uploading the proteins, the parent script then launches the Import_archive_ligands.sh which 
prepares the ligand files and data to be uploaded. The script is discussed further in section 3.5.2.3. 
Import_archive_proteins.sh
Import_archive_ligands.sh
Import_archive_dockings.sh
Create_ligands.sql
Create_proteins.sql
Create_dockings.sql
Figure 3.5: Flowchart of the scripts lunched by the parent docking upload script – 
shown is the flowchart of scripts which are launched by a parent script to upload 
protein-ligand docking data and conformations.  
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Following the preparation of the ligand data, the Create_ligands.sql launches, which will upload the 
data to the database. Section 3.5.2.4 discusses the Create_ligand.sql script further. Finally, after all, 
proteins and ligands have been uploaded, the Create_dockings.sql script is launched to upload the 
docking data and to connect the relevant protein and ligand pairs. Section 3.5.2.6 describes the 
Create_docking.sql script further.  
3.5.1 Data produced by docking algorithms 
After post-processing the docking data conducted by Shipyard 1.5, a zip file is created which contains 
all of the protein and ligand files used in the protein-ligand docking, conformation that had been 
generated by Shipyard 1.5. Each protein-ligand docked pair, and a CSV file which contains all of the 
scores for every docking score function for each of the ten conformations generated for each 
protein-ligand docked pair.  
3.5.1.1 CSV data file 
After post-processing, the next step is creating a CSV file with all data about every molecular docking 
calculated in that batch. This file contains the protein name, ligand name, what conformation the 
scores are related to and 23 scoring function results, shown in table 2.1. 
3.5.1.2 Conformation files 
The post-processed zip file contains three main folders. Shown in figure 3.6 is the folder structure 
used. One is named _proteins_.zip, which contains the original protein MOL2 files used in the 
dockings. Another is named _ligands_.zip which contains the original MOL2 files of the ligands used 
in the dockings. Finally, in the remaining zip files contained within the main zip file are all the 
conformations calculated by the docking algorithms. Each protein has its zip file named after itself, 
for example, “sp_uniprot_Gene_HUMAN.zip”. These conformation zip files are named using the 
ligands PubChem ID number, for example, “pubchemID_3d.mol2”, and contain the ten best 
conformations produced by the algorithms.  
Figure 3.6: Folder structure for Docking Data produced by Shipyard 1.5 – shown is 
the file structure of the docking data generated by Shipyard 1.5 post-processing. 
The batch file contains a ligands folder (containing ligand files), Proteins folder 
(protein files), and a folder containing all conformations generated with a CSV 
containing protein-ligand conformation scores. 
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3.5.2 Import scripts 
A single command on the command line runs the import scripts. This single script is a shell script 
which runs other shell scripts within in it and runs MySQL commands. Before explaining the main 
shell script, there is a need to explain the shell scripts that are launched within it first.  
3.5.2.1 Import_archive_proteins.sh 
This script collects and prepares all the data for the proteins within the _proteins_.zip file. The folder 
name that’s given with the parent script passes to this script (import_archive_proteins.sh). The script 
then locates the directory used for the import of data.  
Within the import data system, there are two directories to which information passes. The 
directories are named “Proteins” and “Ligands”. For this script, the first step is to copy the 
_proteins_.zip file to Proteins file in the system. Shown in figure 3.7 is the bash command used to 
copy the folder. 
When these have been copied over to the Proteins folder, the next stage is to unzip the (directory 
name).zip file. The unzip process uses the bash command “unzip”. The unzipped directory’s data 
transfers to a directory with the name of the original pre-processed folder.  
This folder now contains all the protein structure used in the molecular docking in MOL2 format. The 
viewer used in the user interface is only able to read PDB files, so there is a need to convert the 
MOL2 files to PDB files. A program called OBABEL is used for the conversion. There is an option in 
the program to convert MOL2 files to PDB files by using the command shown in figure 3.8. 
Because all of the MOL2 files in the directory need converting instead of a specific (filename), MOL2 
in the command is replaced with *.MOL2 which means that it will go through and convert every 
MOL2 file within that directory. The 3D viewer that is being used in the interface also needs the 
structure of the PDB file to be defined. The 3D viewer needs this coordinates file in order to display 
the protein structure. The assessing of the structure of the protein’s PDB file utilises a program 
called DSSP (Touw et al., 2014). DSSP is a program that has been designed to calculate the most 
cp (directory name)/_proteins_.zip Proteins/(directory name).zip 
Figure 3.7:Bash command used to copy _proteins_.zip to the Proteins folder – shown is the bash 
command used to copy the _proteins_.zip file from the folder containing all docking data to the Proteins 
file within the system. 
Obabel (filename).MOL2 – opdb -m 
Figure 3.8:Command used to launch OBABEL – shown is the command used to launch OBABEL which performs a file 
conversion from MOL2 to PDB for the file inputted into the “file name” tag. 
73 
 
likely secondary structure and then to assign that to regions of a 3D model structure of a protein. 
Shown in figure 3.9 is the command used to assign the secondary structure to the PDB file. 
The calculation of multiple PDB files in the directory requires a “for loop” to be implemented to go 
through each PDB file. The next stage of the process is to calculate the checksums of each PDB file. A 
checksum is a value used to verify the integrity of a file or a data transfer. It is a sum that’s used to 
check the validity of data. Using checksum allows the 3D models within the data to link to the 
correct data that should be associated. The checksum used is md5. When the checksums have been 
calculated for each PDB file, a tab-delaminated text file is created with two columns, one for the 
checksum called md5, and the other is for the filename associated with it. This text file will be used 
further on in the import process when the dockings are imported. The md5 checksum is calculated 
using the command shown in figure 3.10. 
The calculation provides the md5 checksum for every PDB file in the directory and stores it in a file 
called “pdb.md5”. Column names are then added to each of the columns, and the file name is saved 
as “pdb_checksums.txt”. A summary file is also created by storing data about each protein that has a 
PDB file. The format is that of a tab-delaminated text file with the Filename, Uniprot, and genename. 
Saving the data under the name “pdb_filenames.txt”. The final stage of this script is to copy the 
“pdb_checksums.txt” and “pdb_filenames.txt” to the appropriate place for adding them to the 
database. This process uses a MySQL command with a .sql file used to import the data. The 
command used is shown in figure 3.11. 
3.5.2.2 Create_proteins.sql 
The script used to import the protein data extracted by the import_archive_proteins.sh script into 
the database. In order to assist with the import process, the creation of two tables within the 
database is necessary to store this information. A table called “import_temp_prot_checksums” is 
created to store the data contained in the “pdb_checksums.txt” file and another table called 
Dssp -i (file name).pdb -o (file name).struct  
Figure 3.9: Command used to launch DSSP – shown is the command used to launch DSSP which will calculate the 
secondary structure for the file inputted into the “file name” tag. 
md5sum *.pdb > pdb.md5 
Figure 3.10: Command used to calculate md5 checksums – Shown is the command used to calculate the md5 
checksums for the protein PDB files. 
mysql -u (username) -p (password) <create_proteins.sql 
Figure 3.11:Command to run the create_proteins.sql file – shown is the command used to run the create_proteins.sql 
within mysql which uploads all generated data and text files about the proteins to the MySQL database. 
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“import_temp_prot_filenames” which stores the data contained in the “pdb_filenames.txt” file. 
Shown in table 3.6 are the columns within the Import_temp_lig_checksums database table. Shown 
in table 3.7 are the columns within the Import_temp_prot_checksums table. Because this import 
system will be used multiple times, this script first truncates these two tables so that there is no data 
left from previous imports. The data from the two files are loaded into their respective tables. 
Following this, a new table is created called “import_temp_prot_both” which is used to link the 
checksums with the data within the “import_temp_prot_filenames” table. Shown in table 3.8 are 
the columns that are within the “import_temp_prot_both” table. 
Table 3.6:import_temp_prot_checksums tables –                  Table 3.7: import_temp_prot_filename – shown are the  
shown are the columns within the                                             columns within the Import_temp_prot_checksums table 
 Import_temp_prot_filename table 
 
 
 
 
The two tables are joined together by joining them using the filename column of both the 
“import_temp_prot_filenames” and “import_temp_prot_checksums” table. The SQL command used 
is shown in figure 3.13. After the import_temp_lig_filenames and import_temp_lig_checksums 
tables have been joined, a new table is created which will use a “LEFT OUTER JOIN” SQL query to 
collect all data from the “import_temp_prot_both” table and join it to the Proteins table via the 
Table 3.8: Columns within the import_temp_prot_both table – shown are the columns within the import_temp_prot_both 
table and what data from the “import_temp_prot_filenames” and “import_temp_prot_checksums” tables are stored. 
Column Name Data 
genename The column stores the protein name from the 
“import_temp_prot_filenames” table. 
pdb_file The column stores the filename from the 
“import_temp_prot_filenames” table 
uniprot The column stores the uniprot ID from the 
“import_temp_prot_filenames” table. 
md5 The column stores the md5 checksum from the 
“import_temp_prot_checksums” table. 
 
 
Import_temp_prot_filename 
filename 
uniprot 
genename 
Import_temp_prot_checksums 
md5 
filename 
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“md5” column. During the process of inputting the data into the Proteins table, all data within that 
table is imports even if it has nothing within the “md5” column resulting in a classification of NULL. 
Finally, the data within the import_temp_prot_both_new table is inserted into the Proteins table 
using the Insert command in SQL, shown in figure 3.14. 
3.5.2.3 Import_archive_ligands.sh 
This script is essentially similar to import_archive_proteins.sh shell script, just with some 
modifications. To prepare the ligand files within the _ligands_.zip file firstly it is copied to the Ligands 
directory and under the name of the pre-processed file like the Proteins. Then from this stage, the 
process is the same as the import_archive_proteins.sh shell script. After unzipping the file, the next 
step is moving the _ligands_directory into the unzipped folder.  
Same as for the proteins, the ligand files are in the MOL2 format and need to be converted to PDB 
format so that the 3D viewer will be able to display them. The command used is shown in figure 
3.18. With the ligand PDB files, there is no need for the secondary structure to be assigned so that it 
can be viewed in the 3D viewer, so this is not included within this script. The next step was to 
calculate the md5 checksums as for the proteins. The next step is outputting these into a tab-
delaminated pdb_checksums.txt with the md5 checksums and the filename associated with it. An 
import summary file is also generated but with the filename and PubChem columns. 
JOIN import_temp_prot_filenames on import_temp_prot_checksums.filename = 
import_temp_prot_filenames.filename 
Figure 3.12: Command to join the Import_temp_prot_filenames and import_temp_prot_checksums tables – shown is 
the command used to join the Import_temp_prot_filenames and import_temp_prot_checksums tables by linking 
them using the filename column as the link for the records. 
INSERT INTO Proteins 
(genename, pdb_file, uniprot, Variant, md5, model_type) 
SELECT genename, pdb_file, uniprot, “WildType”, md5, “Homology” 
FROM import_temp_prot_both_new 
WHERE 1; 
Figure 3.13: Command used to import data from the import_temp_prot_both_new to the Proteins table – shown is the 
SQL command used to import data stored within the import_temp_prot_both_new table into the Proteins table. 
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The next step is outputting the columns are into a tab- delaminated pdb_filenames.txt file followed 
by copying to the relevant area allowing uploading to the database. MySQL is used to upload the 
data using a SQL file called “create_ligands.sql”.  
3.5.2.4 Create_ligands.sql 
 This SQL file is identical to the “Create_proteins.sql” file. Creating the same tables, but instead of 
having the word prot in them, replacing it with the word lig. The columns appearing in the tables 
vary according to the requirements. 
 For the ligands, within the database are two tables that have been created to store the data 
produced by the “import_archive_ligand.sh” file. These are called “import_temp_lig_filename” and 
“import_temp_lig_checksums”. As with the proteins, truncating these tables is necessary because of 
the multiple usages of the script. Failing to do this will cause duplication of data within the database. 
Table 3.9 and 3.10 illustrate the tables. The “import_temp_lig_filename” will have the data within 
the “pdb_filenames.txt” loaded into it, and the “import_temp_lig_checksums” table will have the 
data contained in the “pdb_checksums.txt” file loaded into it. A new table is then  
Table 3.9:import_temp_prot_checksums tables –               Table 3.10: import_temp_prot_filename – shown are the      
shown are the columns within the                                             columns within the Import_temp_prot_checksums table 
Import_temp_prot_filename table 
 
created to join the “import_temp_lig_filename” and the “import_temp_lig_checksums” tables 
together. This table is called “import_temp_lig_both”. The resulting table contains the columns and 
data shown in table 3.11. 
Column Name Data Stored 
pdb_file this is the filename from the 
“import_temp_lig_filenames” table 
pubchem This is the PubChem ID from the 
“import_temp_lig_filenames” table. 
md5 This is the md5 checksum from the 
“import_temp_lig_checksums” table. 
Import_temp_lig_checksums 
md5 
filename 
Import_temp_lig_filename 
filename 
pubchem 
Table 3.11: Columns within the import_temp_lig_both table – shown are the columns within the import_temp_lig_both 
table and what data from the “import_temp_lig_filenames” and “import_temp_lig_checksums” tables are stored. 
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As for “create_proteins.sql” file, the two tables are joined together by using the filename column of 
both the “import_temp_lig_filenames” and “import_temp_lig_checksums” table. Shown in figure 
3.14 is the join SQL command used. 
After the import_temp_lig_filenames and import_temp_lig_checksums tables have been joined, 
creating a new table which will use a “LEFT OUTER JOIN” SQL query to collect all data from the 
“import_temp_lig_both” table and join it to the Ligands table via the “md5” column. So that when 
inputting the data into the Ligands table, it will import all data within that table even if it has nothing 
within the “md5” column which instead classifies it as a NULL. 
Finally, like the “create_ligands.sql” file the data within the import_temp_lig_both_new table is 
inserted into the Ligands table using the Insert command in SQL. Figure 3.15 illustrates this.  
3.5.2.5 Import_archive_docking.sh 
Import_archive_docking.sh is the parent shell script file which will run the entire import sequence. 
When an import is needed, the script shown in figure 3.16 is run. 
./import_archive_dockings.sh (data directory) 
Figure 3.16: command used to launch the protein-ligand docking import – shown id the command used to launch the data 
import for the data directory inserted into the “data directory” tag. 
The data directory is the directory which contains all the docking algorithm data. The shell script 
takes this argument and uses it as the location of the directory. The first stage is to run the 
“import_archive_proteins.sh” and “import_archive_ligands.sh” shell script as spoken about 
previously with the directory selected. Figure 3.17 shows the code. 
 
INSERT INTO Ligands(pdb_file, pubchem, md5) 
SELECT pdb_file, pubchem, md5 
FROM import_temp_lig_both_new 
WHERE 1; 
Figure 3.15: Command used to import data from the import_temp_lig_both_new to the Ligands table – shown is the 
SQL command used to import data stored within the import_temp_lig_both_new table into the Ligands table. 
JOIN import_temp_lig_filenames on import_temp_lig_checksums.filename = 
import_temp_lig_filenames.filename 
Figure 3.14: Command to join the Import_temp_lig_filenames and import_temp_lig_checksums tables – shown is the 
command used to join the Import_temp_lig_filenames and import_temp_lig_checksums tables by linking them using 
the filename column as the link for the records. 
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When these have been run and completed the master script then handles the data directory so that 
it can access the CSV file called “summary.csv” that the docking algorithm post-processing had 
generated for the data imported. Not all the data within the “summary.csv” file is required so before 
the upload there is a need to slim down the CSV file and only have the data that the database 
requires. Using the awk command, the required data is extracted from the “summary.csv” file and 
outputted to a new text file called “newsummary.txt”. Shown in table 3.12 are the only results 
needed from the “summary.csv” file. The format of the file is also changed. The names of what the 
scores represent, for example, “Vina_affinity,” classed as a column name in the previous CSV file and 
placed within their column called Enumeration, for the scores to be able to be inputted into the 
scores table correctly. An example of the converted CSV file to be uploaded to the database shown 
in figure 3.19. This conversion is saved as a new text file called “summaryscore.txt”. When the 
conversion process has completed, the “newsummary.txt” file and “newscores.txt” file are copied to 
the appropriate area for uploading to the database. Then these are uploaded to the MySQL database 
using the command and SQL file shown in figure 3.18.  
3.5.2.6 create_dockings.sql 
This SQL script is critical and creates all the correct links necessary between all of the main tables 
within the database, which are the Proteins, Ligands, Docking, and Scores tables. There are multiple 
temporary tables used within this script to prepare all the data. The first stage is to load the two text 
files created by the “Import_archive_dockings.sh” script into the database. There are two temporary 
tables created to store this data, one is called “Import_temp_dockings”, and the other is 
“Import_temp_dockscores”. The “import_temp_dockings” table will store the data within the 
newsummary.txt file, and the “import_temp_dockscores” will store the data within the 
newscores.txt file. Both tables are truncated before every import so that there is no duplication or 
confusion of data due to this script being used multiple times when uploading new data. Loading the 
data begins the linking process one to another. Creating a table called 
“import_temp_dockings_md5” is the first step.  
v1=$1 
archivename=${v1%/*} 
./import_archive_proteins.sh ${v1} 
./import_archive_ligands.sh ${v1} 
Figure 3.17: commands launched within the Import_archive_docking.sh master script – shown is the code used within 
the Import_archive_docking.sh file which launches the import scripts for the proteins and the ligands in a sequence. 
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Column Names 
Protein 
Ligand 
Conformation 
DOCK_Affinity 
DOCK_van_der_Waals 
DOCK_Electrostatics 
DOCK_Internal_energy 
GBSA_Affinity 
GBSA_van_der_Waals 
GBSA_Screened_electrostatics 
GBSA_Born_solvation 
GBSA_Solvent-accessible_surface_area 
Vina_Affinity 
Vina_Repulsion 
Vina_Hydrophobic 
Vina_H-bond 
Vina_rotatable_bond_entropy 
Drug Score X(DSX)_Atom_distance 
DSX_Contact_count 
DSX_Per_contact 
Results_file 
This table will link the “import_temp_dockscores” table results with their related Proteins and 
Ligands within the “import_temp_prot_checksums” and “import_temp_lig_checksums” tables 
created in the previous step when loading the proteins and ligand data to the database. The next 
step is combining these using the “filename” column as the link. The SQL query shown in figure 3.20 
is used to create the “import_temp_dockings_md5” table. 
Table 3.12: Columns within the “summary.csv” file – 
shown are the columns that are stored within the 
“summary.csv” file which will be extracted and converted 
into a new file called “newsummary.txt”  
mysql -u (username) -p (password) < create_dockings.sql 
Figure 3.18: SQL code to upload docking data – this is the code used to upload the docking data to the MySQL 
database. 
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Figure 3.19:Example of a converted CSV file – Shown is an example of how the converted CSV file which will be used to upload the protein-ligand docking data to the MySQL database. 
CREATE TABLE import_temp_docking_md5 AS ( 
SELECT Conformation, Enumeration, Score, results_file, import_temp_lig_checksums.md5 AS lig_md5, import_temp_prot_checksums.md5 AS prot_md5 
FROM import_temp_dockscores 
JOIN import_temp_prot_checksums 
ON import_temp_prot_checksums.filename = import_temp_dockscores.Protein 
JOIN import_temp_lig_checksums 
ON import_temp_lig_checksums.filename = import_temp_dockscores.Ligand 
WHERE 1 ); 
Figure 3.20: Command used to create the import_temp_docking_md5 table – shown is the SQL command used to create the import_temp_docking_md5 table which will import dtata from 
the import_temp_dockscores table and joining data from the import_temp_prot_checksums and import_temp_lig_checksums via the filename column. 
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The SQL command creates the table, as the example in figure 3.21 demonstrates. The “dockscores” 
table is linked with the proteins and ligands used with each docking but using the md5 checksums as 
the protein and ligand identifiers. Creating the table leads on to the next operation of the script to 
insert the data from the “import_temp_dockings” data into the Dockings table. Through the INSERT 
SQL command, the data from this table is also joined to the “import_temp_prot_checksums” and 
“import_temp_lig_checksums”. So, this means that the md5 checksums of the protein and ligands 
are used to identify with the correct scores within the Docking table instead of the file locations. The 
code used is shown in figure 3.22. 
This script uploads the data into the related columns as shown in figure 3.23, the md5 codes in the 
lig_md5 and prot_md5 are used to link with the Protein and Ligand tables at the end of the script. 
When the following data insert has completed, the next stage of the script is to insert the docking 
scores data into the “Scores” table. With the insert of this data, there is a need to link the scores to 
the docking table using the Docking ID of the records with this table. To do this the md5 checksums 
INSERT INTO Docking_Table 
(prot_md5, lig_md5, results_file) 
SELECT import_temp_prot_checksums.md5, import_temp_lig_checksums.md5, results_file 
FROM import_temp_dockings 
JOIN import_temp_prot_checksums 
ON import_temp_prot_checksums.filename = import_temp_dockings.Protein 
JOIN import_temp_lig_checksums 
ON import_temp_lig_checksums.filename = import_temp_dockings.Ligand 
WHERE 1; 
Figure 3.21: Example of the import_temp_docking_md5 table created – shown is an example of the created 
import_temp_docking_md5 after running the SQL command shown in figure 3.24 
Figure 3.22: Command used to import data into the Docking_Table – shown is the SQL code used to link the correct 
protein and ligand to the correct protein- ligand docking pairs within the Docking_Table by using the md5 checksums. 
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of both the Docking table and the temporary table “import_temp_dockings_md5” are used to link 
the docking and Scores tables together. Figure 3.24 shows the SQL insert command.  
Now within the Scores table, each record has an associated Docking_ID so that when docking is 
requested the Docking_ID of the requested docking can be used to collect all associated scores from 
the Scores table for that ID. Figure 3.25 shows an example of the table data created in the Scores 
table.  
Figure 3.23: Example of the Docking table with updated md5 checksums – shown is the updated 
Dockings_Table with the md5 checksums for the proteins and ligands which links to the Proteins 
and Ligands tables. 
INSERT INTO Scores 
(Docking_ID, Conformation, Enumeration, Score) 
SELECT Docking_Table.Docking_ID, Conformation, Enumeration, Score 
FROM import_temp_dockings_md5 
JOIN Docking_Table 
ON Docking_Table.prot_md5 = import_temp_dockings_md5.prot_md5 
AND Docking_Table.lig_md5 = import_temp_dockings_md5.lig_md5 
WHERE 1; 
Figure 3.24:Command used to insert data into the Scores table – shown is the SQL command used to upload docking 
score data into the Scores table and linking the data to the correct protein-ligand record within the Docking_Table. 
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This stage involves uploading all the essential data to the database. The final stage is now to link the 
Dockings table with the Ligands and Proteins tables. The md5 checksums within the Dockings table 
are used to verify that the correct protein and ligand index ID’s are being inputted into the correct 
records.  An UPDATE SQL command and a JOIN command is used so that the correct Index ID’s are 
updated into the table. Shown in figure 3.26 is the code used to perform the update. 
UPDATE `Docking_Table` 
JOIN Proteins on Docking_Table.prot_md5 = Proteins.md5 
SET Docking_Table.Protein_Index = Proteins.Protein_Index 
WHERE 1; 
UPDATE `Docking_Table` 
JOIN Ligands on Docking_Table.lig_md5 = Ligands.md5 
SET 
Docking_Table.Lig_Index = Ligands.Lig_Index 
WHERE 1; 
Figure 3.25: Example of data within Scores Table – shown is the Scores table after 
inserting docking scores using the SQL command shown in figure 3.24. 
Figure 3.26: Code used to update Dockings_Table – shown above is the code used to update the Dockings_Table with the 
md5 codes for the proteins and ligand pairs and their Unique ID which links the table to the Proteins and Ligands Tables. 
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An example of the final data filled table is shown in figure 3.27 which shows the Protein_Index and 
Lig_Index columns with the correct Index ID is that link to the Protein_Index and Lig_Index ID’s 
within the Proteins and Ligand Tables. The data upload process is now completed.   
3.6 Application Programming Interface (API) 
The Application Programming Interface is web-based with communication over HTTP. The API will 
allow users to be able to access the database without a need to download or install any specific 
software. The end-user only needs a web browser and an internet connection, making the database 
widely available and accessible to a wide variety of different devices. 
The Graphical User Interface (GUI) is coded using HTML and JavaScript. The background code will 
link the GUI to the SQL Database by using AJAX function calls and PHP coded files. Section 5.3 has 
the implementation and a more detailed explanation of the use of the API. 
3.7 Conclusion  
The system architecture developed can store a large amount of data produced by the docking 
predictions. The task was to create a database that could store the data relating to proteins and 
drugs and their respective 3D models, each docking pair and their respective conformation scores, 
and each predicted conformation file. There were many versions of the database structure design 
due to the relentless increase in the amount of information to be stored. As discussed in section 3.3, 
the original architecture for the database shown in figure 3.2 was overly simple and did not 
incorporate the extra information that would be required to satisfy users of the system. Basing the 
original design on only using AutoDock Vina and DOCK 6.0 results.  After revision of the original 
design, the second prototype shown in figure 3.3 had an additional table for the DOCK 6.0 results 
Figure 3.27: Image of the Docking table after the data import had completed – shown is an example of the 
complete Docking_Table after all data imports have completed. The Protein_Index and Lig_Index columns are 
now populate with the relevant ID’s for each docking pair record. 
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and new tables for data relating to the drugs within the database from the KEGG and Reactome 
databases. New columns were added to tables that already existed, for example, in the protein 
table, a column noting whether a model was created via homology modelling or protein threading.  
A third prototype of the database was developed after evaluating the second prototype database, 
which is shown in figure 3.4. As discussed in section 3.4.1, the evaluation revealed that duplicate 
information was being stored for the proteins as there could often be different models generated 
and considered for the same protein query. A decision was made to introduce a separate table that 
would only store data for one version of every individual protein and that this would be linked to the 
protein tables using the UniProt code — doing this saved storage space due to the elimination of 
duplicate data, therefore releasing more storage for future addition of richer data. Due to different 
models representing the same protein, introducing an md5 checksum column ensures that each 
protein links to the correct 3D model uploaded with it to the system. The same process applies to 
the ligand data and 3D models.  
The final change from the second prototype database was the method of storing the docking scores. 
The results produced by Shipyard 1.5’s pipeline calculates around 19 different scoring functions. 
Instead of having each row of data in the docking table having 20 columns of data each and placing 
all the scores stored in a separate scores table which is linked to the docking table using the docking 
ID index. The new table helps to increase the querying speed and leads to less scope for confusion in 
the viewing of the dockings table. 
This database is a robust architecture that was able to handle a large amount of docking data 
produced by the docking programs without any trouble and made it possible for the web-based 
interface to be used to query the broader data to obtain the specific information that the user 
requires efficiently. 
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4 Protein Modelling and Molecular docking results 
4.1 Introduction 
This chapter will discuss the process and analysis undertaken for protein modelling and molecular 
docking. The molecular docking is analysed by using the known targets and misses for the 20 most 
valuable drugs and to determine if they are identified correctly. Information about the known 
protein targets for the 20 most valuable sold drugs is stored on the DrugBank (Wishart et al., 2017) 
and TOXCAST (Sipes et al., 2013). The scores for these docking pairs were extracted from the very 
substantial amount of data created by AutoDock Vina and DOCK 6.0 and then analysed to see how 
the predicted docking performed. A baseline will be set by modelling the proteins and molecular 
docking them to the 20 most valuable sold drugs using the original pipeline with no modifications.  
4.2 Protein Modelling 
The first stage of the protein modelling process is to collect and collate the FASTA sequences for all 
proteins in the human proteome. These FASTA sequences were downloaded from the UniProt 
database (UniProt) which has 20,160 human proteome sequences. The FASTA sequences download 
consisted of one large FASTA file which contained all 20,160 FASTA sequences. As there were so 
many sequences to model, it was not possible to model 20,160 FASTA sequences simultaneously. A 
python script to split the FASTA file into seven different files which would contain sequences based 
on their number of amino acids. Shown in Table 4.1 are the 7-different sequence length categories 
applied. 
Category Number Of sequences 
500 or less 12,152 
500 – 800 4,318 
800 – 1000 1,304 
1000 – 1200 803 
1200 – 1500 652 
1500 – 2000 483 
2000 + 448 
 
Shorter sequences were uploaded first to enhance progress with the HPC Wales computing 
resources as they take less time to run than the more extended sequences. As there were a large 
number of sequences with 500 or less amino acid sequences, these were further split into batches of 
2000 and uploaded onto HPC Wales to be modelled using the homology modelling pipeline. The 
Table 4.1: Sequence length categories – the table shows all of the different categories the 20,160 FASTA sequences 
were split into for the modelling process and the amount of sequences that were in each category 
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multiple sequences in these groups could be modelled in parallel, which increased the number of 
proteins modelled at once. Shown in figure 4.1 is the process that was carried out and described in 
more detail below. Each sequence usually takes around 20 minutes each for the 3D modelling to 
complete.  
 
A Perl script was created to split the sequences into specific jobs and copy and define the relevant 
files to run the homology modelling pipeline. Within this, a CSV file was created with all the 
modelling jobs that need to be undertaken. Shown in figure 4.2 is an example of one of these CSV 
files. 
This approach is used for the job submission to the HPC node clusters. Because of the number of 
sequences, to run the jobs in parallel, a job management system was used to help distribute jobs to 
Figure 4.1: Modelling set up and process flowchart – the flowchart shows the four stages that were needed for 
the homology modelling pipeline to be run on HPC Wales. First the FASTA sequences are split into individual jobs, 
then the job management system creates job submission scripts that will be used to execute the homology 
modelling pipeline on HPC Wales. When the job management system has access to a node it the “locks off” that 
node and delegates modelling jobs to it until the time limit on that node runs out. Finally, all of the 3D models 
created are then moved to a model’s folder. 
Figure 4.2: Example of CSV job submission file – at the top of the file are the options that 
need to be determined for the job management system. These options are 
“SetEachTaskNumCores” which tell the management system how many tasks it should 
launch on each single core of the node. The “LimitEachTaskExecutionTime” tells the 
management system the time each job should not exceed and if so, will cancel that job. 
Finally, the “LimitEachTaskMemoryUsage” tells the management system how much 
memory each core should have access to. Below these options are all of the job 
command lines that will be delegated and launched to each available core. 
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each node that was being used. Without this, due to how busy HPC Wales can be in having over 500 
users, if each job was to be submitted separately, as soon as the single sequence was complete that 
node would then be given to the next user in the queue for their job. This method would mean that 
modelling the 20,160 thousand sequences would take a considerable length of time. With the 
assumption that 100 sequences are completed a day without any issues or queues with other users, 
modelling the 20,160 sequences would take ten months to complete. With the job management 
system developed by Karl Austin-Muttitt, each node that was allocated was “locked off”, and the 
management system would delegate the jobs within the CSV file to them. Using this management 
system meant that the node could be used the entire time until it reached its time limit and multiple 
sequences could be modelled one after each other on each node. When applied across several 
nodes, this sped up the modelling process dramatically. Instead of taking ten months to complete 
the modelling, this took less than half of that time. When the modelling had completed, a script 
named and copied all the 3D model files into a folder. 
Not all the sequences produced a 3D model; this is due to low homology and no template coverage. 
Of the 20,160 sequences, 9,321 produced plausible models. The 11,000 sequences that did not 
produce a model underwent modelling using the threading method by using I-TASSER. The 9,321 
sequences that did produce a model were run through PROCHECK (Laskowski et al., 1993), which 
checks that the models are of good quality and analyses the residue-by-residue geometry. Only 
models that have a score of 90%+ were used for docking against the 20 most widely used drugs. The 
9,321 homology models set contained only 49 of the 67 known targets for the top 20 drugs which 
are listed in DrugBank (Wishart et al., 2017). Therefore the remaining 18 would have to be modelled 
via protein threading. For the 49 known protein targets, there are 54 known interactions with the 
top 20 most widely prescribed drugs as there are specific proteins that interact with more than one 
drug. The files for the top 20 most widely prescribed drugs which were used for molecular docking 
were downloaded in SDF files format from the DrugBank database.  
4.3 Molecular Docking Baseline Results 
As stated previously, these results were raw data produced by AutoDock Vina and DOCK 6.0 which 
were used to assess how well the pipeline works and how accurate the algorithms were by seeing if 
they could accurately identify the known targets of each ligand being docked. The 9,321 3D models 
that predicted plausible models through the homology modelling pipeline were used for the 
molecular docking process. The homology modelling pipeline outputs the protein 3D models in a 
PDB format which neither AutoDock Vina nor DOCK 6.0 use to predict dockings. The PDB files were 
converted to the respective formats for AutoDock Vina (PDBQT) and DOCK 6.0 (MOL2). The program 
OBABEL (O'Boyle et al., 2011) was used to convert the PDB files. With the 3D protein models 
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converted to the correct file formats, they are then docked against the top 20 most widely 
prescribed drugs.  
4.3.1 Docking results using the original docking pipeline 
There are two sets of results that are investigated, those of AutoDock Vina and those of DOCK 6.0.  
4.3.1.1 AutoDock Vina Results 
AutoDock Vina only outputs a single scoring function called the binding affinity. The method that will 
be used to determine if AutoDock Vina can identify the known targets of the top 20 most widely 
prescribed drugs, a mean and standard deviation outlier method (2SD) will be applied to the binding 
affinity scores. The mean and standard deviation outlier method is applied to each ligand column 
and consists of the following calculations. For each ligand column, the total mean is calculated. The 
variance is then calculated for each ligand’s column. Finally, the standard deviation is calculated for 
the entire scores associated with each ligand. With the mean, variance and standard deviation 
calculated for each ligand, the standard deviations were then calculated for all binding affinity scores 
in the docking set. Shown in table 4.2 is an example of an excel spreadsheet that shows the results 
of the calculations. The standard deviations are calculated for each column. For example, to 
calculate the standard deviation for all the predicted scores in the ligand column “Tadalafil”, each 
docking pairs binding affinity score will firstly have the total mean of the column subtracted.  
Table 4.2: example of calculations made to the docking scores – shown is the output generated after the 2 standard 
deviation rule (2SD) was applied to the Autodock Vina affinity results of each docking pair. The example shows a sample of 
results for the Ligands Tadalafil and Tazobactam and 2SD results against 8 proteins. The 2SD rule is applied column-based, 
and if an affinity is either -2 standard deviations away or more, it is classified as an interaction (green highlight). If an 
affinity score is between -2 and -1 standard deviation away, it is then classified as a potential interaction (yellow highlight). 
 Tadalafil Tazobactam 
Mean -48.787 -44.939 
Variance 53.621 52.045 
Standard Deviation 7.323 7.214 
Dehydrogenase/reductase SDR family member 12 0.094 -0.997 
Sodium/glucose cotransporter 5 0.079 0.066 
Calcium and integrin-binding family member 4 -0.048 0.167 
Anoctamin-9 -0.095 -0.347 
Acetolactate synthase-like protein -0.414 -0.647 
Synaptonemal complex central element protein 3 1.468 1.682 
Peptidyl-prolyl cis-trans isomerase A-like 4G 0.08 -0.322 
Threonine--tRNA ligase 2, cytoplasmic -2.857 -1.399 
90 
 
When the mean has been subtracted from the binding affinity, the resultant number is then divided 
d by the standard deviation of the entire ligand column. This calculation will give each docking pair 
binding affinity a result of how many standard deviations the binding affinity is from the standard 
deviation of the ligand column. The following rules were applied to the calculated standard deviation 
scores; If the score is -2 or less away from the standard deviation, the docking pair is classed as an 
interaction. The second rule being if it is between -1 and -2, it is classed as a potential interaction. As 
shown in Table 4.2, the dockings that are possible interactions are highlighted in yellow and the 
dockings classed as interactions are highlighted in green.   
After the mean and standard deviation outlier method had been applied to the entire docking 
homology modelling set, the known protein targets were then extracted. Table 4.3 shows the 
predicted binding affinities standard deviation results for AutoDock Vina. A script was developed to 
analyse the entire file of docking results that would calculate the mean, variance, and standard 
deviation for each ligand automatically and then generates two extra columns called “Affinity is a 
hit” and “Affinity is a potential interaction” which will either have the words “TRUE” or “FALSE”. The 
docking binding affinity would be classified as a hit if there was a “TRUE” within the “Affinity is a hit” 
column. The docking binding affinity would be classified as a potential interaction if a “TRUE” was 
within the “Affinity is a potential interaction” column. If both columns have a “FALSE” within them, 
the docking pair would be classified as a miss. The baseline results for AutoDock Vina shown in table 
4.3 were not very promising. Of the 54 known protein target interactions within the homology 
modelling set, only two were classified as being a hit. 12 of the 54 known protein target interactions 
within the homology modelling set were classified as a potential interaction. This result is of very low 
accuracy as only 3.7% of the known protein target interactions were being classified correctly as a 
hit. 
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Table 4.3: AutoDock Vina Results from preliminary docking –the table shows the results of the known targets for the top 20 
drugs and indicates if the docking pair is classified as and interaction or potential interaction. Of the 54 known interactions, 
two were classified as interactions and 18 were classified as potential interactions. 
Ligand Protein Affinity SD Affinity is a hit Affinity is a Potential 
Interaction 
LENALIDOMIDE Q96SW2_HUMAN_CRBN 0.0338076 FALSE FALSE 
LENALIDOMIDE P33151_HUMAN_CADH5 1.1242816 FALSE FALSE 
LENALIDOMIDE P35354_HUMAN_PGH2 -0.560996 FALSE FALSE 
LENALIDOMIDE O14788_HUMAN_TNF11 -0.16446 FALSE FALSE 
FLUTICASONE PROPIONATE P04150_HUMAN_GCR -1.021302 FALSE TRUE 
FLUTICASONE PROPIONATE P06401_HUMAN_PRGR -0.067525 FALSE FALSE 
FLUTICASONE PROPIONATE P47712_HUMAN_PA24A -1.108009 FALSE TRUE 
IMATINIB P00519_HUMAN_ABL1 -0.859543 FALSE FALSE 
IMATINIB P09619_HUMAN_PGFRB -0.94922 FALSE FALSE 
IMATINIB P16234_HUMAN_PGFRA -0.94922 FALSE FALSE 
TADALAFIL O76074_HUMAN_PDE5A -1.228432 FALSE TRUE 
EZETIMIBE Q9UHC9_HUMAN_NPCL1 -0.813683 FALSE FALSE 
EZETIMIBE P15144_HUMAN_AMPN -0.900076 FALSE FALSE 
FORMOTEROL P07550_HUMAN_ADRB2 -1.441168 FALSE TRUE 
GABAPENTIN Q05586_HUMAN_NMDZ1 -1.72506 FALSE TRUE 
GABAPENTIN Q12879_HUMAN_NMDE1 0.6783725 FALSE FALSE 
GABAPENTIN Q13224_HUMAN_NMDE2 -0.713088 FALSE FALSE 
GABAPENTIN Q14957_HUMAN_NMDE3 -1.472067 FALSE TRUE 
GABAPENTIN O60391_HUMAN_NMD3B -0.586592 FALSE FALSE 
GABAPENTIN P30542_HUMAN_AA1R -0.333599 FALSE FALSE 
GABAPENTIN O15399_HUMAN_NMDE4 -1.345571 FALSE TRUE 
LEVETIRACETAM Q7L0J3_HUMAN_SV2A -2.608714 TRUE FALSE 
BUDESONIDE P04150_HUMAN_GCR -0.831187 FALSE FALSE 
ARIPIPRAZOLE P08172_HUMAN_ACM2 -0.903412 FALSE FALSE 
ARIPIPRAZOLE P08173_HUMAN_ACM4 -0.223935 FALSE FALSE 
ARIPIPRAZOLE P08908_HUMAN_5HT1A -0.733543 FALSE FALSE 
ARIPIPRAZOLE P08912_HUMAN_ACM5 0.6254114 FALSE FALSE 
ARIPIPRAZOLE P11229_HUMAN_ACM1 -1.24315 FALSE TRUE 
ARIPIPRAZOLE P14416_HUMAN_DRD2 -1.837693 FALSE TRUE 
ARIPIPRAZOLE P18089_HUMAN_ADA2B -1.41302 FALSE TRUE 
ARIPIPRAZOLE P18825_HUMAN_ADA2C -0.393804 FALSE FALSE 
ARIPIPRAZOLE P20309_HUMAN_ACM3 -0.903412 FALSE FALSE 
ARIPIPRAZOLE P21728_HUMAN_DRD1 -1.158216 FALSE TRUE 
ARIPIPRAZOLE P21917_HUMAN_DRD4 -1.41302 FALSE TRUE 
ARIPIPRAZOLE P21918_HUMAN_DRD5 -0.054066 FALSE FALSE 
ARIPIPRAZOLE P28221_HUMAN_5HT1D -1.41302 FALSE TRUE 
ARIPIPRAZOLE P28222_HUMAN_5HT1B -0.988347 FALSE FALSE 
ARIPIPRAZOLE P28223_HUMAN_5HT2A -0.733543 FALSE FALSE 
ARIPIPRAZOLE P28335_HUMAN_5HT2C -0.903412 FALSE FALSE 
ARIPIPRAZOLE P28566_HUMAN_5HT1E -0.478739 FALSE FALSE 
ARIPIPRAZOLE P34969_HUMAN_5HT7R 0.2856728 FALSE FALSE 
ARIPIPRAZOLE P35348_HUMAN_ADA1A -1.073281 FALSE TRUE 
ARIPIPRAZOLE P35367_HUMAN_HRH1 0.2007382 FALSE FALSE 
ARIPIPRAZOLE P35368_HUMAN_ADA1B -0.563673 FALSE FALSE 
ARIPIPRAZOLE P50406_HUMAN_5HT6R -1.497954 FALSE TRUE 
SITAGLIPTIN P27487_HUMAN_DPP4 -1.079737 FALSE TRUE 
TIOTROPIUM P08172_HUMAN_ACM2 -0.520533 FALSE FALSE 
TIOTROPIUM P11229_HUMAN_ACM1 -1.57036 FALSE TRUE 
TIOTROPIUM P20309_HUMAN_ACM3 -0.940464 FALSE FALSE 
SOLIFENACIN P08172_HUMAN_ACM2 -1.228106 FALSE TRUE 
SOLIFENACIN P08173_HUMAN_ACM4 -0.851307 FALSE FALSE 
SOLIFENACIN P08912_HUMAN_ACM5 -0.323788 FALSE FALSE 
SOLIFENACIN P11229_HUMAN_ACM1 -1.755625 FALSE TRUE 
SOLIFENACIN P20309_HUMAN_ACM3 -2.057064 TRUE FALSE 
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4.3.1.2 DOCK 6.0 results 
Ligand Protein Affinity SD Affinity 
is a hit 
Affinity is a 
potential 
Interaction 
LENALIDOMIDE Q96SW2_HUMAN_CRBN -0.381899 FALSE FALSE 
LENALIDOMIDE P33151_HUMAN_CADH5 1.058491 FALSE FALSE 
LENALIDOMIDE P35354_HUMAN_PGH2 -0.805543 FALSE FALSE 
LENALIDOMIDE O14788_HUMAN_TNF11 0.182153 FALSE FALSE 
FLUTICASONE PROPIONATE P04150_HUMAN_GCR -1.221498 FALSE TRUE 
FLUTICASONE PROPIONATE P06401_HUMAN_PRGR 0.6006648 FALSE FALSE 
FLUTICASONE PROPIONATE P47712_HUMAN_PA24A -0.358854 FALSE FALSE 
IMATINIB P00519_HUMAN_ABL1 -0.990565 FALSE FALSE 
IMATINIB P09619_HUMAN_PGFRB -0.75223 FALSE FALSE 
IMATINIB P16234_HUMAN_PGFRA -0.016082 FALSE FALSE 
TADALAFIL Q9HCR9_HUMAN_PDE11 -0.548684 FALSE FALSE 
TADALAFIL O76074_HUMAN_PDE5A -1.823438 FALSE TRUE 
EZETIMIBE Q9UHC9_HUMAN_NPCL1 -0.762048 FALSE FALSE 
EZETIMIBE P15144_HUMAN_AMPN -1.187156 FALSE TRUE 
FORMOTEROL P07550_HUMAN_ADRB2 -0.686749 FALSE FALSE 
GABAPENTIN Q05586_HUMAN_NMDZ1 -0.862706 FALSE FALSE 
GABAPENTIN Q12879_HUMAN_NMDE1 -1.228385 FALSE TRUE 
GABAPENTIN Q13224_HUMAN_NMDE2 0.243769 FALSE FALSE 
GABAPENTIN Q14957_HUMAN_NMDE3 0.0833419 FALSE FALSE 
GABAPENTIN O60391_HUMAN_NMD3B -0.905172 FALSE FALSE 
GABAPENTIN P30542_HUMAN_AA1R 1.3148556 FALSE FALSE 
GABAPENTIN O15399_HUMAN_NMDE4 -1.398249 FALSE TRUE 
DB01076 P04035_HUMAN_HMDH 0.1516774 FALSE FALSE 
LEVETIRACETAM Q7L0J3_HUMAN_SV2A -1.70653 FALSE TRUE 
BUDESONIDE P04150_HUMAN_GCR -1.065434 FALSE TRUE 
ARIPIPRAZOLE P08172_HUMAN_ACM2 -0.581759 FALSE FALSE 
ARIPIPRAZOLE P08173_HUMAN_ACM4 0.0747974 FALSE FALSE 
ARIPIPRAZOLE P08908_HUMAN_5HT1A -2.080225 TRUE FALSE 
ARIPIPRAZOLE P08912_HUMAN_ACM5 0.4566719 FALSE FALSE 
ARIPIPRAZOLE P11229_HUMAN_ACM1 -0.684485 FALSE FALSE 
ARIPIPRAZOLE P14416_HUMAN_DRD2 -1.789911 FALSE TRUE 
ARIPIPRAZOLE P18089_HUMAN_ADA2B 0.0323669 FALSE FALSE 
ARIPIPRAZOLE P18825_HUMAN_ADA2C -0.680019 FALSE FALSE 
ARIPIPRAZOLE P20309_HUMAN_ACM3 -2.292377 TRUE FALSE 
ARIPIPRAZOLE P21728_HUMAN_DRD1 -1.591158 FALSE TRUE 
ARIPIPRAZOLE P21917_HUMAN_DRD4 -1.611256 FALSE TRUE 
ARIPIPRAZOLE P21918_HUMAN_DRD5 0.0524656 FALSE FALSE 
ARIPIPRAZOLE P28221_HUMAN_5HT1D -1.856907 FALSE TRUE 
ARIPIPRAZOLE P28222_HUMAN_5HT1B -0.782745 FALSE FALSE 
ARIPIPRAZOLE P28223_HUMAN_5HT2A -0.776046 FALSE FALSE 
ARIPIPRAZOLE P28335_HUMAN_5HT2C 0.2556853 FALSE FALSE 
ARIPIPRAZOLE P28566_HUMAN_5HT1E 0.4790037 FALSE FALSE 
ARIPIPRAZOLE P34969_HUMAN_5HT7R -0.088225 FALSE FALSE 
ARIPIPRAZOLE P35348_HUMAN_ADA1A -0.293678 FALSE FALSE 
ARIPIPRAZOLE P35367_HUMAN_HRH1 -0.432135 FALSE FALSE 
ARIPIPRAZOLE P35368_HUMAN_ADA1B 0.409775 FALSE FALSE 
ARIPIPRAZOLE P50406_HUMAN_5HT6R -0.930135 FALSE FALSE 
SITAGLIPTIN P27487_HUMAN_DPP4 -0.968113 FALSE FALSE 
TIOTROPIUM P08172_HUMAN_ACM2 0.5587708 FALSE FALSE 
TIOTROPIUM P11229_HUMAN_ACM1 -1.047007 FALSE TRUE 
TIOTROPIUM P20309_HUMAN_ACM3 0.1487851 FALSE FALSE 
Table 4.4: Figure 15: DOCK 6.0 Results from preliminary docking - the table shows the results of the known targets 
for the top 20 drugs and indicates if the docking pair is classified as and interaction or potential interaction. Of the 
54 known interactions, two were classified as interactions and 18 were classified as potential interactions. 
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The same mean and standard deviation outlier method was applied to the predicted DOCK 6.0 
results. The analysing script used on the AutoDock Vina results was also used for the DOCK 6.0 
results to apply the mean and standard deviation outlier method. Shown in table 4.4 are the 
predicted binding affinities standard deviation results for DOCK 6.0. Like the AutoDock Vina results, 
DOCK 6.0 has not predicted promising results as it as well has only predicted 2 of the 54 known 
protein interactions in the homology modelling set as hits. It has also categorised 11 of the 54 known 
protein target interactions as potential interactions. Questions were subsequently raised regarding 
the poor predictive performance, which led to a review of the modelling and molecular docking 
approaches. 
4.4 An investigation into the poor predictive performance of Molecular docking 
The review began by investigating the quality of the generated 3D models by the homology 
modelling. To analyse the created homology modelled 3D protein, the models created for the 49 
known protein targets within the homology set were analysed.  
4.4.1 Analysis of the 49 Known protein targets homology models 
When investigating the homology 3D models for the 49 known protein targets, it was clear to see 
that the models were not of the highest quality. The quality of modelling was due to inadequate 
homologue coverage to model the protein structures. Of the 49 known protein targets, ten had poor 
quality models predicted. The inadequate homologue coverage of the 3D protein models could be 
the cause for such a poor docking performance by AutoDock Vina and DOCK 6.0.  
This analysis then raised another question, “could more models within the homology modelling set 
be of poor quality, causing the poor docking performance?”. It would be an unrealistic task to 
analyse each protein model’s quality by hand, which led to the development of a python script that 
automated the process. The python script is dependent on a program called DSSP (Touw et al., 2014) 
to determine the homologue coverage of a 3D protein model. DSSP is used to assign secondary 
structure to 3D protein models by using a vast database of structure assignment for all proteins 
stored in the Protein Data Bank (Burley et al., 2018). Within the development model analysis script, 
DSSP was run against each 3D protein model file of the homology set which created a dssp file for 
each. Shown in figure 4.3 is an example of a dssp file that was created for each 3D protein model file. 
With the created dssp file, it is then possible to calculate the percentage of coverage of each 
homology model. The developed model analysis script uses a column within the dssp file called 
“structure” to calculate the percentage. This column contains information detailing which amino 
acids have an associated secondary structure. If the column contains an “S+”, it signifies that the 
corresponding amino acid has a known structure. By using the length of the FASTA sequence and the 
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amount of “S+” symbols contained in the “structure” column of the dssp file, it is possible to 
calculate the percentage of structure coverage.  
4.4.2 Model analysis for the homology modelling set 
Shown in figure 4.4 is the result of the structure quality of the 9,321 homology models after applying 
the developed model analysis script. Figure 4.4 shows that only 3,420 of the 9,321 homology models 
had a structured coverage of 80% and above. Out of the 49 known protein targets within the set, 
only 19 were in this bracket. The results in figure 4.4 have determined that 5,901 3D protein models 
have less than 80% structure coverage.  
This outcome could be the cause of why the molecular docking programs have poorly performed as 
there is potential for a drug to be docked in an incorrect location, which can cause false-positive and 
false-negative results. To discover if the 3D protein models caused the poor docking performance 
only the scores for the 3,420 models with 80% and above structure coverage were further analysed.  
4.4.2.1 Analysis of the 80%+ structures coverage homology models 
The predicted binding scores for the 3,420 high-quality homology models were extracted from the 
excel file created initially. The same mean and standard deviation outlier method was applied to the 
results of AutoDock Vina and DOCK 6.0, as discussed in section 4.3.1.1.  
Figure 4.3: DSSP file example – the example shows the type of information that the DSSP program adds 
to a protein PDB file. DSSP adds additional information such as hydrogen bonds. 
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AutoDock Vina results 
Shown in table 4.5 are the extracted AutoDock Vina results for the high-quality homology models. 
Only 17 of the 49 known targets were included in the high-quality homology model set. The results 
surprisingly deteriorated further, not predicting any of the targets in the set as a hit and identifying 
only 6 of them were classified as potential interaction. Neither of the two known interactions that 
were previously predicted correctly was within the extracted set.  
DOCK 6.0 results 
Shown in table 4.6 are the extracted DOCK 6.0 results for the high-quality homology models. The 
shown results in table 5 are not qualitatively any different for predicting the known interactions. Like 
the AutoDock Vina results, none of the known interactions was strongly predicted as a hit, though  
Figure 4.4:Structual coverage of the 9,321 homology models – the graph shows the different 
percentage groups of structural coverage and how many of the 9,321 homology models were classified 
in each group. 
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seven were identified as potential interactions, still a very disappointing performance regarding 
Ligand Protein 
Affinity 
SD 
Affinity 
is a hit 
Affinity is 
a potential 
interaction 
LENALIDOMIDE Q96SW2_HUMAN_CRBN 0.299 FALSE FALSE 
LENALIDOMIDE P35354_HUMAN_PGH2 -0.375 FALSE FALSE 
FLUTICASONE 
PROPIONATE P47712_HUMAN_PA24A -0.937 FALSE FALSE 
EZETIMIBE P15144_HUMAN_AMPN -0.694 FALSE FALSE 
FORMOTEROL P07550_HUMAN_ADRB2 -1.327 FALSE TRUE 
ARIPIPRAZOLE P14416_HUMAN_DRD2 -1.711 FALSE TRUE 
ARIPIPRAZOLE P28221_HUMAN_5HT1D -1.253 FALSE TRUE 
ARIPIPRAZOLE P18825_HUMAN_ADA2C -0.156 FALSE FALSE 
ARIPIPRAZOLE P35367_HUMAN_HRH1 0.483 FALSE FALSE 
ARIPIPRAZOLE P18089_HUMAN_ADA2B -1.253 FALSE TRUE 
ARIPIPRAZOLE P28222_HUMAN_5HT1B -0.796 FALSE FALSE 
ARIPIPRAZOLE P08908_HUMAN_5HT1A -0.522 FALSE FALSE 
ARIPIPRAZOLE P28335_HUMAN_5HT2C -0.705 FALSE FALSE 
ARIPIPRAZOLE P21917_HUMAN_DRD4 -1.253 FALSE TRUE 
ARIPIPRAZOLE P28566_HUMAN_5HT1E -0.248 FALSE FALSE 
ARIPIPRAZOLE P08172_HUMAN_ACM2 -0.705 FALSE FALSE 
SITAGLIPTIN P27487_HUMAN_DPP4 -0.892 FALSE FALSE 
TIOTROPIUM P08172_HUMAN_ACM2 -0.306 FALSE FALSE 
SOLIFENACIN P08172_HUMAN_ACM2 -1.012 FALSE TRUE 
Ligand Protein 
Affinity 
SD 
Affinity 
is a hit 
Affinity is 
a potential 
interaction 
LENALIDOMIDE Q96SW2_HUMAN_CRBN -1.000 FALSE TRUE 
LENALIDOMIDE P35354_HUMAN_PGH2 1.035 FALSE FALSE 
FLUTICASONE 
PROPIONATE P47712_HUMAN_PA24A 1.01 FALSE FALSE 
EZETIMIBE P15144_HUMAN_AMPN 1.035 FALSE FALSE 
FORMOTEROL P07550_HUMAN_ADRB2 1.036 FALSE FALSE 
ARIPIPRAZOLE P14416_HUMAN_DRD2 -1.329 FALSE TRUE 
ARIPIPRAZOLE P28221_HUMAN_5HT1D -1.345 FALSE TRUE 
ARIPIPRAZOLE P18825_HUMAN_ADA2C -1.057 FALSE TRUE 
ARIPIPRAZOLE P35367_HUMAN_HRH1 -0.996 FALSE FALSE 
ARIPIPRAZOLE P18089_HUMAN_ADA2B -0.883 FALSE FALSE 
ARIPIPRAZOLE P28222_HUMAN_5HT1B -1.082 FALSE TRUE 
ARIPIPRAZOLE P08908_HUMAN_5HT1A -1.4 FALSE TRUE 
ARIPIPRAZOLE P28335_HUMAN_5HT2C -0.828 FALSE FALSE 
ARIPIPRAZOLE P21917_HUMAN_DRD4 1.035 FALSE FALSE 
ARIPIPRAZOLE P28566_HUMAN_5HT1E 1.035 FALSE FALSE 
ARIPIPRAZOLE P08172_HUMAN_ACM2 1.035 FALSE FALSE 
SITAGLIPTIN P27487_HUMAN_DPP4 -1.128 FALSE TRUE 
TIOTROPIUM P08172_HUMAN_ACM2 1.027 FALSE FALSE 
Table 4.5: AutoDock Vina results for the 3,420 high-quality models – the table shows the results for the 
known target interactions that were within the high structural coverage. the results show that none of the 
known targets were classified as interaction and 6 of them were classified as potential interactions. 
Table 4.6: DOCK 6.0 results for the 3,420 high-quality models - the table shows the results for 
the known target interactions that were within the high structural coverage. the results show 
that none of the known targets were classified as interaction and 7 of them were classified as 
potential interactions. 
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predicting known interactions.  
Conclusion of the High-quality homology model set results 
The results that have been analysed for the high-quality homology model set have determined that 
the binding affinity scoring function together with the mean and standard deviation outlier method 
could not identify the known target interactions of the vast amount of data. After firstly investigating 
the quality of the protein models, it was discovered that only 36.7% had structure coverage of 80% 
or above. This finding indicated that the models could be the cause for the poor docking 
performance. This presumption was then disproved after analysing the results data for the 3,420 
high-quality proteins as it failed to rank any of the known interactions as hits. The result leads to the 
conclusion that attempting to predict a known interaction using only the binding affinity scoring 
function does not work. After this conclusion, to try and develop a method to determine known 
interaction with a higher level of accuracy, new scoring functions will be obtained for all docking 
results.  
4.5 Development of higher-accuracy molecular docking 
The baseline results were gained early in the project (2013), so it was necessary to re-model the 
sequences in 2017 following updating the pipeline databases such as the UniProt and PDB database 
(September 2017), which is continually updated with new template structures.  
4.5.1 New molecular docking pipeline 
Following examination of the baseline results, it was decided to revise aspects of the molecular 
docking approaches. A new molecular docking pipeline will be used to dock the newly homology 
modelled proteins against the top 20 most valuable sold drugs. The pipeline called Shipyard 1.5, 
developed by Karl Austin-Muttitt was used for the molecular docking. Shipyard 1.5 is discussed 
further in section 2.3.4. A new addition to the pipeline is the ability to identify possible protein 
docking sites. In the baseline homology docking work; there was no defined search space applied in 
use of either AutoDock Vina or DOCK 6.0 algorithms. The default search space given is effectively a 
3D grid that covers the entire protein model surface, but this could lead to ligands being docked in 
incorrect positions, which would not be biologically plausible in real life. For many functionally 
essential proteins, the active site has been characterised, and this information is available on the 
UniProt database (UniProt Consortium, 2018). Not all active sites are fully determined, though, so 
for the next round of dockings, a program called DogSite (Volkamer et al., 2012) is employed to 
determine possible active sites. DogSite is a program that can calculate/predict the location of where 
a protein models’ active site is located. Using this program, it is possible to reduce in a fully 
automated way the search space considered by the docking algorithms, which should improve 
accuracy and also speed up each docking process. Shown in figure 4.5 is an example of the search 
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space of a protein without applying DogSite and shown in figure 4.6 is an example of the search 
space adopted after applying DogSite. As shown, it dramatically lowers the search space used to 
attempt to calculate a docking. This method can potentially increase the accuracy of the dockings as 
only the large active sites are being considered for the positioning of the ligand and better-quality 
dockings will result from the focusing of search space.  
Another addition to the molecular docking pipeline is new scoring functions. These added scores 
that were produced by the Shipyard docking pipeline are GBSA (Generalised Born with solvent-
accessible Surface Area) (Genheden and Ryde, 2015) and Drug Score X (DSX). The GBSA scoring 
function is a more in-depth physics-based function that attempts to account for solvation effects. 
Drug Score X(DSX) is a machine learning knowledge-based scoring function which attempts to model 
Figure 4.5: Image of docking search space without DogSite applied - shown is an example of an all the 
potential sites that Autodock Vina and DOCK 6.0 would attempt to dock a ligand too. Each colour of 
bundle spheres represents a different potential active site. 
Figure 4.6:Image of docking search space after DogSite being applied - shown is an example of 
an output of DogSite’s potential active site search which would then be inputted as a search 
areas for AutoDock Vina and DOCK 6.0 would attempt to dock a ligand. Each colour of bundle 
spheres represents a different potential active site. 
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the overall binding energy. Both of these new scoring methodologies produce multiple different 
scoring functions. The scoring functions shown in Table 2.1 were applied to the newly homology 
modelled protein. These scoring functions will also further help to determine if there is an 
interaction between the ligand and the protein.  
4.5.2 Updated Homology Protein models 
All sequences that were previously modelled were re-modelled using the same homology modelling 
pipeline but with updated BLAST databases (September 2017) and updated Protein Data Bank 
database (September 2017). As these databases are updated regularly, it could make a difference in 
the quality of each model and could increase the number of models that have 80% or above 
structural content (2013). Shown in figure 4.7 is a graph that shows the new homology modelling 
coverage of the whole proteome set (2017). Overall, 16,806 of the 20,386 sequences modelled have 
generated a model. The number of created models is an increase of 7,000 models compared to the 
original run in 2013. The result provides more evidence that homology modelling is improving all the 
time as more and more protein structures are being added to the PDB database from structural 
determination studies, leading to greater availability of more suitable templates for homology 
modelling. In the baseline homology model set results, only 17 of the 67 known protein targets were 
within the top bracket of structural coverage of 80% or more. In the new homology modelling set, 20 
of the 67 known protein targets are within the top bracket of structure coverage. Figure 4.7 shows 
that the number of good models generated has increased from the previous 3,420 in the original set 
(2013) to 6,653 good models in the new set (2017).  
Figure 4.5: Homologue coverage of 2017 re-modelled proteins – the graph shows the different 
percentage groups of structural coverage and how many of the 16,806 homology models were 
classified in each group. 
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4.5.3 New homology modelling set molecular docking results 
The new set of 6,653 high-quality homology models, from the 16,806 new homology models were 
then docked against the top 20 ligands using the same method and scoring functions. For the 
following results, only the affinity scoring functions for each docking scoring method (Vina, DOCK, 
GBSA, DrugScore X) will be analysed. The reason being that these are the primary scoring function 
for determining if a protein-ligand docking has had an interaction. For the new results, the overall 
score rule applied to the docking data is  If any of the affinity “hit” columns have a TRUE within it, 
then the overall meta-score will equal TRUE and If any of the affinity “med” columns have a TRUE 
within it, then the overall meta-score will equal TRUE. Figure 4.9 shows the predicted TRUE’s and 
FALSE’s for the “hit” scoring function columns for Shipyard’s predicted scores for the new homology 
model set (2017). The rules applied to the docking scoring function for the “hit” column were if a 
docking pairs score is -2 or more standard deviations away from the mean, then the scoring function 
classifies the docking pair as a TRUE. Figure 4.10 shows the predicted TRUE’s and FALSE’s for the 
“med” scoring function columns for Shipyard’s predicted scores for the new homology model set 
(2017). The rules applied to the docking scoring function for the “med” column were if a docking 
pairs score is between -1 and -2 standard deviations away from the mean, then the scoring function 
classifies the docking pair as a TRUE. The table used to generate figure 4.9 and 4.10 is shown in the 
Appendix Table 8.2 and 8.3. 
The DOCK 6.0 Affinity hit scoring function predicted 2 of the 23 known protein interactions as a hit 
and these being the same ones that previously were predicted correctly in the original 3,420 high-
quality homology models set. The DOCK 6.0 med predicted Six of the 23 known targets as a potential 
interaction. These DOCK affinity hit results were an improvement from the previous 3,420 high-
quality homology model set as DOCK did not predict any of the known protein interactions as a hit. 
The new AutoDock Vina hit scoring function  predicted 3 of the 23 known protein interactions as hits 
The AutoDock Vina med scoring function predicted 6 of the 20 known targets as a potential 
interaction. The AutoDock Vina affinity hit results were also an improvement on the previous 3,420 
high-quality homology model set, where the AutoDock Vina hit scoring function did not predict any 
of the known targets as a hit. The GBSA Affinity hit scoring function predicted 1 of the 23 known 
targets as a hit. The GBSA Affinity med scoring function predicted six of the 23 known targets as a 
potential interaction. As the GBSA affinity hit scoring function is a new scoring function added, there 
was no previous data to compare it. Finally, the Drug Score X hit scoring function predicted none of 
the known targets as a hit.  The Drug Score X med scoring function predicted 6 of 23 known targets 
as potential interactions. As the DSX affinity score is a new scoring function added, there is no 
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previous data to compare it to, but it has performed poorly compared to the other three scoring 
functions being analysed. 
The next columns of the docking scores shown in figure 4.9 are the Meta-score-hit. Using the rule 
applied, 4 of the 23 known targets were predicted as a hit. The last column shown in figure 4.10 is 
the meta-score-med. Using the same rule as applied previously, 13 of the 23 known targets were 
predicted as potential interactions. These results are an improvement compared to the baseline 
high-quality homology model set results as neither AutoDock Vina or DOCK 6.0 binding affinity 
4.5.3.1 scores classified any of the known protein interactions as hits. Overall there had been a slight 
improvement to the results with the new homology models (2017) that were created using the 
homology modelling pipeline but not nearly as much as had been hoped. The next step was to 
investigate if the docking algorithms were correctly predicting known misses of each of the ligands, 
that is to investigate whether the algorithms are producing false positives for proteins that are 
known to not interact with ligands. 
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Figure 4.6: the “hit” result for the Scores produced by Shipyard for the known protein interactions using the new homology modelling set 
(2017) – shown in the graph are hit  results for the analysed scoring functions produced by Shipyard 1.5. the graph displays the number of 
TRUE’s and FALSE’s every scoring function predicted by following the rule of the docking pair score being between -1 and -2 standard 
deviations from the mean. The meta-score med scoring function follows a different rule of If any of the affinity “hit” rule results have a 
TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in Appendix Table 8.1. 
Figure 4.7: the med result for the scores produced by Shipyard for the known protein interactions using the new homology modelling set 
(2017) – shown in the graph are med  results for the analysed scoring functions produced by Shipyard 1.5. the graph displays the number of 
TRUE’s and FALSE’s every scoring function predicted by following the rule of the docking pair score being between -1and -2 standard 
deviations from the mean. The meta-score med scoring function follows a different rule of If any of the affinity “med” rule results have a 
TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in Appendix Table 8.2.
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4.5.3.1 Known protein misses for the top 20 most valuable sold drugs 
As well as known interactions confirmed by in vitro work, each of the top 20 most valuable sold 
drugs also has known misses which have been stored in databases such as DrugBank (Wishart et al., 
2017) and ToxCast (Sipes et al., 2013). Known misses are ligands that have been tested against these 
proteins in vitro and have provided a non-interaction. With this information, it is possible to extract 
the relevant protein-ligand data from the docking data for comparison. The same rule that has been 
applied to the known protein interaction results previously in section 4.3.1.1 will also be applied to 
the known protein misses’ results. Shown in figure 4.11 are hit results and shown in figure 4.12 are 
the med results for the known misses that have had dockings performed for their respective ligands. 
Only 9 of the known misses were included in the 6,653 set, but 7 of these were for the same protein, 
namely Nuclear factor NF-kappa-B p105 subunit. With the Dock Affinity hit score scoring function, 8 
of the known misses were correctly classified as FALSE. The docking pair that gave a false positive 
result was the ligand Imatinib (PubChem ID: 5291) against the protein Nuclear factor NF-kappa-B 
p105 subunit (UniProt code: P19838). For the Dock Affinity med score, It classified 3 of the 9 known 
non-interactions as a TRUE. The Dock affinity result only predicting one as a hit overall. AutoDock 
Vina Affinity hit score classified 2 of the 9 known non-interactions as TRUE. The AutoDock Affinity 
med score classified 1 of the 9 non-interactions as a potential interaction. The predicted hits were 
Imatinib/ Nuclear factor NF-kappa-B p105 subunit docking (same as the Dock algorithm) but with the 
addition of the Lenalidomide (PubChem ID: 216326) and Nuclear factor NF-kappa-B p105 subunit 
(UniProt code: P19838) docking.  The GBSA Affinity hit score predicted 1 of the 9 known non-
interactions as TRUE. The GBSA Affinity med score predicted two of the 9 as a potential interaction. 
The docking that had predicted as a hit is the same conformation as AutoDock Vina results predicted 
(Lenalidomide/ Nuclear factor NF-kappa-B p105 subunit). Finally, Drug Score X hit scores predicted 2 
of the 9 known non-interactions as TRUE, and the Drug Score X med score predicted three of the 9 
as potential interactions. One of these dockings predicted as a hit is the Lenalidomide/ Nuclear 
factor NF-kappa-B p105 subunit docking which has consistently been predicted as a hit with 3 of the 
4 scoring functions, the other being the Levothyroxine (PubChem ID: 5819) against the protein 
Transforming growth factor beta-1 (UniProt: P01137) which was the first time this pair had been 
flagged as a hit. Overall the meta-score hit column shown in figure 4.11 predicted 3 of the nine 
known misses as a hit. To possibly discover the reason for the three false positives, the predicted 
dockings were examined to check for any anomalies more closely. The Meta-score med column 
shown in figure 4.12 predicted 5 of the 9 known non-interactions as a potential interaction.  
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Figure 4.8: the hit result for the Scores produced by Shipyard for the known protein non-interactions using the new homology modelling 
set (2017) – shown in the graph are hit results for the analysed scoring functions produced by Shipyard 1.5. the graph displays the number 
of TRUE’s and FALSE’s every scoring function predicted by following the rule of the docking pair score being between -1and -2 standard 
deviations from the mean. The meta-score hit scoring function follows a different rule of If any of the affinity “hit” rule results have a TRUE 
within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in Appendix Table 8.3. 
 
Figure 4.9: the med result for the Scores produced by Shipyard for the known protein non-interactions using the new 
homology modelling set (2017) – shown in the graph are med results for the analysed scoring functions produced by 
Shipyard 1.5. the graph displays the number of TRUE’s and FALSE’s every scoring function predicted by following the rule of 
the docking pair score being between -1 and -2 standard deviations from the mean. The meta-score hit scoring function 
follows a different rule of If any of the affinity “med” rule results have a TRUE within it, then the overall meta-score will 
equal TRUE. The data used to create the graph is shown in Appendix Table 8.4. 
0
1
2
3
4
5
6
7
8
9
Dock Affinity hit Vina Affinity hit GBSA Affinity hit DSX Atom distances
hit
Meta-score hit
Results of the "hit" results for the known non-interactions 
predictions for the new homology model set (2017) using 
Shipyard 1.5 
TRUE FALSE
0
1
2
3
4
5
6
7
8
9
DOCK Affinity med Vina Affinity med GBSA Affinity med DSX Atom distances
med
Meta-score med
Results of the "med" results for the known non-interactions 
predictions for the new homology model set (2017) using 
Shipyard 1.5 
TRUE FALSE
105 
 
One of the dockings that were investigated was the Lenalidomide/ Nuclear factor NF-kappa-B p105 
subunit docking as this docking was predicted to be a hit with 3 of the four scoring functions used. 
Images of the docking are shown in figures 4.13 and 4.14 where the ligand is being docked in a 
region where there is low homologue coverage which can affect the overall docking result. Low 
homologue coverage areas can affect docking as the algorithm might incorrectly regard a particular  
Figure 4.10: Docking conformation for the Lenalidomide/ Nuclear factor NF-kappa-B p105 subunit – shown is the generated 
conformation for Lenalidomide/ Nuclear factor NF-kappa-B p105 subunit where the ligand Lenalidomide has docked near a 
low homologue coverage area of the protein. 
 
Figure 4.11: Docking conformation for the Lenalidomide/ Nuclear factor NF-kappa-B p105 subunit close up – shown is a 
close up of the generated conformation for Lenalidomide/ Nuclear factor NF-kappa-B p105 subunit where the ligand 
Lenalidomide has docked near a low homologue coverage area of the protein. 
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region area as a potential docking site. The low homologue coverage area might be the reason why 
this docking is being predicted as a false positive. The analysis outcome led to the development of a 
docking analysis script. 
4.5.3.2 Development of a docking analysis script 
To investigate if drugs were docking in low homologue areas of the protein might be the cause for 
the poor docking performance, a python script was developed that could analyse each predicted 
docking conformation. This script would be able to parse through every docking conformation 
predicted through Shipyard 1.5 and remove docking results that could be classed as incorrect due to 
the ligand being docked in a location with low homologue coverage.  The script first considers each 
protein-ligand pair and calculates the distances of each residue of the protein from the ligand 
docked with it. The residues that are within 12 angstroms of the ligand are then put into a list. The 
12 angstrom threshold is based on the upper end of the range of amino acid side chain length (to 
include regions of models where the position and conformation of the backbone is computed 
accurately, but where the exact positions of the side chains may not have been computed 
accurately), added to the typical distance range of interaction applied in analysis of docking results, 
which is around 4 angstroms. This list of residues is cross-referenced with data produced by the 
DSSP program (Touw et al., 2014) to see if there is a known structure related to those residues. 
When this phase is over, a rule is then applied to the effect that if at least 75% or more of the known 
binding location has a structure, then the docking result is kept, but if not, the entire docking pair 
conformation result is discarded.
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4.5.3.3 New Homology model set (2017) after docking location analysis 
The newly formed CSV file for the new homology model set (2017) only contains the dockings that 
had good structure around the docking site. The same rules and methods that were applied to the 
new homology set (2017) before the docking location analysis was also applied to the new extracted 
homology model set.  
After the docking location analysis script had been applied to the new homology model set (2017), a 
new data file was generated. The new data consisted of 79,000 results compared to the original 
128,400 results. The outcome showed that 38.5% of all the new homology model set results had 
drugs that were docked in low homologue coverage areas of the protein. For the analysis, the known 
protein interaction data were extracted from the newly created CSV file. Shown in table 8 are the 
results for the known interactions. Shown in figure 4.15 are the hit results for the newly revised 
homology docking set, and the results turned out the same with 4 of the known protein  
 
Figure 4.12: the hit result for the Scores produced by Shipyard for the known protein targets using the new homology 
modelling set (2017) with 80%+ structural coverage after docking site analysis script – shown in the graph are hit results for 
the analysed scoring functions produced by Shipyard 1.5 after docking site analysis script. the graph displays the number of 
TRUE’s and FALSE’s every scoring function predicted by following the rule of the docking pair score being between -1 and -2 
standard deviations from the mean. The meta-score hit scoring function follows a different rule of If any of the affinity “hit” 
rule results have a TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown 
in Appendix Table 8.5. 
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Figure 4.13: the med result for the Scores produced by Shipyard for the known protein targets using the new homology 
modelling set (2017) with 80%+ structural coverage after docking site analysis script – shown in the graph are med results 
for the analysed scoring functions produced by Shipyard 1.5 after docking site analysis script. the graph displays the number 
of TRUE’s and FALSE’s every scoring function predicted by following the rule of the docking pair score being between -1 and 
-2 standard deviations from the mean. The meta-score med scoring function follows a different rule of If any of the affinity 
“med” rule results have a TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is 
shown in Appendix Table 8.6. 
targets being classified as a hit. shown in figure 4.16 are the med results for the same revised set 
which 12 of the 21 known targets remaining as a TRUE. Only 2 known protein interaction dockings 
were lost after running the docking location analysis script. As it seemed that homology models 
could be causing an issue, analysis began on the protein models that had been generated using 
protein threading. 
4.6 Proteins Modelled by Protein Threading 
To see if there is a difference in accuracy, the models generated by protein threading were put 
through the same steps as the homology modelling set. This set contained the protein models that 
could not be modelled by the homology modelling pipeline from the baseline results in section 4.4.2 
which consisted of 10,839 sequences, 5,901 protein sequences that produced homology models 
with less than 80% structural coverage, and also included the 67 known targets for the top 20 most 
valuable sold drugs. This set was used in docking against the 20 most valuable sold drugs using the 
same method as the homology modelling set.  
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4.6.1 Protein threading model quality 
The first step was to run the model structure coverage script that was run on the homology 
modelling set on the new set that had undergone protein threading. A total of 7,821 models were 
generated using protein threading. Figure 4.16 shows the results of the structure coverage check. 
Compared to the homology modelling set, nearly all models processed by the script had 80% or 
more homologue coverage with only 750 models (less than 10%) not being given a high-quality 
model status. Compared to the homology modelling set this is a much more significant percentage 
of models being given a high-quality model status, only 36.69% of the homology models were given 
good models status compared to the threaded models of which 90.35% were given good models 
status. These results are a massive improvement on the homology modelling pipeline results. Like 
the homology model’s set, only the high-quality models will be used and docked against the top 20 
most valuable sold drugs using the Shipyard 1.5 pipeline. Firstly, the known protein interactions 
were extracted from the overall set that had undergone protein threading.  
4.6.2 Known protein interaction results 
Shown in figure 4.17 are the hit column results for the extracted results for the known protein 
interactions within the set that had undergone protein threading. Like the homology modelling set 
discussed in section 4.5.3, the same methods and rules were applied to the results. The two 
standard deviation rules were only looking at the affinity scores of the four types of scoring functions 
(Vina, DOCK, GBSA, DSX). There was an increase in known target proteins within the high-quality 
Figure 4.14: Percentages of homologue coverage for the 7,821 threaded model set – shown are the numbers of 
protein models within the protein threaded sequences which were within each structural coverage percentage 
group. The majority of the models possessed 80% or more structural coverage. 
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model's bracket compared to the homology modelling set. The high-quality set that had undergone 
protein threading contained 33 of the 67 known protein interactions. The results have shown an 
increase of 19.4% of the known protein targets generating models. Looking firstly at the DOCK 
Affinity hit results, only two of the 33 known targets in the set were predicted correctly as TRUE 
these being Histamine H1 receptor (UniProt: P35367) with the ligand Aripiprazole (PubChem: 60795) 
and Dipeptidyl peptidase 4 (UniProt: P27487) and Atorvastatin (PubChem: 60823). Shown in figure 
4.18 were the med column results for the protein threaded set. The DOCK Affinity med results 
predicted 10 of the 33 known targets as a TRUE which is  a potential interaction. AutoDock Vina hit 
results predicted  2 of the 33 known targets as a TRUE, these being the Tumour necrosis factor 
ligand superfamily member 11 (Uniprot: O14788) and Lenalidomide (PubChem: 216326) pairing and 
the Synaptic vesicle glycoprotein 2A (Uniprot: Q7L0J3) and Levetiracetam (PubChem: 441341) 
pairing. The AutoDock Vina med results predicted 15 of the 33 known targets a TRUE and potential 
interaction. The GBSA affinity hit scoring function predicted 3 of the 33 known targets as TRUE’s 
these being Steroid 17-alpha-hydroxylase/17,20 lyase (UniProt: P05093) and Abiraterone (PubChem: 
132971), Cytosolic phospholipase A2 (UniProt: P47712) and Fluticasone Propionate (PubChem: 
444036), and Histamine H1 receptor (UniProt: P35367) and Aripiprazole (PubChem: 60795) which 
are shown in table “” of the Appendix. The GBSA affinity med results predicted 5 of the 33 as a 
potential interaction. 
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Figure 4.15: the hit result for the Scores produced by Shipyard for the known protein targets using the new protein 
threaded model set with 80%+ structural coverage using Shipyard 1.5 – shown in the graph are hit results for the analysed 
scoring functions produced by Shipyard 1.5 after docking site analysis script. the graph displays the number of TRUE’s and 
FALSE’s each scoring function predicted by following the rule of the docking pair score being between -1 and -2 standard 
deviations from the mean. The meta-score hit scoring function follows a different rule of If any of the affinity “hit” column s 
have a TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in the 
Appendix Table 8.7, 8.8, and 8.9. 
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Figure 4.16: the med result for the Scores produced by Shipyard for the known protein targets using the new protein 
threaded model set with 80%+ structural coverage using Shipyard 1.5 – shown in the graph are med results for the analysed 
scoring functions produced by Shipyard 1.5 after docking site analysis script. the graph displays the number of TRUE’s and 
FALSE’s every scoring function predicted by following the rule of the docking pair score being between -1 and -2 standard 
deviations from the mean. The meta-score med scoring function follows a different rule of If any of the affinity “med” rule 
results have a TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in 
Appendix Table 8.10, 8.11, and 8.12. 
The DSX Atom distances hit scoring function predicted 1 of the 33 known targets as a hit, this being 
the pairing of Cytosolic phospholipase A2 (UniProt: P47712) and Fluticasone Propionate (PubChem: 
444036). The DSX Atom distances med results predicted 8 of the 33 known targets as a potential 
interaction. 
These final two columns are the “Meta-score-hit” and “Meta-score-med” (potential interaction). The 
columns followed the same rules as previously for the homology modelling protein sets this being if 
at least one of the scoring functions have a TRUE in it, it will be classed as a TRUE overall. The 
columns with “hit” in the name will be linked to the Meta-score column and the columns with “med” 
will be linked to the Meta-score-med column. The Meta-score column predicted 6 of the known 
targets as a hit. The result is an increase of two compared with the 2017 homology modelling set. 
The Meta-score-med column predicted 21 of the 33 known targets as dockings to investigate. 
Comparing this to the 2017 homology modelling, this is an increase of 8 targets being identified as a 
potential interaction.  
4.6.3 Known Protein non-interaction results 
The known protein misses were also extracted from the set that had undergone protein threading so 
that they could also be analysed. Shown in figure 4.19 are the results for hit columns for the known 
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non-protein interactions for the set that had undergone protein threading. There were 71 known 
protein-ligand misses within the high-quality set that had undergone protein threading set, 
compared to only 9 in the 2017 homology modelling set. The number of models generated for the 
known protein misses is a substantial increase of protein-ligand interaction models for testing. A 
miss is denoted by a “FALSE” statement in the columns. The DOCK affinity hit results correctly 
predicted 67 of the 71 known non-interactions as a FALSE. The results by DOCK gave an overall 
accuracy of 94.3% for correctly classifying a known interaction correctly. Within the DOCK affinity 
“med” column (potential interaction) shown in figure 4.20, 13 of the 67 known non-interactions 
were classified as potential interactions. The Vina Affinity “hit” column, 69 of the 71 were predicted 
correctly as a miss. The Vina binding affinity has given an accuracy of 97.2% for predicting non-
interactions correctly, which is very good. For the Vina Affinity med column (potential interaction), 
18 of the 67 known non-interactions were classified as potential interactions.  
 
Figure 4.17: the hit result for the Scores produced by Shipyard for the known non-interactions predictions for the new 
protein threaded model set with 80%+ structural coverage – shown in the graph are hit results for the analysed scoring 
functions produced by Shipyard 1.5 after docking site analysis script. the graph displays the number of TRUE’s and FALSE’s 
every scoring function predicted by following the rule of the docking pair score being between -1 and -2 standard deviations 
from the mean. The meta-score hit scoring function follows a different rule of If any of the affinity “hit” rule results have a 
TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in Appendix Table 
8.13, 8.14, and 8.15. 
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Figure 4.18: the med result for the Scores produced by Shipyard for the known non-interactions predictions for the new 
protein threaded model set with 80%+ structural coverage – shown in the graph are med results for the analysed scoring 
functions produced by Shipyard 1.5 after docking site analysis script. the graph displays the number of TRUE’s and FALSE’s 
every scoring function predicted by following the rule of the docking pair score being between -1 and -2 standard deviations 
from the mean. The meta-score med scoring function follows a different rule of If any of the affinity “med” rule results have 
a TRUE within it, then the overall meta-score will equal TRUE. The data used to create the graph is shown in Appendix Table 
8.16, 8.17, and 8.18. 
The GBSA affinity hit column, 69 of the 71 were predicted correctly as a non-interaction. The GBSA 
affinity has predicted the same number of known non-interactions correctly as the Vina binding 
affinity. The GBSA affinity med results predicted 57 of the 71 known non-interactions correctly as a 
FALSE. For the DSX atom distance column, the hit column shown in figure 4.19, predicted 66 of 71 
known misses correctly, which is a 92.5% accuracy. The DSX atom distance med column predicted 16 
of the 71 known non-interactions as potential interactions. Finally, the meta-score hit (figure 4.19) 
and meta-score-med (potential interaction) (figure 4.20) columns. The same rule as was applied to 
the homology models set (2017) was applied to the high-quality set that had undergone protein 
threading. Firstly, looking at the Meta-Score hit column, 61 of the 71 known non-interactions were 
correctly classified which is an accuracy of 86%. For the meta-score-med column 31 of the 71 were 
classified as potential interactions. 
These results appear to show that overall, the set that had undergone protein threading did not 
perform better than the homology models for both the 2013 and 2017 sets. Comparing the known 
targets which overlap the 2017 homology modelling and the protein threaded sets, the accuracy had 
marginally increased with 18.2% of the known protein interactions being correctly classified 
compared to the homology modelling models set that only predicted 17.4% correctly. This is not a 
significant improvement which would indicate that one of the modelling methodologies are better 
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than the other for helping to generate higher accuracy docking conformations. From the following 
results it has determined that the method used for the analysis of both the homology model (2017) 
and the set that had undergone protein threading is not suitable to determine interactions. With this 
conclusion, another analysis method was investigated to attempt to increase docking accuracy. 
4.7 Development of a second docking results analysis method 
A new method known as Sensitivity (true positive rate) and specificity (true negative rate) was 
applied to the docking conformations generated for the 2017 homology modelling and protein 
threaded sets with the aim to improve the accuracy of the docking algorithms. These are used to 
measure the actual positives that are being correctly predicted and true misses that are correctly 
being predicted. With the collected data of both the 2017 homology modelled and protein threaded 
sets, firstly there is a need to pick the best scoring functions within the sets that are the most 
accurate in predicting the known targets and known misses correctly. To do this a Receiver operating 
characteristic curve (ROC Curve) needs to be created for each of the scoring functions separately. A 
ROC curve is a way of plotting the sensitivity tests (true positive rate) which are plotted on the y-axis 
and the specificity (false positive rate) plotted on the x-axis. The ROC method can evaluate the 
quality or performance of a diagnostic test. (Park, Goo and Jo, 2004) 
The data used to create the ROC curve were the known targets of the top 20 drugs and the known 
non-interactions for the top 20 most widely prescribed drugs. Within the protein threaded set there 
were 33 known targets and 70 known non-interaction, and within the 2017 homology modelling set, 
21 known targets and 33 known non-interaction conformations have been generated. A python 
script was created to calculate out the ROC curve and the area under the curve. Calculating the area 
under the curve helps identify the best scoring functions that predict a known target correctly as 
well as predicting known protein-ligand non-interaction correctly. Shown in table 4.5 are the Area 
Under the Curve scores given for the high-quality homology model set (2017) and in figure 4.6 shows 
the Area Under the Curve scores for the set of high-quality models which had undergone protein 
threading.  
For this analysis, the scoring functions with a result of 0.7 or higher will be used. The most accurate 
scoring functions are used for the next part of the analysis. The most accurate scoring functions for 
the high-quality homology model set are the GBSA Affinity, GBSA Solvent-accessible surface area, 
Vina Gauss 1, Vina Gauss 2, Vina Rotatable Bond entropy, and the DSX Contact count. 
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Table 4.5: Area Under the Curve Scores for high-quality homology modelling set (2017) – shown are all of the results after 
the ROC and AUC calculations. The best scoring functions were the GBSA Affinity, GBSA Solvent-accessible surface area, 
Vina Gauss 1, Vina Gauss 2, Vina Rotatable Bond entropy, and the DSX Contact count. 
Scoring Function Area Under the curve 
DOCK Affinity 0.65 
Vina Affinity 0.62 
GBSA Affinity 0.76 
DSX Atom distances 0.86 
DOCK van der Waals 0.66 
DOCK Electrostatics 0.51 
DOCK internal Energy 0.60 
GBSA van der Waals 0.65 
GBSA Screened electrostatics 0.53 
GBSA Born Solvation area 0.57 
GBSA Solvent-accessible Surface Area 0.73 
Vina Gauss 1 0.74 
Vina Gauss 2 0.78 
Vina Repulsion  0.66 
Vina Hydrophobic 0.60 
Vina H-Bond 0.54 
Vina Rotatable Bond entropy 0.74 
DSX Contact count 0.83 
DSX per contact 0.70 
 
The most accurate scoring functions for the set of high-quality models which had undergone protein 
threading are the Vina Affinity, GBSA Affinity, DSX Atom distances, Vina Gauss 1, Vina Gauss 2, and 
the DSX Contact count. Comparing the two lists of scoring functions, it seems that the scoring 
functions GBSA Affinity, Vina Gauss 1, Vina Gauss 2, and DSX Contact count are the most accurate in 
both instances. These scoring functions will now be used to do some combinational forecasting to 
see if it is possible to make a model that is more accurate to pick out known protein interactions and 
non-interactions correctly. 
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Table 4.6: Area Under the Curve Scores for a set of models which have undergone protein threading - shown are all of the 
results after the ROC, and AUC calculations for the protein threaded set. The best scoring functions were the Vina Affinity, 
GBSA Affinity, DSX Atom distances, Vina Gauss 1, Vina Gauss 2, and the DSX Contact count. 
Scoring Function Area Under the curve 
DOCK Affinity 0.68 
Vina Affinity 0.71 
GBSA Affinity 0.75 
DSX Atom distances 0.72 
DOCK van der Waals 0.68 
DOCK Electrostatics 0.56 
DOCK internal Energy 0.52 
GBSA van der Waals 0.69 
GBSA Screened electrostatics 0.59 
GBSA Born Solvation area 0.62 
GBSA Solvent-accessible Surface Area 0.65 
Vina Gauss 1 0.75 
Vina Gauss 2 0.71 
Vina Repulsion  0.54 
Vina Hydrophobic 0.68 
Vina H-Bond 0.67 
Vina Rotatable Bond entropy 0.65 
DSX Contact count 0.73 
DSX per contact 0.56 
 
4.7.1 Analysis of combinational forecasting for the high-quality homology model set 
For the high-quality homology model set selected scoring functions that have been determined as 
the most accurate, thresholds were then calculated for each. The threshold was determined by 
which score produced the most accurate predictions of targets/misses. A python script was created 
to work out the Area Under the Curve of the ROC curve for each of the scoring function. The python 
script would run through a variety of thresholds between the lowest and the highest scores within 
that scoring function to determine the best threshold. Shown in table 4.7 is the determined 
threshold that was used for each of the scoring functions. 
These scores will now be used to help predict the known targets and misses to the highest accuracy. 
For the scores in the selected threshold, if a docking pair score is less than the calculated threshold  
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for that particular scoring function, the score will be classed as true. However, if the score is higher 
than the calculated threshold for that scoring function, that score will be classed as false. The 
thresholds for each scoring function determined are used to attempt to increase the accuracy of the 
selected scores by using combinational forecasting. Combinational forecasting is a method of making 
predictions. It refers to the idea that predictions can be made from a consensus of models rather 
than just one model. In this case, the models are the scoring functions. These rules help the 
combinational forecasting determine if a docking pair is a potential interaction or a non-interaction. 
The method that combinational forecasting uses is to set criteria of how many of the scoring 
functions have to be classified as a true for the docking pair to be determined as a potential 
interaction. As the best criteria had not been identified for the combinational forecasting 
predictions, a test was carried out on every possible criterion. Shown in table 4.13 are all the 
possible criteria for the combinational forecasting and the percentages of accuracy.  
The criteria that were tested were if 1/6 of the scoring function are classified as true; the overall 
prediction is true. If 2/6 of the scoring function are classified as true, the overall prediction is true. If 
3/6 of the scoring function are classified as true, the overall prediction is true. If 4/6 of the scoring 
function are classified as true, the overall prediction is true. If 5/6 of the scoring function are 
classified as true, the overall prediction is true. If 6/6 of the scoring function are classified as true, 
the overall prediction is true. From the results shown in table 4.8, it can be determined that the 
most accurate criteria to be used for the combinational forecasting is 4/6 of the scoring results have 
to be classified as a true for the overall prediction to be classified as a potential interaction. This 
result was auspicious as it has increased the accuracy of predicting known protein interactions by 
73.1%. The prediction of known non-interactions is still low at 42.4% which means there are still 
some docking pairs that are being mispredicted.  
The result of the combinational forecasting is a very positive step to the aim of increasing the 
prediction accuracy of docking results. With an overall prediction accuracy of 66.45% with results 
that have not had docking sites analysed is a promising outcome. As it was previously proven that 
Scoring Function Threshold 
GBSA Affinity -23.9 
GBSA Solvent-accessible surface area -4.6 
Vina Gauss 1 -3 
Vina Gauss 2 -6.3 
Vina Rotatable Bond entropy 3.5 
DSX Contact count 634.4 
 
Table 4.7: Threshold scores selected for the combinational forecasting for the high-quality homology model dataset. 
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protein threading had generated more high-quality protein models than homology modelling and 
there is a bigger test set of known protein interactions and known protein non-interactions, the 
same analysis will be carried out to determine the overall accuracy of the combinational forecasting 
method. 
4.7.2 Analysis of combinational forecasting for the high-quality protein threading set 
The analysis carried out on the high-quality homology model set will now be applied to the high-
quality protein model set. The thresholds were calculated using the same method by using a ROC 
curve for each scoring function and calculate the area under the curve. Shown in Table 4.9 are the 
calculated thresholds for each selected scoring function. With the best combinational forecasting 
criteria not yet determined, the same test was carried out on all possible criteria options to 
determine the one with the highest accuracy. Shown in table 4.10 are the results for the 
combinational forecasting criteria tests. From the results, it was determined that the most accurate 
criteria to use are if 4/6 scoring functions have to be classified as true for the overall prediction to be 
classified as a potential interaction. Comparing the overall accuracy with that of the homology model 
set (2017), the set of models which had undergone protein threading combinational forecast was 
5.6% more accurate. The result that gives the highest overall accuracy is that the 4/6 criteria 
Criteria Known protein 
interactions predicted 
correctly (%) 
Known non-
interactions correctly 
predicted (%) 
Overall Accuracy (%) 
1/6 100% 0% 50% 
2/6 100% 0% 50% 
3/6 100% 0% 50% 
4/6 90.5% 42.4% 66.45% 
5/6 76.2% 51.5% 63.85% 
6/6 19% 100% 59.5% 
Scoring Function Threshold 
DSX Atom distances -98 
GBSA Affinity 34.5 
Vina Affinity -6.6 
Vina Gauss 1 -2.6 
Vina Gauss 2 732.2 
DSX Contact count -6.2 
 
Table 4.8: the table shows all the possible criteria options and their resulting prediction accuracies for the high-quality 
homology model dataset. 
Table 4.9: Threshold scores selected for the combinational forecasting for the high-quality set of models which had 
undergone protein threading. 
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successfully predicted 90.9% of the known protein targets correctly, which is similar to the homology 
modelling set’s 90.5%. 
4.7.3 Overall conclusion of the developed combinational forecasting method 
Overall this method has shown that it can be accurate for predicting known targets and predicting 
known misses correctly. These results have also shown that it seems that a set of models which had 
undergone protein threading are more likely to predict correctly than the homology modelling 
models. With an overall accuracy of 72.05%, the set of models which had undergone protein 
threading seemed to give better docking predictions than homology.  
4.7.4 Investigation of Conformations 
After examining the entire set of docking results and using the combinational forecasting to get a 
high correct predicting percentage, the next stage is to investigate the data greater in-depth to see if 
the calculated docking data produces useful data for drug discovery or to repurpose drugs. For the 
analysis, known targets were used, including panel 44 proteins. These  are looked at more closely to 
see how they have been docked and classified within the 7,066 high-quality threaded sets. Panel 44 
is a group of 44 target proteins which are used by four large pharmaceutical companies 
(AstraZeneca, GlaxoSmithKline, Novartis and Pfizer) to evaluate a drug’s potential for causing 
adverse drug events (ADR’s) (Bowes et al., 2012). Within the high-quality protein threaded set are 23 
of the panel 44 set in which 9 of these are known targets of the top 20 most valuable sold drugs 
which are listed in table 4.11. The analysis of the biological accuracy of the conformations was a 
good test to see how the combinational forecasting performs to detect known targets. 
Results were split into four sections, those being true positive predictions, True negative predictions, 
false-positive predictions, and false-negative predictions. Due to there being no score as such to 
determine how “strong” an interaction is a heuristic has been developed to solve this problem. 
Criteria Known protein 
interactions predicted 
correctly (%) 
Known protein non-
interactions predicted 
correctly (%) 
Overall Accuracy (%) 
1/6 100% 0% 50% 
2/6 100% 0% 50% 
3/6 90.9% 44.6% 67.75% 
4/6 90.9% 53.2% 72.05% 
5/6 81.8% 57.6% 69.7% 
6/6 51.5% 82.7% 67.1% 
 
Table 4.10: the table shows all the possible criteria options and their resulting prediction accuracies for the high-quality set 
that had undergone protein threading dataset. 
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Table 4.11 : table shown drug from the top 20 most widely prescribed drug and their known targets within the panel 44 set. 
 
4.7.4.1 Development of a heuristic for determining a docking predictions strength 
A heuristic indicator for predicting the strength of binding of a docked protein-ligand complex was 
developed. Each calculated docking score is represented in terms of standard deviations away from 
the mean for that scoring function. For example, the AutoDock Vina score for a protein-ligand 
complex would be -2.5 if it is 2.5 standard deviations lower than the mean for the distribution of all 
AutoDock Vina scores measured in this study. Scoring functions have natural differences in scale. For 
example, DOCK scores are typically around -60, whereas AutoDock Vina scores are typically around -
8. By converting all the scores to the same scale of "standard deviations away from the mean", such 
that they are all in the approximate range -3 to +3, it is possible to meaningfully take an average of 
them. This step enables us to create a consensus "meta-score" (a.k.a. "z-score") later. The creation 
of this meta-score is now discussed. 
Firstly, the "two standard deviation" (2SD) rule was applied to the scores as previously defined in 
section 4.3.1.1. This heuristic is worked so that if a score is better-than two standard deviations 
Protein Target Drug 
Prostaglandin G/H synthase 2 Lenalidomide 
D(1A) dopamine receptor Aripiprazole 
D(2) dopamine receptor Aripiprazole 
Muscarinic acetylcholine receptor M3 Solifenacin, 
Tiotropium 
5-hydroxytryptamine receptor 2A Aripiprazole 
5-hydroxytryptamine receptor 1A Aripiprazole 
Muscarinic acetylcholine receptor M1 Solifenacin, 
Tiotropium 
Histamine H1 receptor Aripiprazole 
Muscarinic acetylcholine receptor M2 Aripiprazole, 
Solifenacin, 
Tiotropium 
Ligand Protein Score 1 Score 1 
Combinational 
forecasting 
Score 2 Score 2 
combinational 
forecasting 
Score 3 Score 3 
combinational 
forecasting 
Meta 
score 
Overall 
Score 
Ligand-1 Protein-1 -2.01 TRUE -0.05 FALSE -3.02 TRUE TRUE -5.03 
Ligand-1 Protein-2 -0.02 FALSE 0.1 FALSE -2.01 TRUE FALSE 0.08 
Ligand-1 Protein-3 -2.00 TRUE -3.43 TRUE -5.3 TRUE TRUE -10.73 
Ligand-1 Protein-4 -0.56 FALSE -0.15 FALSE -0.78 FALSE FALSE -1.49 
 Table 4.12: Example of the results table that is created by the developed heuristic 
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below the mean, it is counted as a strong prediction of binding activity. A consensus ensemble 
methodology is used to create a system of voting between the three different scoring functions. If a 
simple majority of the scoring functions meet the 2SD rule, then the meta-score prediction is that a 
strong binding took place (TRUE in Table 4.12); otherwise, if there is no majority vote amongst the 
different score methods, the meta-score prediction will be that the docked conformation does not 
illustrate a binding of interest (FALSE in Table 4.12). To calculate the numerical component of the 
meta-score, the winning voters in the ensemble - e.g. if the meta-score prediction is TRUE, then the 
scores that met the 2SD rule - are summed. For example, shown in table 4.12 is an example table of 
the predicted results after the mean and standard deviation outlier method and the combinational 
forecasting has been applied. There are four rows of data, each with three scoring functions these 
being scored 1, score 2, and score 3. Each of these scores has a combinational forecasting result, 
these being Score 1 Combinational forecasting, score 2 Combinational forecasting, and Score 3 
Combinational forecasting. Finally, there are two columns of meta-score and an Overall score. Meta-
score is the overall combinational forecasting result for each protein pairing (If it is classified as a 
potential interaction or a non-interaction). The Overall score is the final interaction score that will 
determine the interactions “strength”. The Meta-score is a crucial element of deciding how the 
standard deviations are combined. The developed heuristic determines which standard deviation 
scores are combined depending on the result of the Meta-score. If the Meta-Score is TRUE (classified 
as a potential interaction), all standard deviation that has the combinational forecast result equalling 
TRUE will be combined. If the Meta-Score is FALSE (classified as a miss), all standard deviation that 
has the combinational forecast result equalling FALSE will be combined. For example, as shown in 
table 4.12, in row one is the docking pairing of Ligand-1 and Protein-1. This pairing shows that score 
1 and score three have been classified as true and score two has been classified as false. The meta-
score for this pairing has been classified as a potential interaction (true). As the meta-score is true, 
to work out the overall score for that pairing only the score that had a combinational result of true 
will be combined. In this case score 1 (-2.01) and score 3 (-3.02) will be combined which equals an 
overall score of -5.03. For the second row of data in table 4.12, the docking pair of Ligand-1 and 
Protein-2, the meta-score has been classified as a non-interaction (false). The difference the data in 
row 1 and the data in row 2 are that the meta-score is classified as false. This classification 
determines that only scores that have a combinational forecasting result of false will be combined. 
In this case score, 1 and two will be combined which gives an overall score of 0.08. With row 3 all of 
the scoring functions have been predicted as true which produces the overall meta score as true. In 
turn this means that all of the scoring function 2SD score are added together to generate the 
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strength score. This also goes for row 4 as the overall meta score is equal to false which then means 
that all of the scoring functions are added together to generate the overall strength score.  
With this heuristic, the lower the overall score is, the “stronger” the result. The heuristic will help 
distinguish the non-interactions from the possible interactions where there should be a clear score 
difference and provide non-interactions with a lower score than those classified as a possible 
interaction. In the case of the example, it can be seen that the docking pair of ligand-1 and protein-1 
is a much “stronger” interaction than ligand-1 and protein-2.  
4.7.4.2 Conformation analysis 
Shown in Table 4.13 are known targets of the top 20 most valuable sold drugs that are within the 
panel 44 set. These protein-drug interactions were analysed to determine how well the 
combinational forecasting is performing and if so, are the predicted conformations matching the 
result given by the combinational forecasting. The panel 44 set had been selected for this analysis as 
these are classified as the industry standard in the pharmaceutical industry. The purpose of this 
conformation analysis is to determine if the scores predicted correlate with biologically viable 
conformations. 
True Positive Predictions 
Of the 11 predicted dockings for the panel 44 set with known interactions, all interactions were 
classified as potential interactions. Shown in table 4.18 are all of the strength scores calculated for 
all of the panel 44 known targets within the protein threaded set. All of the conformations for the 
known interactions were analysed to determine if the dockings were biologically viable. Discussed 
below are 3 examples of the analysis that had taken place. 
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Table 4.13: Panel 44 and known targets within the protein threaded set – shown in the table are all of the known targets for 
the panel 44 that are within the protein threaded set with the strength score calculated using the developed heuristic. 
 
Prostaglandin G/H synthase 2 and Lenalidomide 
The combinational forecasting classified this docking pair as a potential interaction. Prostaglandin 
G/H synthase 2 is a known target of Lenalidomide which has been predicted correctly. Using the 
created heuristic to determine the strength of the interaction, the calculated result of 0.09, which 
was the lowest strength score generated of the whole panel 44 threaded set. The strength score 
does seem to indicate that there is no interaction, though it must be stated that the strength score is 
used to help rank the conformations from strongest to weakest and so does not necessarily mean 
that no prediction is predicted. Information that was stored on the UniProt database which gave 
known active site residues for Prostaglandin G/H synthase 2, these being atom 106 (ARG), 193 (HIS), 
341 (TYR), 371 (TYR), and 516 (SER). Shown in figure 4.21 is the top calculated conformation for this 
docking pair. Lenalidomide (magenta) has docked near to the known active residue 93 (HIS). Figure 
4.22 shows a closeup of the active atom 193 where Lenalidomide has docked 4.919 angstroms away. 
This result proves that the combinational forecasting has predicted this conformation correctly. This 
Protein Uniprot Ligand PubChem Strength Score 
Prostaglandin G/H synthase 2 P35354 Lenalidomide 216326 0.09 
5-hydroxytryptamine receptor 
2A 
P28223 Aripiprazole 60795 -6.65 
5-hydroxytryptamine receptor 
1A 
P08908 Aripiprazole 60795 -5.07 
D(1A) dopamine receptor P21728 Aripiprazole 60795 -3.08 
D(2) dopamine receptor P14416 Aripiprazole 60795 -2.74 
Muscarinic acetylcholine 
receptor M3 
P20309 Solifenacin 154059   -2.31 
Muscarinic acetylcholine 
receptor M1 
P11229 Solifenacin 154059   -2.58 
Histamine H1 receptor P35367 Aripiprazole 60795 -6.54 
Muscarinic acetylcholine 
receptor M2 
P08172 Aripiprazole 60795 -3.02 
Muscarinic acetylcholine 
receptor M2 
P08172 Solifenacin 154059   -2.27 
Muscarinic acetylcholine 
receptor M2 
P08172 Tiotropium 5487427   4.88 
Muscarinic acetylcholine 
receptor M3 
P20309 Tiotropium 5487427 5.57 
Muscarinic acetylcholine 
receptor M1 
P11229 Tiotropium 5487427 3.34 
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result also provides some explanation as to why the “strength” score was weak as Lenalidomide is 
not close enough to have the potential for interaction.  
Figure 4.19 : Prostaglandin G/H synthase 2 and Lenalidomide docking - Image of the top conformation for the Prostaglandin 
G/H synthase 2 and Lenalidomide docking. 
Figure 4.20:close up image of the Prostaglandin G/H synthase 2 and Lenalidomide docking -  Image Lenalidomide docking 
near the known active atom 193 (HIS) of Prostaglandin G/H synthase 2 
5-hydroxytryptamine receptor 2A and Aripiprazole 
The combinational forecasting classified this docking pair as a potential interaction. 5-
hydroxytryptamine receptor 2A is a known target of Aripiprazole which has been predicted correctly. 
Using the created heuristic, the “strength” score for the predicted interaction was -6.65, which 
indicates that this is a strong interaction. This strength score was the highest score of all the panel 
44-drug pairings shown in table 4.18. Shown in figure 4.23 is the top conformation predicted for 5-
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hydroxytryptamine receptor 2A and Aripiprazole (magenta). The UniProt database had stored 
information about known active residues for 5-hydroxytryptamine receptor 2A this atom being 229 
(LEU). Shown in figure 4.24 is a close up of the known active atom 229 and it shows that Aripiprazole 
has docked near. When the distance between the two was measured, it showed that Aripiprazole 
had docked 5.352 angstroms away from the leucine residue. The distance is close enough to bring 
about an interaction and justifies the strong “strength” score produced by the created heuristic.  
  
Figure 4.24: close up image of 5-hydroxytryptamine receptor 2A/ Aripiprazole docking – shown is a close up image of 
the 5-hydroxytryptamine receptor 2A/ Aripiprazole docking which is 3.336 angstroms away from a known active residue 
229 (LEU). 
Figure 4.23: 5-hydroxytryptamine receptor 2A/ Aripiprazole docking – shown is the top conformation generated for the 5-
hydroxytryptamine receptor 2A/ Aripiprazole docking 
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5-hydroxytryptamine receptor 1A and Aripiprazole 
The combinational forecasting classified the docking pair as a potential interaction. 5-
hydroxytryptamine receptor 1A is also a known target for Aripiprazole which had been predicted 
correctly. The created heuristic gave a “strength” score of -5.07, which indicates a strong interaction. 
Shown in figure 4.23 is the top conformation predicted for the 5-hydroxytryptamine receptor 1A and 
Aripiprazole (magenta) docking pair. There was no known data about known active residues for 5-
hydroxytryptamine receptor 1A on the UniProt database to help determine if Aripiprazole had 
docked in the correct location. However, there was a known crystal structure for a close relative 5- 
hydroxytryptamine receptor 2B (gene HTR2B). The crystal structure 5TUD (Ishchenko et al., 2017) 
has the drug ERM bound. The RMSD score between 5-hydroxytryptamine receptor 1A threaded 
model and the 5TUD crystal structure was 1.947. Shown in figure 4.24 is an image of the crystal 
structure 5TUD docked ligand ERM (red) superimposed onto the generated model for 5-
hydroxytryptamine receptor 1A with both Aripiprazole (magenta) bound. Both drugs have docked in 
the same location, which indicates that the predicted docking is biologically plausible. This outcome 
has proven that both the combinational forecasting and the “Strength” score had predicted 
correctly. 
Figure 4.21: 5-hydroxytryptamine receptor 1A and Aripiprazole docking -  Image of the top generated conformation 
for the 5-hydroxytryptamine receptor 1A and Aripiprazole docking pair. 
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True Negative Predictions 
Due to none of the panel 44 protein having in vitro data that indicates that they are a known non-
interaction with any of the top 20 most widely prescribed drugs. Randomly selected docking pairs 
involving panel 44 proteins are used to determine if the combinational forecasting and “strength” 
score have predicted correctly. Shown in Table 4.14 are the 3 predicted interactions that are 
analysed. 
 Table 4.14:Examples of True Negative within the protein threaded set – shown are 3 known non-interactions for the top 20 
ligands docked against the protein threaded set from In vitro data which have been predicted correctly using the developed 
combinational forecasting. 
 
D(2) dopamine receptor and Pregabalin 
is no in vitro data to suggest that the docking pair of D(2) dopamine receptor and Pregabalin should 
have an interaction. The combinational forecasting predicted the docking pair as a non-interaction 
and an interaction “strength” score of 4.08, which indicates a very poor interaction. UniProt contains 
information about known active residues for D(2) dopamine receptor these being residues 114 
(ASP), 194 (SER), and 197 (SER). Shown in figure 4.25 is the top predicted conformation for the 
docking pairing of D(2) dopamine receptor and Pregabalin (magenta) and the known active residues 
highlighted (red). From this single image, it shows that this is a non-interaction. Initially, the first 
indication that this conformation is a non-interact is the fact that Pregabalin has not docked near 
Protein Uniprot Ligand PubChem Strength Score 
D(2) dopamine receptor P14416 Pregabalin 5486971   4.08 
D(1A) dopamine receptor P21728 Gabapentin 3446 3.172 
Adenosine receptor A2a P29274 Levothyroxine 5819 8.43 
 Figure 4.22: Close up image of top conformation 5-hydroxytryptamine receptor 2A/ Aripiprazole 
docking superimposed with 5TUD crystal structure docking. 
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any of the known active residues of the D(2) dopamine receptor. The second indication is that 
pregabalin has docked in a location that biologically would not be accessible due to it being blocked 
off by a span domain of lipids. The area of the protein that pregabalin has docked is known as the 
protein-binding domain. The outcome indicates that the combinational forecasting has correctly 
predicted that this docking pair is a non-interaction and the “strength” score was also correct. 
Figure 4.23 : D(2) dopamine receptor and Pregabalin docking - Image of the top predicted conformation for the D(2) 
dopamine receptor and Pregabalin docking pair 
D(1A) dopamine receptor and Gabapentin 
There is no in vitro data to suggest that the docking pair of D(1A) dopamine receptor and 
Gabapentin should have an interaction. The combinational forecasting predicted the docking pair as 
a non-interaction and the “strength” score given was 3.172, suggesting a very weak interaction. 
There is no known active residues information stored on UniProt about D(1A) dopamine receptor, 
but there is a known crystal structure for a close relative D(4) dopamine receptor. The crystal 
structure 5WIV (Wang et al., 2017) has an RMSD of 1.957 when matched with the D(1A) dopamine 
receptor generated model. Shown in figure 4.26 is an image of the top-ranked conformation for the 
D(1A) dopamine receptor and Gabapentin (magenta) docking pair. It seems that Gabapentin has 
been docked near an area of low homologue coverage which is caused by low template coverage. 
Shown in figure 4.27 is an image of the crystal structure 5WIV (dark blue) docked ligand 
Nemonapride (AQD)(green) superimposed onto the generated model for D(1A) dopamine receptor 
(Gold) with both Gabapentin (magenta) bound. From the image, it displays that Gabapentin has 
docked in a different location to the crystallised docking of Nemonapride. With both findings, it can 
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be determined that this is a non-interaction and that the combinational forecasting had predicted 
the conformation correctly. The “strength” score also gave a valid score of 3.172.  
Figure 4.24 : D(1A) dopamine receptor and Gabapentin docking - Image of the top-ranked conformation for the D(1A) 
dopamine receptor and Gabapentin docking pair. 
Figure 4.25 :close up image of the crystal structure 5WIV bound ligand Nemonapride (AQD)(green) – shown is a 
superposition of the crystal structure 5WIV’s bound ligand AQD onto the generated model for D(1A) dopamine receptor 
with Gabapentin (magenta) bound locations. 
Adenosine receptor A2a and Levothyroxine 
No in vitro data could be obtained to suggest that the docking pair of Adenosine receptor A2a and 
Levothyroxine should have an interaction. The combinational forecasting predicted the docking pair 
130 
 
as a non-interaction and gave a “Strength” score of 8.43 which also ranks the interaction as weak. 
There is no known active atom information stored on the UniProt database to analyse if 
Levothyroxine has docked near them. However, there is a known crystal structure for Adenosine 
receptor A2a, which has the drug Adenosine bound. The crystal structure 2YDO (Lebon et al., 2011) 
has an RMSD of 1.998 when compared to the generated model for Adenosine receptor A2a. Shown 
in figure 4.28 is an image of the top-ranked conformation predicted for the Adenosine receptor A2a 
and Levothyroxine (magenta) docking pair. It's clearly shown that Levothyroxine has docked on the 
outside of Adenosine receptor A2a. From this image, it is already clear that the prediction suggests 
that this is a non-interaction. Shown in figure 4.29 is an image of the crystal structure 2YDO’s docked 
ligand Adenosine (green) superimposed with the generated model of Adenosine receptor A2a with 
Levothyroxine (magenta) bound. From this image, it can be seen that Levothyroxine has not bound 
in the correct place which justifies the combinational forecasting and “strength” score predicted 
results for this docking pair.  
Figure 4.26: Adenosine receptor A2a and Levothyroxine docking -  shown is an image of the top-ranked conformation 
predicted for the Adenosine receptor A2a and Levothyroxine docking pair. 
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Figure 4.27: Image of the crystal structure 2YDO docked ligand Adenosine (green) superimposed onto the generated model 
of Adenosine receptor A2a with Levothyroxine (magenta) bound. 
4.7.4.2.1 False Positive predictions 
There were false positives that had been predicted by the combinational forecasting method. Some 
conformations that the combinational forecasting had predicted as a possible interaction even 
though the ligand had bound in locations that for some were not biologically plausible. Here is the 
analysis of 3 of the false positive that had been predicted. The analysed predicted dockings are 
shown in table 4.15. 
Table 4.15: Examples of False Positive within the protein threaded set – shown are 3 known non-interactions for the top 20 
ligands docked against the protein threaded set from In vitro data which have been predicted correctly using the developed 
combinational forecasting. 
 
D(2) dopamine receptor and Tadalafil 
There are no in vitro data that indicates that Tadalafil should have an interaction or should not have 
an interaction with D(2) dopamine receptor. However, the combinational forecasting had predicted 
Protein Uniprot Ligand PubChem Strength score 
D(2) dopamine 
receptor 
P14416 Tadalafil 110635   -5.365 
Adenosine 
receptor A2a 
P29274 Tazobactam 123630   -0.642 
D(2) dopamine 
receptor 
P14416 Budesonide 5281004   -1.457 
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the docking pair as a potential interaction and a “strength” score of -5.365. UniProt’s database had 
stored data about known active residues for D(2) dopamine receptor, these being residues 114 
(ASP), 194 (SER), and 197 (SER). Shown in figure 4.30 is an image of the top-ranked conformations 
generated for the D(2) dopamine receptor and Tadalafil (magenta) docking pair. The known active 
residues are highlighted in orange and shown that Tadalafil has not bound near any of them, which 
indicates that this is a non-interaction. The drug has found a flexible protein-protein interaction 
domain. The domain is largely hydrophobic, and the molecule is very nonpolar overall which could 
be the reason that the drug has been attached to that area. In real life, that region would not be 
exposed to ligands as it is in the intracellular domain. The part of the protein that is inside of the cell, 
the ligand interactions would happen at the other end. AutoDock Vina & DOCK 6.0 does not know 
this fact, and it could be that Tadalafil would bind to the G-protein domain area if the protein 
binding domain was not accessible. After this analysis, it concluded that this was a false positive. 
Figure 4.28: D(2) dopamine receptor and Tadalafil docking - Image of the top-ranked conformations generated for the D(2) 
dopamine receptor and Tadalafil docking pair. 
Adenosine receptor A2a and Tazobactam 
There are no in vitro data that indicates that Tazobactam has a known interaction with Adenosine 
receptor A2a. However, the combinational forecasting has classified the docking pair as a potential 
interaction. The result is then causing the “strength” score to be -0.642, which is a weak interaction. 
The crystal structure 2YDO was used to analyse the conformation and the location of Tazobactam 
docking. Shown in figure 4.31 is an image of the top-ranked conformation for the Adenosine 
receptor A2a and Tazobactam docking pair. Tazobactam appears to have bound to the outside of the 
protein and not within. This is due to a modelling error. The G-protein domain has modelled with 
low structural content to the side of the protein, where the cell wall would be in vivo. This has made 
a "fake" pocket which would not exist in life, and it's that pocket which has captured the drug in the 
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simulation. This discovery has indicated that this would be a non-interaction. Figure 4.32 shows an 
image of the crystal structure 2YDO bound ligand Adenosine (green) bound superimposed onto the 
generated model for Adenosine receptor A2a  with Tazobactam (magenta) and. Figure 4.32 clearly 
shows that Adenosine (green) has bound within the cavity of Adenosine receptor A2a which is the 
active site. This outcome gives another indication that the docking pair of Adenosine receptor A2a 
and Tazobactam should have been classified as a non-interaction.  
Figure 4.29 : Adenosine receptor A2a and Tazobactam docking – Shown is an image of the top-ranked conformation for the 
Adenosine receptor A2a and Tazobactam docking pair. 
Figure 4.30: Image of the crystal structure 2YDO (purple) overlapping the generated model for Adenosine receptor A2a 
(gold) with both drugs Tazobactam (light blue) and Adenosine (green) bound. 
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D(2) dopamine receptor and Budesonide 
There are no in vitro data that indicates that Budesonide should have an interaction with the D(2) 
dopamine receptor. The combinational forecasting predicted the docking pair as a potential 
interaction which also led to the “strength” score of -1.457, which indicates a good interaction. D(2) 
dopamine receptor has got known active residues these being atom 114 (ASP), 195 (SER), and 197 
(SER). Shown in figure 4.33 is an image of the top-ranked conformation for the D(2) dopamine 
receptor and Budesonide docking pair. Budesonide has docked far away from the known active 
residues (orange) which indicates that this is a non-interaction. It seems like the docking programs 
had found a good shape-matching ("lock and key") between an area of the protein that is hydrophilic 
and the similarly hydrophilic hydroxyl groups on those phenol rings. This region would be blocked off 
by lipids in the cell wall in life, so the drugs would never be bound within that area in vivo. 
Figure 4.31: D(2) dopamine receptor and Budesonide docking – Shown is an image of the top-ranked conformation for the 
D(2) dopamine receptor and Budesonide docking pair. 
4.7.4.2.2 False Negative predictions 
These predictions are when a drug that is known to have an interaction with a protein, yet the 
combinational forecasting does not classify as a potential interaction. Of the 33 known protein 
interactions within the set of high-quality models which had undergone protein threading, only 
three were classified as a non-interaction. Shown in table 4.16 are three protein-ligand pairings that 
were classified as non-interactions by the combinational forecasting with their calculated strength 
score. These three dockings were investigated to determine the cause of why they were classified as 
non-interactions by the combinational forecasting. 
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Table 4.16:False Negative results – the following table shows the three protein-ligand pairings that the combinational 
forecasting classified as a non-interactions instead of being classified as a potential interaction. These have been shown 
with their calculated strength scores. 
 
Synaptic vesicle glycoprotein 2A and Levetiracetam 
There is in vitro data that has confirmed that Synaptic vesicle glycoprotein 2A is a known target of 
Levetiracetam (Lynch et al., 2004). However, the combinational forecasting has classified the docking 
pair as a non-interaction. When investigating the conformation, it was discovered that the generated 
model for Synaptic vesicle glycoprotein 2A had many areas of low homologue coverage which was 
surprising as it was part of the set of high-quality models which had undergone protein modelling. 
Figure 4.34 shows an image of the top-ranked conformation for the Synaptic vesicle glycoprotein 2A 
and Levetiracetam (magenta) docking pairing. Levetiracetam has bound to the outside of the 
protein, which does indicate that this is a non-interaction. This outcome could be as the areas of 
low-homologue coverage could be blocking entrances into the protein which otherwise would be 
accessible. This is a false negative result, but from the predicted conformation, the combinational 
forecasting has predicted correctly that this is a non-interaction. This result was not caused due to 
Protein Uniprot Ligand PubChem Strength Score 
Synaptic vesicle 
glycoprotein 2A 
Q7L0J3 Levetiracetam 441341 3.15 
Adenosine 
receptor A1 
P30542 Gabapentin 3446 3.39 
Thyroid hormone 
receptor beta 
P10828 Levothyroxine 5819 5.1 
Figure 4.32: Synaptic vesicle glycoprotein 2A and Levetiracetam docking – shown is an image of the 
top ranked conformation for the Synaptic vesicle glycoprotein 2A and Levetiracetam docking pairing. 
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the combinational forecasting but by the generated threaded model of Synaptic vesicle glycoprotein 
2A. 
Adenosine receptor A1 and Gabapentin 
There is in vitro data that has proven that Adenosine receptor A1 is known to interact with 
Gabapentin (Zuchora, Wielosz and Urbańska, 2005). However, the combinational forecasting has 
classified the docking pair as a non-interaction. Shown in figure 4.35 is an image of the top-ranked 
conformation for the Adenosine receptor A1 and Gabapentin (magenta) docking pair. Gabapentin is 
shown to have docked on the top of Adenosine receptor A1 on the outside. As this seemed like an 
excellent generated protein model, it was not clear why Gabapentin did not dock within the protein. 
After investigating the model further, it was clear to see the reason why the docking programs had 
bound Gabapentin to that location. Shown in figure 4.36 is an image of the conformation from above 
which shows that there is an area of low-homologue coverage which is blocking the entrance into 
the protein. The area of low homologue coverage is highlighted in orange. Based on the location that 
Gabapentin has bound, the combinational forecasting correctly classified the docking. The cause of 
the erroneous result was a weakness in the generated protein model. 
Figure 4.33: Adenosine receptor A1 and Gabapentin docking -shown is an image of the top-ranked conformation for the 
Adenosine receptor A1 and Gabapentin (magenta) docking pair 
. 
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Figure 4.34:Low-homologue modelled area of Adenosine receptor A1 – shown is an image of the conformation from above 
which shows that there is an area of low-homologue coverage which is blocking the entrance into the protein. The area of 
low homologue coverage is highlighted in orange. 
Thyroid hormone receptor beta and Levothyroxine 
There is much in vitro data that indicates that the Thyroid hormone receptor has an interaction with 
the synthetic thyroid hormone drug Levothyroxine (DrugBank). However, the combinational 
forecasting has classified the docking pair as a non-interaction. This outcome led to investigating the 
predicted conformation. Shown in figure 4.37 is an image of the top-ranked conformation for the 
Thyroid hormone receptor beta and Levothyroxine docking pair. The Thyroid hormone receptor has 
had a high-quality model generated as this is a very well characterised protein with many crystal 
structures like 1XZX (Sandler et al., 2004) and 1Y0X (Sandler et al., 2004). Levothyroxine (magenta) 
has ended up being docked on the outside of the protein. the only conclusion is that this was caused 
by a docking failure due to possible errors caused within the process. 
4.7.4.2.3 Conclusion of the conformation analysis 
After analysing the conformations to evaluate the performance of the combinational forecasting 
method that was developed, the outcome was very promising. The combinational forecasting had 
clearly performed well with the true positive dockings that had been classified correctly as potential 
interactions. All 11-known interaction with proteins within the panel 44 set were classified correctly. 
Three of the 11-known interaction from proteins within the panel 44 set were investigated to 
determine if the conformations were biologically plausible to be a potential interaction. Each of the 
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investigated docking pairs concluded that the drugs were bound correctly near either know active 
residues or in a similar location to known crystal structures. The true negatives conformation results 
had shown good performance for the combinational forecasting developed method. A sample of 3 
proteins from panel 44 was selected that were classified as a non-interaction with one of the top 20 
most widely prescribed drugs. All 3 dockings that were investigated provided conformations that 
would be determined as a non-interaction due to the locations that the drugs had docked. Two of 
the drugs had docked into a protein-binding domain which is not biologically plausible as this would 
be blocked by lipids. Another had bound outside of the protein. The false positives conformations 
results showed that there is a combination of protein modelling and protein-ligand docking errors 
that have caused the non-interactions to be classified incorrectly by the combinational forecasting. 
For two of the three false-positive examples that were investigated, the docking programs had 
docked the proteins in areas that would not be accessible. The docking programs do not have the 
knowledge of protein domain areas of proteins or areas that would not be accessible, which is the 
reason they have been docked in those positions. For the other docking pair, the issue was that the 
model had an area of the protein with low-homologue coverage which causes a “fake” pocket to be 
created. The false-negative conformation results that were examined were 3 known targets of the 
top 20 most widely prescribed drugs that were classified as non-interactions by the combinational 
forecasting. When the conformations were examined, it was clear to see that the generated 
threading models for 2 proteins had areas of low-homologue coverage that either blocked entrances 
that generally drugs would enter which caused for all three cases for the drug to bind to the outside 
Figure 4.35: Thyroid hormone receptor beta and Levothyroxine docking – shown is an image of the top ranked 
conformation for the Thyroid hormone receptor beta and Levothyroxine docking pair. 
139 
 
of the protein. The third docking pairing of Thyroid hormone receptor beta and Levothyroxine was 
due to a docking error which had caused Levothyroxine to dock on the outside of the protein. The 
combinational forecasting had predicted correctly from the scoring function results given as these 
were non-interactions based on the conformation predicted.  
Overall the combinational forecasting method has performed exceptionally well. Considering that no 
a priori analysis of binding regions of proteins had been undertaken , to get this level of accuracy is 
promising. The combinational forecasting had predicted all the analysed examples correctly from 
only the scores that were produced by the docking programs with no interaction with the 
conformation themselves. There is potential for this method to be improved with the addition of 
conformation analysis prior to loading data through the combinational forecasting method. 
4.8 Conclusion 
The final accuracy produced by the combinational forecasting method developed has been very 
promising for predicting known targets from a vast field of docking data. The study provided many 
valuable results in the process of developing more accurate predictive methods. Firstly, from the raw 
homology modelled baseline structural data without any proccessing it was shown that the 
identification of known targets of the ligands from a large set of virtual dockings was less than 50% 
accurate. This would not give sufficiently useful results to be beneficial for the users of the system 
for lead drug discovery or repurposing. Reasons for this were discovered such as low homologue 
coverage of some protein models and incorrect ligand binding sites predicted by AutoDock Vina and 
DOCK6. This led to the adoption of the Shipyard 1.5 pipeline which calculated a total of 19 different 
scoring functions for each protein-ligand conformation also with the added stage of DoGSite which 
calculates possible pockets within a protein that could be favourable for docking a ligand. With the 
use of this docking pipeline, the development of the database was improved so that it was able to 
store the wide array of data being generated. The protein sequences were also re-modelled using an 
updated PDB template database (2017) which generated 3,233 more high homology covered protein 
models. With the extra scoring function and improved model generation, the possibility of improved 
accuracy of dockings being generated would be expected to improve compared to unprocessed 
data. This was the case but not an improvement that would substantially increase the value of the 
data. With the outcome of the analysis, the data for the known misses for the top 20 drugs were 
analysed to evaluate that the analysis method was predicting them correctly as non-interactions. Of 
the known misses within the new homology modelled set, 66.6% were predicted correctly, but the 
overall accuracy of correct prediction of interactions and non-interactions was still low, leading to 
many possible targets/off-target interactions being missed.  
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A protein threading modelling approach that had an overlap of FDA known target proteins with the 
homology modelling set was used to determine if the model quality was affecting docking results. 
The protein threading provided 413 more high-quality proteins compared to the re-modelled 
homology modelling set (2017). The protein threaded models were run using the same Shipyard 1.5 
pipeline as for the homology modelling set. The results outcome was not significantly different to 
the new homology modelling set which led to the conclusion that a more thorough analysis was 
needed of the scoring functions used in order to improve the accuracy of the predicted outcomes 
with the aim of reaching as near to 100% as possible. A new approach using combinational 
forecasting and analysis of the scoring function using ROC curves was introduced. The ROC curve 
identified the most accurate scoring functions for the homology modelling set and the protein 
threading set. Each of the set showed only 6 of the 19 scoring functions were producing 70% or 
more accuracy for predicting known targets and known non-interactions correctly. The results 
showed that there were 4 scoring functions that were consistently accurate in both models sets, 
these being the GBSA Affinity, Vina Gauss1, Vina Gauss 2, and DSX Contact count scoring functions. 
Threshold scores were calculated for each of the scoring function which would produce the highest 
accuracy possible for the predictions. A threshold then had to be calculated for the combinational 
forecasting which would produce the most accurate results possible which led to the outcome of 4 
of the 6 identified scoring functions needing to pass a threshold for a protein-ligand pairing to be 
classified as a potential interaction. The accuracy produced for correctly predicting known targets 
and known non-interactions increased dramatically compared to the raw baseline results at the 
beginning. The combinational forecasting used for the homology modelling set produced an overall 
accuracy of 66.45%. The combinational forecasting used for the protein threaded set produced a 
better result of 72.05%. Both sets produced a 90%+ accuracy for predicting known targets correctly, 
the only difference being that the combinational forecasting set had a higher accuracy of predicting 
known non-interactions correctly with 53.2% compared with homology sets 42.4%. To verify that 
conformations generated were not producing false scores, a conformation analysis was undertaken 
on the panel 44 proteins and on known non-interactions. Shown in table 4.17 is a summary of the 
findings of the 12-conformation example shown in section 4.7.4.2. 
This level of accuracy that has been produced from a large amount of docking data generated is a 
promising outcome and indicates that the approach can yield useful data that can lead to off-target 
interactions being identified or potential new targets due to strongly indicated  interactions being 
identified. The combinational forecasting can be improved by adding other factors to the modelling 
and docking process, but this has produced a promising outcome which can lead to further 
development and the use of large-scale virtual screening in the future. 
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Protein Ligand Combinational 
Forecasting 
Result 
Combinational 
forecasting  
Correct/incorrect 
Reason? 
Prostaglandin G/H 
synthase 2 
Lenalidomide TRUE Correct Bound near 
active residue 
5-
hydroxytryptamine 
receptor 2A 
Aripiprazole TRUE Correct Bound near 
active residue 
5-
hydroxytryptamine 
receptor 1A 
Aripiprazole TRUE Correct Bound in the 
same location 
as crystal 
structure drug 
D(2) dopamine 
receptor 
Pregabalin FALSE Correct Bound in 
protein binding 
domain 
D(1A) dopamine 
receptor 
Gabapentin FALSE Correct Bound in 
incorrect area 
near an area of 
low homologue 
coverage 
Adenosine 
receptor A2a 
Levothyroxine FALSE Correct Bound on 
outside of 
protein 
adjacent to 
area of low 
homologue 
coverage 
D(2) dopamine 
receptor 
Tadalafil TRUE Incorrect Bound in the 
protein binding 
domain 
Adenosine 
receptor A2a 
Tazobactam TRUE Incorrect Bound in an 
area of low 
homologue 
coverage which 
created a 
“fake” pocket 
D(2) dopamine 
receptor 
Budesonide TRUE Incorrect Binding region 
inaccessible 
due to 
membrane  
lipid bilayer 
Synaptic vesicle 
glycoprotein 2A 
Levetiracetam FALSE Incorrect Modelling error 
Adenosine 
receptor A1 
Gabapentin FALSE Incorrect Weakness in 
the generated 
model 
Thyroid hormone 
receptor beta 
Levothyroxine FALSE Incorrect Docking error 
Table 4.17: the results of the investigation of the conformations – shown are the summary of results discovered in the 
conformation analysis discussed in section 4.7.4.2 
142 
 
5 Graphical User Interface 
This chapter describes the architecture, assembly and functionality of the Graphical User Interface 
(GUI).  
5.1 Graphical User Interface Overview 
The Objective for this Graphical User Interface (GUI) is to provide a simple and easy way for the 
users of the system to access and visualise critical data from the MySQL database. This GUI should 
be easy to read, intuitive for the user to use and not be complicated. The Graphical User Interface 
will be a web-based interface and will need to be able to be used to undertake the following tasks: 
• Link to the MySQL database 
• Visualise data within the Proteins, Ligand, and Docking tables 
• Search within the Proteins, Ligand, and Dockings tables 
• Visualise a 3D docking 
• Display all result scores for each docking selected 
Shown in figure 5.1 is a flowchart of the process for design and the coding needed to produce the 
final graphical user interface for the protein-ligand docking database. The first stage would be to 
create a  
 
basic design of the screen layout for each page to determine where certain items should be located. 
The basic design process is explained in section 5.2. and this acts as a guide to develop code that will 
produce the visual design and also create the backend code that will make it possible for the 
Figure 5.1:Flowchart for process of creating the Graphical User Interface (GUI) – shown is a flowchart of the process 
undertaken to produce a working graphical user interface for a user to view protein-ligand docking data within the 
database 
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frontend to be used to be able to communicate and extract data from the MySQL database. This 
process is discussed further in section 5.3. After the coding has been completed, the final graphical 
user interface is then implemented which users will then be able to use and view protein-ligand 
docking data which is discussed in section 5.4 with details of what the user is able to do on the 
system. 
5.2 GUI Design 
The first stage of creating the Graphical user interface is the design - how the interface should look 
and what data needs to be available for the user to view and the method of accessing the vital data 
they need.  
5.2.1 Visual Design 
The first page the user will view is the login page. A login page is required to enable users to save 
lists within the system under a personal account name. The login page is a simple login panel where 
users can either register or login. The login panel as shown in figure 5.2 was placed in the middle of 
the page and have the standard username and password inputs with a login button and also a 
register button for users who do not have an account.  
The data that the user would need to view is within the Proteins and Ligands tables. This is the first 
important stage for the user to select which proteins and ligand dockings they would like to view. 
This requires two tables to be displayed listing all the available Proteins and Ligands on the system. 
The user would also need to view the results that are available on the system in order to select the 
desired docking to view. This necessitates another table, to list the available dockings 
Login Panel 
Username 
Password 
Register Login 
Figure 5.2: Basic design of Login Page – shown is a basic design of how the 
login page would look to the user 
144 
 
on the system.  The basic layout for the design of the database web page is shown in figure 5.3. It 
allocates sections of the screen to each table. The design has been created to encourage the user to 
use the system in an intuitive manner when selecting the items required.  The tables are placed in 
the order shown in figure 5.3, which gives the user the option to either select a protein or a ligand 
first as users may have a different preference for what they are investigating. This would make the 
results concise and easy to read for the user.   
The method of the best way of displaying 3D results was the next important decision. The results 
required three separate pages to display detailed information about the protein, ligand, and docking 
selected by the user. The first page displayed specific protein data, the second for ligand-specific 
data and the third for displaying specific docking pair data. The design had to be user-friendly, 
displaying the data in a clear and simple format in each case. The design adopted for the protein 
data page is shown in figure 5.4. There are three panels within the page design. The Proteins Data 
table contains all the relevant data for the protein selected, such as Protein name, Gene name, 
sequence, modelling type etc. These were displayed in a vertical table with column name along the 
y-axis. To the right side of the protein, the data table is the 3D viewer. The 3D viewer shows the 
structure of the selected proteins obtained by either homology modelling or protein threading. This 
enables the user to visualise the protein they are researching. The third table, below this 3D viewer 
provides a list of all the drugs that have been docked against the selected protein stored on the 
system. The user has the option of looking at the selected protein-specific dockings making it easier 
for the user to find the results they require. Figure 5.5 shows the design for the ligand data page. 
Proteins Table Ligands Table 
Dockings Table 
Figure 5.3: Basic design of the database page - shown is a basic design of how the database page would look to the user after login 
in to the system. 
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This is a similar broad layout to the protein data page but displays data about the ligand selected 
instead of the protein. The ligands data table displays information such as ligand name, PubChem ID, 
Reactome ID’s, KEGG ID’s etc. The Ligand 3D Viewer displays the 3D PDB file of the Ligand selected. 
Finally, below the 3D viewer is a table with all dockings that have been performed using the ligand 
selected.  
The docking’s results page has details about both the protein and ligand involved in the docking that 
has been selected. This required separate tables for the protein data and ligand data. The following 
design shown in figure 5.6 was adopted for the docking results page. As shown, there is a Proteins 
data table on the left of the screen which displays the data of the protein involved in the 3D docking 
selected. On the right side of the screen, there is a ligands data table which displays information 
about the ligand involved in the selected docking. In-between these two tables is a 3D viewer which 
displays the 3D conformation of the calculated docking that has been selected. Finally, below these 
is a docking results table. This displays the results for the selected docking and all the scores that 
have been calculated for the conformation, which are stored on the system database. 
 
Proteins Data  
Table 
Protein 3D Viewer 
Relevant dockings calculated  
with this protein 
Figure 5.4: Design of the Proteins results page - shown is a basic design of how the protein viewer page would look to the 
user after selecting a protein within the protein table on the database page. A table contain all about the selected protein 
will be place on the left of the page. On the right of the page the 3D viewer and relevant docking s table will be placed. 
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Proteins 
Data 
Table 
3D Docking Viewer 
Ligand  
Data 
Table 
3D Docking results 
Ligands Data  
Table 
Ligand 3D Viewer 
Relevant dockings calculated  
with this Ligand 
Figure 5.5: Design of the Ligand results page - shown is a basic design of how the ligand viewer page would look to the 
user after selecting a ligand within the ligand table on the database page. A table contain all about the selected ligand 
will be place on the left of the page. On the right of the page the 3D viewer and relevant dockings table will be placed. 
Figure 5.6: Basic design for the Docking results page - shown is a basic design of how the protein-ligand docking viewer 
page would look to the user after selecting a specific docking pair within the docking table on the database page. A table 
contain all about the selected protein will be place on the left of the page. On the right of the page a table containing the 
data about the selected ligand will be placed. the 3D viewer will be place in between the two tables with a table with the 
docking scoring function results at the bottom of the page. 
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5.3 GUI coding 
To Create the GUI required the key components required are PHP pages which are used for database 
querying and to create the visual pages for the user. Also JQuery/JavaScript/AJAX pages which are 
used for seamless interaction between the visual pages and the MySQL database. 
5.3.1 Database Page 
How Protein data is generated and displayed on the GUI 
The process of bringing protein data from the database to the GUI requires the use of PHP, AJAX, 
JavaScript, and HTML. The first part of the process was to create a method of querying the database 
to extract the correct information.  
Protein Table Query 
A PHP file was created to call ajax_proteins_from_temp-2.php to store the query to extract the 
protein data needed. This same file is also used to query the Ligand table; this will be explained 
further on. This file is used to query different tables when required; the queries are placed within an 
IF statement. Information is passed to the PHP file with a request to extract data from a particular 
table and which “temp” table to use to gather the protein ID’s required. These are stored as 
variables; the table is stored as “$opt_table” and the temp table under “$opt_level”. For the protein 
data, the query extracts data from the Proteins table of the database.  This is then linked with the 
Protein_Info table which has more information about the proteins such as name and other 
associated ID’s. The query checks the “temp” table created for the user which stores all of the ids of 
the proteins that need to be extracted. For this query, the “$opt_table” equals “Proteins” and the 
“$opt_level” equals “0”. This is then inputted into another variable which equals the name of the 
temp table within the database. In this case the variable is called “$table_name” and is equal to 
“’temp_’.$opt_table.’_’.$opt_level”. For the IF statement as the table is equal to “Proteins” all the 
set variables for this query are shown in table 5.1. The variables set by the IF statement are then 
inputted the MySQL query shown in row 1 of Table 5.2. 
 
Variable Name Variable 
$idcolname ‘Protein_Index’ 
$info ‘Protein_info.uniprot’ 
$info2 ‘Proteins.uniprot’ 
$table_info ‘Protein_Info’ 
Table 5.1: Variables set within the ajax_proteins_from_temp-2.php file – the table shows the four variables that are set 
within the ajax_proteins_from_temp-2.php to extract protein data from the MySQL database. 
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Row 
Number 
Code 
1 SELECT * FROM $opt_table INNER JOIN $table_info ON $info2 = $info WHERE $idcolname IN (SELECT * 
FROM $table_name); 
 
2 $connection = mysqli_connect(“Server”, “username”, “password”, “database”) ; 
3 $result = mysqli_query($connection, (SQL Query)); 
4 $data = array(); 
5 $(‘(TABLE TAG)’).html(rowHtml); 
6 $(‘(TABLE TAG)’).DataTable(); 
7 SELECT * FROM Docking_Table JOIN Proteins ON Docking_Table.Protein_Index = Proteins.Protein_Index 
JOIN Ligands ON Docking_Table.Lig_Index = Ligands.Lig_Index JOIN Protein_Info ON Proteins.uniprot = 
Protein_Info.uniprot JOIN Ligand_Info ON Ligands.pubchem = Ligand_Info.pubchem WHERE Docking_ID IN 
(SELECT * FROM $table_name); 
8 SELECT $table_name.*, Docking_Table.Protein_Index, Docking_Table.Lig_Index, Proteins.uniprot, 
Proteins.Variant, Proteins.model_type, Ligands.pubchem, Protein_Info.*, Ligand_Info.*  
FROM $table_name  
JOIN Docking_Table ON $table_name.id = Docking_TableDocking_ID 
JOIN Proteins ON Docking_Table.Protein_Index = Proteins.Protein_Index 
JOIN Ligands ON Docking_Table.Lig_Index = Ligands.Lig_Index 
JOIN Protein_Info ON Proteins.uniprot = Protein_Info.uniprot 
JOIN Ligand_Info ON Ligands.pubchem = Ligand_Info.pubchem; 
9 $(‘(TABLE TAG) tbody’).on(‘click’,’tr’,function(){ 
10 Window.open((PHP file name).php?ID=+selectedValue); 
11 var selectedIDs = document.getElementById(“runid”).innerHTML; 
12 SELECT * FROM $opt_table WHERE $idcolname = ‘$selectvalue’; 
13 $exe_str2= “cd (location of where all protein PDB’s are stored) ; dssp2pdb -35 (name of pdb structure file to 
be created) (protein pdb file location) > (new Protein pdb file name) 2>&1”; 
14 $execute=shell_exec($exe_str2); 
15 If (file_exists($pdb) && is_readable($pdb)) 
16 mysqli_select_db($connection, '3DProteomeDatabase'); 
$result=mysqli_query($connection, " 
 SELECT * 
 FROM $opt_table 
 WHERE Docking_ID = '$RunID' 
 "); 
17 $result = mysqli_query($connection, "SELECT FROM $opt_table 
WHERE $idcolname = '$selectvalue' 
"); 
Table 5.2: Coding Table – this table shows all of the key code of MySQL, PHP,  Javascript, and AJAX that were used in 
the creation of the system. 
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Before this query can be executed, a connection between the PHP script and the database has to be 
made. The “$connection” variable is created so that a command can be inputted to establish a 
connection. The “$connection” variable was defined at the start of each PHP file that requires a 
database connection by the code shown in table 5.2 in row 2. The “Server” is the machine on which 
the database is stored. The “username” is the username of the MySQL server, and “password” is the 
password for that server. Finally, the name of the database is placed where “database” is located in 
the command. Now that a connection is established; the query can be run and be able to output a 
result. The query is executed by using the PHP code shown in table 5.2 in row 3. The output of this 
query is put into an array. This is so that the data can be easily accessed and sorted through using 
JavaScript. For this a “$data” variable by using the code shown in table 5.2 in row 4. This created a 
blank array. The array is used in a while loop which inputs each row of data one by one as an array 
record. This is subsequently encoded in JSON and is echoed so that the JavaScript file will be able to 
decrypt and read the results.  
JavaScript protein query process 
The JavaScript file decodes the JSON encoded data by using the “JSON.parse” function. The data is 
sorted through to obtain the relevant information needed for the table. A FOR loop is used to go 
through each record in the array and gather the relevant information. Within the FOR loop, the 
following variables are created, and a record column is assigned to it where the information can be 
extracted. The variables used are shown in table 5.3. 
Variable Name Variable 
ProteinID output[‘Protein_Index’] 
Gene output[‘proteinname’] 
UniProt output[‘UniProt’] 
Variant output[‘Variant’] 
Modeltype output[‘model_type’] 
Date output[‘Date_Created’] 
proteinName output[‘Protein_Name’] 
 
The data extracted from each record is added to a variable called “rowHtml” which contains HTML 
code for creating a table row. The extracted data is placed in the order of the columns, which are a 
part of the graphical user interface table. Once the FOR loop has completed, and each record’s data 
has been extracted the table is loaded onto the interface. The HTML code stored in the variable 
Table 5.3: Protein Query variables – shown in the table are what variables have been set for each column for the data 
extracted via JSON. 
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“rowHtml” is outputted using the JavaScript code shown in row 5 of table 5.2 with the “TABLE TAG” 
being set as “#protein_table”. This code outputs the HTML within the ‘protein_table’ DIV that has 
been created for the table in the HTML of the main page. This is initialized in DataTables, using the 
JavaScript code shown in row 6 of table 5.2 with the “TABLE TAG” variable being set as 
“#protein_table”. This outputs the table with added functionality such as a search bar and also 
options of how many records the user would like to view on each page. It will also add the selected 
CSS styling chosen for the table. 
Ligand Table Query 
The query used to extract data from the Ligand table is the same as the query used for the Protein 
Table. The only differences are the variables used within the query. The same PHP file is used as the 
protein table query. As an IF statement was created, the options that are passed to the PHP file will 
be different from those for the protein query. The “$opt_table” variable is set as ‘Ligands’, and for 
this, the “$opt_level” variable is set as ‘0’. The IF statement follows the “$opt_table” variable in 
order to set the other variables. For this query the variables set to query the Ligands table are shown 
in table 5.4. 
 
This is inputted into the same query as the proteins query, which is shown in row 1 of Table 5.2. Like 
the proteins query, a connection is established with the database, and the query is executed with 
the same commands. The output is inputted into an array and encoded using JSON. 
JavaScript Ligand query process 
The JavaScript process to extract the data from the Ligand data array provided by the PHP file is the 
same as the proteins query, the only difference being the columns of data which are collected. The 
encoded data is decoded with the “JSON.parse” function and put into a FOR loop to go through each 
record one at a time. The columns that are extracted are shown in table 5.5. 
Variable Name Variable 
$idcolname ‘Lig_Index’ 
$info ‘Ligand_info.uniprot’ 
$info2 ‘Ligands.uniprot’ 
$table_info ‘Ligand_Info’ 
Table 5.4: Set variables for extracting Ligand table data – shown are the set varables used to extract data from the 
Ligands Table. These will be used in the same query used for the protein table query. 
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The data that is extracted from each record is added to a “rowHtml” variable the same as the 
protein query within the loop. Once the FOR loop has completed the “rowHtml” variable is 
outputted to the graphical user interface using the JavaScript code shown in row 5 of Table 5.2. The 
“ligand_table” is the DIV that the HTML coded on the ligand viewer page. The DataTables is 
initialized on this HTML code by the JavaScript code shown in row 6 of table 5.2 with the 
“TABLE_TAG” set to “ligand_table”. Like the protein query, this gives the table added functionality. 
Docking Table Query 
For querying the docking table, a new separate PHP file is created. This newly created PHP file is 
required so that a large query can be passed to the database as there is a large amount of data 
involving multiple tables that have to be extracted. To provide the correct data for the user in the 
Docking table of the interface, 6 tables have to be queried within the database. These tables are the 
Docking_table, Protein_table, Protein_Info, Ligands_table, Ligand_info, and finally the temp table 
level, which is in use. The dockings that are extracted from the database all depend on the ids within 
the temp level table. Like the previous queries for the temp table level and for tables that are 
requested, the query criteria is as follows: the “$opt_table” equals “Docking_Table” and the 
“$opt_level” equals “0”. This then creates the “table_name” variable as 
“temp_Docking_Table_(user)_0”. The original query created for this is shown in table 5.2 in row 7. 
This query firstly requests all data within the Dockings table. The next step is to join this table with 
the Proteins table. This is so that details about the proteins involved in the docking can be matched. 
The tables are joined by using the “Protein_Index” columns of each table. Next, the Ligands table is 
joined to the Docking Table. This is done by using the link of the “Lig_Index” column of each table. 
Once these tables have been linked the next stage is to link the Proteins and Ligands table to each of 
their information tables. For the proteins table the “uniprot” column is used to link to the 
“Protein_Info” table, and for the Ligands table, it is linked with the “Ligand_Info” table using the 
“pubchem” column. The dockings requested to be displayed depending on the ID’s stored within the 
Variable Name Variable 
ligID output[‘Lig_Index’] 
pubchem output[‘pubchem’] 
Ligname output[‘Lig_Name’] 
Drugbank output[‘drugbank_id’] 
Date output[‘Date_Created’] 
Table 5.5: Ligand Query variables – shown in the table are what variables have been set for each column for the data 
extracted via JSON. 
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“temp_Docking_Table_(user)_0” table. The temp docking table number can vary according to the 
number of filters the user applied, e.g. “temp_Docking_Table_(user)_1”, 
“temp_Docking_Table_(user)_2”, etc. To do this a WHERE and IN clause is added to the end of the 
query. The WHERE clause is used so that only the records that follow this rule are extracted. The 
“Docking_ID” column is used within an IN clause which means if the “Docking_Id” is within for 
example a list, those results would be extracted. After the IN clause the “(SELECT * FROM 
$table_name)” is placed. This MySQL query extracts every ID within the temp table used as a list for 
the IN clause.  
When running this query on PHPMyAdmin, the query was extremely slow due to the number of 
records stored within the “Docking_Table”. It was taking up to 10 minutes to load and sometimes it 
crashed it. There was a need to optimize the query as 10 minutes is too long for a user to wait for 
results to load. After looking at the original MySQL query created and looking at different ways to 
optimize a query, the best method was only to extract specific columns from each table. For the 
Docking table, the only columns that are required are the Docking ID, Protein_Index, Lig_Index, and 
Date Created. Using an IN clause in a query slowed down the query considerably. The temp table 
only stores one column which is the id, and this id has numbers that relate to the Docking_ID in the 
docking table. So instead of using the IN clause, the temp docking table is included at the start within 
the SELECT clause. The query shown in row 8 of Table 5.2 is used to query the docking table of the 
MySQL database. The first line with the SELECT clause asks for specific columns from the 
Docking_Table, Proteins table, and Ligands table. Then for the Protein_Info, Ligand_Info, and temp 
table, the query asks for all the data within them. This is telling MySQL specifically what data is 
needed for the table so instead of getting every record and every piece of data associated with it the 
query now only gets the minimum amount of data required to satisfy the table outputted to the 
user. The query is run in the same manner as the Protein and Ligand queries using the 
“mysqli_query” command. The results are put into an associated array and encoded using JSON.  
JavaScript Docking query process 
As for the Protein and Ligand user interface tables, the JSON encoded data outputted by the PHP file 
is decoded and parsed using the “JSON.parse(output)” command. This is put into a FOR loop so that 
for each record the required data is extracted and inputted into a “rowHtml” variable with HTML 
code so that it can be uploaded to the User interface. The data required from each record within the 
array were the Docking ID, Protein Name, Gene Name, UniProt Code, Variant, Model type, Ligand 
Name, and PubChem ID. Once the loop has completed, and all the data has been extracted it is 
outputted to the user interface using the same code as the Protein and Ligand tables which are 
shown in row 5 of table 5.2 where the “TABLE TAG” variable is set to “#docking_table”. DataTables is 
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initialised using following code shown in row 6 of table 5.2 where the “TABLE TAG” is also set to 
“#docking_table”. Like the Protein and Ligand tables, this will give the Docking table extra 
functionality. 
Protein Selection 
The way the system has been designed enables the user to click on one of the proteins within the 
table outputted to the interface which creates another tab which displays all data about the selected 
protein, a 3D viewer showing the structure predicted and also a table showing a list of all dockings 
that have been calculated using that specific protein. Firstly, a is code created that makes it possible 
for a user to click a protein record in the table. To make it possible, the javascript code shown in row 
9 of Table 5.2 is used with the “TABLE TAG” set as “#protein_table”. This launches when a row is 
clicked within the “tbody” where the table items are stored. The function determines where the new 
window is created, and it contains all the information related to the selected protein.   
For the protein-specific page to be created the protein ID need to be pushed to a PHP file which 
extracts all the relevant data for it. The code shown in row 10 of Table 5.2 is used to launch a new 
tab within the web browser with the “PHP file name” set as Proteins_view.php. The “window.open” 
function creates a new tab in the web browser instead of loading the page in the current tab. This 
enables the user to look at multiple proteins at a time instead of the option of only looking at one 
protein at a time in a single tab. This opens the “Proteins_view.php” page and pushes the Protein 
“ID” of the row selected to it.  
5.3.2 Protein Viewer Page 
The “Proteins_view.php” page displays all information about the selected protein and ligands that 
this protein has been docked with, in two different tables. This page has a mixture of HTML, PHP and 
JavaScript within it. Between PHP tags the pushed “ID” is added to a variable in the page called 
“$RunID”. This is echoed in the page and is used to extract the relevant data from the database. A 
JavaScript file called “pViewer.js” is used to load up all the tables and the 3D Viewer with the data.  
Protein Viewer Page Protein data table 
The first data to be displayed is the Protein information table which is on the left side of the screen. 
A JavaScript function called “tableData” launches when the “Proteins_view.php” is opened. Within 
the function, a variable is created called “selectedIDs” which will store the ID of the Protein that has 
been selected. This is extracted from the PHP file “Proteins_view.php” by using the code shown in 
row 11 of Table 5.2. By using AJAX, to get the protein data, the protein ID is pushed to another PHP 
file called “get_database_data2.php”. The name of the table that needs to be queried is also pushed 
to this file.  
154 
 
The “get_database_data2.php” file is the primary way for data to be extracted for a single protein, 
Ligand or docking for the system. Due to this file being used for multiple query purposes, an IF 
statement is within it so that depending on what table data is requested it will set the correct 
variables for the query.  
To extract data from the proteins table, the table name pushed to this file is “Proteins” and is added 
to the variable “$opt_table”. This sets a variable called “$idcolname” to “Protein_Index” which is the 
column of the table that the variable “$selectedvalue” will be searched against. The “selectedvalue” 
variable will be the Protein ID that is pushed from the “pViewer.js” JavaScript file. Like the other 
queries for the main page, a connection is established to the MySQL database. This connection is 
used to submit the query shown in row 12 of table 5.2 using the variables. This gets all data from the 
Proteins table that has a “Protein_Index” value equal to the “$selectedvalue” value. The result of 
this query is put into an array and encoded using JSON to push back to the “pViewer.js” JavaScript 
file.  
The “pViewer.js” JavaScript file decodes the JSON encoded array and inputs it into a FOR loop so that 
each column of data needed can be extracted and inputted into a variable. The data extracted from 
the following array were the Protein ID, Gene name, UniProt, Model type, and Variant. After this, a 
second query is required to extract the relevant data from the “Protein_Info” table. This uses the 
“get_database_data2.php” file again to query the table, the difference being the “$selectedvalue” 
variable pushed is the uniprot code of the protein and the “$opt_table” variable is set as 
“Protein_Info”. As there is an IF statement in the PHP file this sets the “$idcolname” variable as 
“uniprot”. The same query is used as for querying the Proteins table earlier but using the variable set 
here. This will output all data within that table, which has an equal uniprot column value as the 
“$selectedvalue” value. These are also put into an array and encoded in JSON to be pushed to the 
JavaScript file.  
Using the same method as before the output is extracted to get all data from each column in the 
array and each column gives a separate variable. The data extracted from the query were the 
Protein Name, Organism, Other Known Gene names, Sequence length, and Sequence. All of this data 
is going to be stored into a “rowHtml” variable with HTML code which is uploaded to the user 
interface as a table. This table is outputted to a DIV called “prottable” which puts it into the correct 
location on the page which the CSS file has set it.  
Protein Viewer Page Docking results table 
On the protein viewer page, there is also a table which will include a list of drugs that have had a 
docking calculated with the selected protein. The user is also able to click on one of the drugs which 
155 
 
will then open another window and display that selected docking. To display this, a function called 
“dockingdata” is run on page load which will extract the docking data for the selected protein. 
Within this JavaScript function, it uses the Protein ID that is echoed in the page from earlier to 
search the docking table for all relevant results for that protein. The protein ID is set as the variable 
“selectedIDs” like previously discussed for the protein data table, and this is then pushed to a PHP 
file. Using AJAX, the ID and table used are pushed to the PHP file called “get_database_data.php”. 
For this query, as there are if statements which set a variable for the query, the table variable is set 
as “dockdata”. This is because this file is used for other queries and there is already an IF statement 
option with the table “Docking_Table”. By pushing these options, the variables set to query the 
database are shown in table 5.6. 
Variable name Variable 
$selectedvalue Protein ID pushed via AJAX/JSON 
$idcolname ‘Protein_Index’ 
$opt_table ‘Docking_Table’ 
 
These variables are applied to the query in row 12 in table 5.2. The next step is to set up a 
connection to the database and run the query. The query results are inputted into an array and 
encoded using JSON. This is pushed back to the JavaScript file. The “pViewer.js” file decodes the 
JSON output and is put into a loop to go through each record and extract the relevant column 
needed for the table. The columns extracted are the Docking ID, Protein ID, and the Ligand ID. The 
next stage is to get the information about the ligand so that it can be displayed in the table. The 
ligand ID that is extracted and pushed to the same PHP file but instead the “selectedvalue” is now 
equal to the ligand ID, and the table is now equal to the “Ligands” table. As the table is now the 
“Ligands”, the IF statement sets the variables shown in table 5.7 for the query. 
Variable name Variable 
$ selectedvalue Ligand ID pushed from the pViewer.js file via 
AJAX/JSON 
$idcolname ‘Lig_Index’ 
$opt_table ‘Ligands’ 
 
Table 5.6: Variables set within the get_database_data.php file for extracting docking data – the table shows the three 
variables that are set within the get_database_data.php to extract docking data from the MySQL database. 
Table 5.7: Variables set within the get_database_data.php file for extracting ligand data for protein docking table – the 
table shows the three variables that are set within the get_database_data.php to extract ligand data from the MySQL 
database. 
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These are put into the same query discussed above. These results are added into an array and 
encoded using JSON. As with the other results, these are decoded in the JavaScript file and run 
through a loop to extract data from each record. The data extracted from the ligand table is the 
PubChem ID. This is used to get the ligand name from the “Ligand_Info” table by using the same 
method but the variables set are shown in table 5.8. 
Variable name Variable 
$ selectedvalue PubChem Id pushed from “pViewer.js” via 
AJAX/JSON 
$idcolname ‘pubchem’ 
$opt_table ‘Ligand_Info’ 
  
The Ligand name is extracted from the array produced by the query. When all of the data has been 
gathered, all data is inputted into a “rowHtml” variable with HTML code which will create a table. 
This is outputted to the “docking_table” HTML tag in the protein viewer page, and DataTables is 
initialised to add extra functionality to it.  
Protein Viewer page 3D Viewer 
On the protein viewer page will be a 3D viewer which enables the user to view the predicted 
structure from either the homology or threading pipelines. The 3D viewer is created by using an 
open-source JavaScript library called PV - JavaScript Protein Viewer (https://biasmv.github.io/pv/). 
The viewer can show PDB structures and has a built-in secondary structure assignment to give the 
best visuals of the protein. Within the “pViewer.js” file the location of the PDB file of the protein is 
needed so that it can be loaded into the 3D viewer. A function called “load3Dprotein” was created 
for this process. Firstly, the protein ID is put into a variable called “thisPID”. This is pushed (svalue) 
with the table “Proteins” to the “get_database_data.php” page using AJAX to retrieve the location. 
The variables set within the PHP file are shown in table 5.9. 
Variable Name Variable 
$selectvalue svalue pushed from Javascript file 
$opt_table table pushed from Javascript file 
 
Table 5.8: Variables set within the get_database_data.php file for extracting ligand information data for the protein 
docking table – the table shows the three variables that are set within the get_database_data.php to extract ligand 
information data from the MySQL database. 
Table 5.9: Variables set to extract protein PDB file location – shown are the variable and their set data required to 
extract the file location of the PDB file for a selected protein from the MySQL database. 
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This variable, after going through the IF statement, sets the “$idcolname” variable as Protein_index 
which are used in the query for the database. The results of the query are put into an array and 
encoded using JSON. The “load3Dprotein” function decodes the output, and a loop is run to access 
the correct column of the record. The data extracted from the record is the Protein Name and the 
location of the PDB. To access the PDB file, a PHP script called “pdb_proxy2.php” is used to open it 
and extract all of the text within it and also process that data. Using AJAX, the protein ID as the 
variable “pdb” and the table the data is stored in is pushed from the “pviewer.js” JavaScript file to 
this PHP file. Within the PHP file, the protein ID is set as the variable “filename” and the table as 
“opt_table”.  
Firstly, in the PHP file, a query is used on the Proteins table to get the location of the PDB file for the 
protein with the selected ID using the “Protein_Index” column. The PDB file location is given as the 
variable “filename2”. For the protein to be able to show its secondary structure in the 3D viewer, 
this needs to be calculated before being uploaded to it. To do this a program called DSSP is used. 
DSSP is a program that has been developed by Wolfgang Kabsch and Chris Sander which has a 
database of secondary structure assignments for all proteins that have been inputted into the 
Protein Data Bank. To run this program in PHP, the code shown in row 13 of Table 5.2 is used. to 
execute that command within the PHP file the function shown in row 14 of Table 5.2 is used which 
allows the command to be executed in a shell which will, in turn, run the dssp program on the 
desired PDB file. This creates a new file with data about the secondary structure of the protein. The 
next stage is for the newly created file to be read and pushed to the JavaScript file. Firstly, an IF 
statement is created which checks that a location of the original PDB is set by using the “isset” 
function. If this condition is true, within the statement, a variable is created called “pdb” which will 
set the location of the newly created PDB file. When pdb variable has been set, another IF statement 
is created within the same IF statement that first checks if the file exists and if the file is readable. 
The IF statement used is shown in row 15 of table 5.2 where the “pdb” variable is inserted. If this 
condition is true, the content with the PDB file is extracted by using the “file_get_contents” function 
and is echoed. The file contents are passed back and put into a variable called “thisProteinText”. 
Some other variables are also created which are shown in table 5.10 which store  
Variable Name Variable 
thisIndex thisPID 
thisProtName ProteinName 
 
Table 5.10: Set variables for pdb information – shown are variable that are set in the javascript file that store 
additional information about the extracted protein PDB file.  
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other information about the extracted PDB file. The final variable that is created is “thisProtein”. This 
is where the molecules are constructed for the model using an I/O function built in the PV viewer. 
The final variable set is the “proteinStackData” which is set as a dictionary to store the data shown in 
table 5.11. 
Variable Name Variable 
struct: thisProtein the calculated molecules for the viewer 
text: thisProteinText the contents of the protein PDB file 
name: thisProtName Name of the protein 
 
Finally, a function called “drawSingleProt” is launched to initialise the 3D viewer in the Protein 
viewer page. The “drawSingleProt” contains the code that sets the settings for the 3D viewer. Firstly, 
two variables are created, one is called “protein” which stores the data stored within the 
“proteinStackData” variable, which is used in the “load3Dprotein” function. The other being 
“drawType” which sets how the 3D protein model looks within the 3D viewer. The viewer can display 
the protein in different ways that are built into the viewer, such as balls and sticks, lines, spheres, 
and cartoon. A Switch statement is used so that when a particular condition is set, this will 
determine how the protein will be viewed. The Switch function is shown in figure 5.5. The variable 
“drawType” is set to “drawTypep”; this sets options that are for the protein in the viewer and 
nothing else. The “drawTypep” is automatically set to “cartoonStr” when the protein viewer page is 
first loaded, but this can be changed by the user depending on which button the user clicks for the 
viewer which will be explained further on. This means that the function will set the “thisProtStruct” 
as “viewer.cartoon('protein', protein['struct']);” which will initialise the viewer with that setting. The 
user will have multiple buttons next to the 3D viewer on the Graphical user interface for the protein 
viewer. Each of these buttons is linked to a function within the “pViewer.js” file which sets the value 
of the “drawTypeP” variable which in turn changes what “thisProtStruct” variable is equal to and 
alters the way the Protein is displayed on the screen. The protein viewer is outputted to the 
“protimg” div tag which places it in the centre of the screen by the linked CSS. The User is able to 
zoom in and of the structure and also alter the viewing angle by turning it using the mouse. 
 
 
 
Table 5.11: Variables set to for the data stored within the protein PDB – shown are what parts of the extracted protein 
PDB are set to within the “pdb_proxy2.php” file. 
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Ligand Selection 
The user is also able to click a ligand within the table outputted to the interface which creates 
another tab which displays all data about the selected Ligand, a 3D viewer showing the structure, 
and also a table showing a list of all dockings that have been calculated using that specific Ligand. 
Like the proteins table, the code created makes it possible for a user to click a Ligand record in the 
table. To make it possible, a JavaScript function is created. The code that is used is shown in row 9 of 
table 5.2 which is applied to each table row. This code launches when a row is clicked within the 
“tbody” where the table items are stored. Within the function, the new window is created and has 
all the information related to the selected Ligand. Firstly, for the ligand-specific page to be created 
the ligand ID is pushed to a PHP file which extracts all the relevant data for it. The code shown in row 
10 of Table 5.2 is used to launch a new web browser window. The “PHP file name” in the code is set 
to “Ligand_view.php” with the selected value being the ligand ID of the clicked table row. The 
“window.open” function creates a new tab in the web browser instead of loading the page in the 
current tab. This is so that the user is able to look at multiple proteins at a time instead of the option 
of only looking at one protein at a time in a single tab.  
switch(drawType){ 
   case ("sticks"): 
    var thisProtStruct=viewer.ballsAndSticks('protein', protein['struct']); 
    break; 
   case ("lines"): 
    var thisProtStruct=viewer.lines('protein', protein['struct']); 
    break; 
   case ("spheres"): 
    var thisProtStruct=viewer.spheres('protein', protein['struct']); 
    break; 
   case ("cartoonPos"): 
    var thisProtStruct=viewer.cartoon('protein', protein['struct'], { color: 
color.rainbow() }); 
    break; 
   case ("cartoonStr"): 
    var thisProtStruct=viewer.cartoon('protein', protein['struct']); 
    break; 
   case ("tube"): 
    var thisProtStruct=viewer.tube('protein', protein['struct']); 
    break; 
   case ("points"): 
    var thisProtStruct=viewer.points('protein', protein['struct']); 
    break; 
  } 
 
Figure 5.5: Switch function which will change view type of the 3D protein within the 3D viewer 
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5.3.3 Ligand Viewer Page 
The “Ligand_view.php” page displays a 3D image of the Ligand and two tables, one with information 
about the Ligand and one with all proteins that have stored dockings which have been calculated 
using the selected ligand. This page has the same structure as the Protein viewer page. The only 
difference being the tables that are queried to extract the information from the database. Like the 
protein viewer page, a variable “$RunID” is pushed from this page to a JavaScript page called 
“lViewer.js” which sets up the page with the correct information and structure.  
Ligand Viewer Page Ligand data table 
Like the protein viewer page, the first item to be displayed is the Ligand data table which stores all 
data about the selected ligand. The only difference between the “pViewer.js” file and the 
“lViewer.js” file is that it uses Ligand data to extract the database instead of protein data. When the 
page is first loaded the function “tableData” is launched straight away which creates and fills the 
Ligand data table. The “$RunID” that was extracted from the “Ligand_Viewer.php” file is put as the 
value of the variable “selectedIDs” in the JavaScript file. By using AJAX, this variable is pushed to the 
“get_database_data.php” file the table value as “Ligands”. The data is extracted from the Ligand 
table for the selected ID and added to an array which is encoded using JSON. Shown in table 5.12 are 
the variables that were set in the “get_database_data.php” file. 
 
These variables are inputted into the query shown in row 12 of table 5.2 and executed. The JSON 
array is decoded by the “lViewer.js” JavaScript file, and the data extracted were the Ligand ID, 
PubChem ID, and Drugbank ID. After these have been extracted the PubChem ID is used to extract 
the correct ligand data by being pushed to the “get_database_data.php” file as the svalue and the 
table being “Ligand_Info”. By using the table name, shown in table 5.13 are the variables that were 
set. These variables are used in the query shown in row 12 of table 5.2 to extract the Ligand info for 
the selected ligand. The result is added to an array and encoded. The encoded array is decoded by 
the “lViewer.php” file and by using a loop extracts the Ligand name. When all the appropriate data 
has been extracted, these are added to a “rowHtml” variable which will set up the HTML code for 
Variable Name Variable 
$selectedvalue Ligand ID pushed via AJAX/JSON 
$idcolname ‘Lig_Index’ 
$opt_table ‘Ligands’ 
Table 5.12: Variables set within the get_database_data.php file – the table shows the three variables that are set 
within the get_database_data.php to extract ligand data from the MySQL database. 
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the table to be created. Like the Protein viewer page, this is uploaded to the “ligtable” DIV tag which 
is placed in the location on the screen determined by the CSS file.  
Table 5.13: Variable set within the get_database_data.php file to extract ligand data from the Ligand_Info table - the table 
shows the three variables that are set within the get_database_data.php to extract ligand information data from the 
Ligand_Info table within the MySQL database 
 
Ligand Viewer Page Docking results table 
Like the protein viewer page, there is a table on the right side of the screen which will have a list of 
all the proteins that have had dockings calculated using the selected Ligand. The user is also able to 
click on them, which will open another tab with the selected docking. To create this table like the 
protein viewer page, a function called “dockingdata” is run on the page load. This function will be 
used to extract the docking data and data of the proteins from the database. The core of this 
function is the same as the one used in the protein viewer page, the only difference being the 
variables pushed to the PHP files, and that ligand data is extracted not protein data. This function 
firstly gets the ID of the Ligand selected and push this to the “get_database_data.php” file as the 
“svalue” variable and the “table” variable will be set as “dockdata2”. Within the 
“get_database_data.php” file the dockdata2 the variables set are the same as shown in table 5.12 
the only difference being that the variable “$opt_table” is set to “Docking_Table” instead of 
“Ligands”. These variables are entered into the query shown in row 12 in table 5.2 like for the Ligand 
Viewer Page Ligand data table. The results are added to an array and encoded in JSON. The encoded 
results are pushed back to the JavaScript file where they are decoded. The decoded array is put into 
a loop so that each row is read individually to the Docking ID, Protein ID, and Ligand ID. For each 
record, the Protein ID is pushed to the “get_database_data.php” file so that data about the proteins 
can be extracted. The “table” variable is set to “Proteins” which sets the variables shown in table 
5.14. 
 
Variable Name Variable 
$selectvalue PubChem ID pushed via AJAX/JSON 
$idcolname ‘pubchem’ 
$opt_table ‘Ligand_Info’ 
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Table 5.14: Variable set within the get_database_data.php file to extract protein data from the Proteins table - the table 
shows the three variables that are set within the get_database_data.php to extract protein data from the Proteins table 
within the MySQL database. 
 
These variables are inputted into the query shown in row 12 of table 5.2 like previously for Ligand 
viewer page ligand data table. Like previously, these results are added to an array and encoded. The 
JSON array is decoded, and the UniProt, Model type, and Date created columns are extracted. The 
UniProt value is used to extract the Protein data from the “Protein_Info” table for each protein. So 
again the “get_database_data.php” file is used to extract this data with the UniProt value and the 
“table” variable set to “Protein_Info”. This sets the variables shown in table 5.15.  
Table 5.15: Variable set within the get_database_data.php file to extract protein data from the Protein_Info table - the 
table shows the three variables that are set within the get_database_data.php to extract protein information data from the 
Protein_Info table within the MySQL database. 
 
These are also used in the query shown in row 12 of Table 5.2. The query is executed and added to 
an array. The array is encoded and pushed back to the “lViewer.js” JavaScript file. The JSON array is 
decoded and inserted into a loop where the Protein Name and Gene column data are extracted. The 
Docking ID, Protein Name, Gene, Model type, and Date created for each docking are all added to a 
“rowHtml” variable which adds HTML tags to them so that a table can be created. The code that is 
used is shown in row 5 and 6 of table 5.2, which uploads the table to the “Ligand_view.php” 
interface and initialise DataTables. The “TABLE TAG” for both lines of code were set to 
“#dock_table”. Like the protein viewer page, the user is able to select individual dockings which 
open a new tab with that docking. 
Ligand Viewer page 3D Viewer 
Identical to the 3D viewer in the Protein_viewer.php web page, the user is able to view every single 
ligand on their page which is selected from the ligand table of the database.php page. The 
“Ligand_viewer.php” page has its JavaScript file called “lViewer.js” which has all the code that is 
Variable Name Variable 
$opt_table ‘Proteins’ 
$svalue Protein ID pushed via AJAX/JSON 
$idcolname ‘Protein_Index’ 
Variable Name Variables 
$opt_table ‘Protein_Info’ 
$selectvalue uniprot value pushed via AJAX/JSON 
$dcolname ‘uniprot’ 
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within the “pViewer.js” file but modified to satisfy the need to display the ligand instead of a 
protein. To get the location of the ligand PDB file, a function called “load3DLigand” is used. This is 
the same as the “load3Dprotein” function used in the “pViewer.js” file. The 
“get_database_data.php” is passed the variables shown in table 5.16.  
Table 5.16: Variables set within the “get_database_data.php” to extract Ligand PDB data – shown are the variables set to 
extract Ligand PDB data for use within the 3D viewer. 
 
Within the PHP file, the information about that ligand is extracted from the Ligand table and outputs 
it as a JSON array back to the JavaScript file which the ligand file location is extracted with the 
PubChem ID. The next stage is to access the ligand PDB and extract its contents. A PHP file is used 
called “pdb_proxy3.php” which uses the drug ID used at the beginning and the table “Ligands” as its 
variables which are pushed to it using AJAX. The PHP file is based on the “pdb_proxy2.php” file used 
for the Protein viewer but with some minor changes. There is no need for DSSP to be used on the 
Ligand as it is not a protein with secondary structure.  
Within the PHP file, the PDB file is opened if it exists and the contents within are extracted which are 
then echoed back to the JavaScript file so that it can be read. All the contents, as for the protein 
viewer page are added to a dictionary called “ligandStackData” with the variables shown in table 
5.17. 
Table 5.17: Variables set to for the data stored within the Ligand PDB – shown are the part of the Ligand PDB that is set to 
within the “pdb_proxy2.php” file. 
Variable Name Variable 
struct: thisLigand the calculated molecules for the viewer 
text: thisLigandText the contents of the Ligand PDB file 
name: thisLigName Name of the Ligand 
 
By using the same method as that used in the protein viewer section, the contents are pushed to the 
“drawSingleLigand” which is the same as “drawSingleProt” function used in “pViewer.js” file, which 
displays the Ligand in the viewer on the page. The slight differences compared to the protein viewer 
page is that the drawType sets as “drawTypel”.  This is so that only display options with drawType = 
drawTypel can be used for changing how the ligand is displayed in the 3D viewer, for example, to use 
the view options Tube, sticks, spheres and dots. The Ligand viewer is outputted to the “ligimg” div 
Variable Name Variable 
Table Ligands 
Pdb The ID of the Ligand 
164 
 
tag which places it in the centre of the screen by the linked CSS. The user is able to zoom in and of 
the structure and alter the view by turning it using the mouse. 
Docking Selection 
Finally, the user will be able to click a single docking within the docking table on the main page, 
which will open a single tab for that selected docking. The docking page will contain a table with 
information about the protein used in the selected docking and information about the ligand used in 
the selected docking. Also, a 3D Viewer which shows the 3D docking which the user is able to view 
and analyse. The user is also able to view any of the ten conformations predicted by the docking 
algorithms, separately or all together, in the single viewer. Finally, there is a table displaying all the 
associated scores with the selected conformation of the selected docking. The entire page is loaded 
by using a single JavaScript file called “viewer.js”. 
Protein information and Ligand Information Tables 
These are created by using the same method used in the Protein Viewer and Ligand Viewer pages to 
display all the data associated with the protein used within the selected docking. The function called 
“dockingdata” is used to gather the information needed for the tables. Firstly, there is a need to 
extract what protein and ligand are used in the selected docking. To do this, AJAX is used to extract 
this information from the database. The ID of the docking selected is pushed to the JavaScript file as 
the variable “thisDID” which is used as the docking ID pushed to the “get_database_data.php” with 
the Table variable as “Docking_Table”. Within the PHP file, the data of the selected docking is 
extracted from the “Docking_Table” which is encoded using JSON and pushed back to the JavaScript 
file. The function decodes the data and extracts the Protein ID and Ligand ID of the protein and 
ligand used in the selected docking and adds them to the variables shown in table 5.18. 
Table 5.18: Variables set for the get_database_data.php file to extract docking data for the protein and ligand information 
data tables – these are the set variables to extract protein and ligand information form the protein_info and lig_info tables 
in the MySQL database. 
Variable Name Variable 
LigaID Ligand ID 
ProtaID Protein ID 
 
These ID’s is used to extract the associated data for the protein and ligand. The data for the protein 
is first extracted using the identical method used for the Protein Viewer page. Using the same AJAX 
call to the “get_database_data.php” the protein ID extracted previously (ProtaID) is used as the 
svalue with the table variable being set as “Proteins”. This will extract all the information about the 
protein with the same ID in the Proteins table and pushes it back to the “viewer.js” JavaScript file. 
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With the results pushed, the function extracts the Protein Name, Uniprot ID, model type, and 
Variant. Next, the uniprot id’s that were extracted are used to get the information associated with 
the selected protein from the “Protein_Info” table. The PHP file returns the extracted data to the 
JavaScript file, which extracts the protein data Gene, alternative names, sequence length, protein 
sequence. These are all put into a variable called “rowHtml” with HTML code which creates a table 
on the selected docking viewer page. This is outputted to the docking viewer page using the code 
shown in row 5 of table 5.2 with the “TABLE TAG” being set as “#protein_table”. 
The same process is used but, in this case, to extract the Ligand data from the database. The “LigaID” 
is pushed to the “get_database_data.php” with the table variable “Ligands” which will extract the 
data associated with the ligand ID. This is encoded and pushed back to the “viewer.js” JavaScript file 
which decodes and extracts the PubChem ID, drugbank ID, and Date loaded to the database. The 
PubChem ID is used to extract the data from the “Ligand_Info” table for the ligand used in the 
docking. The data extracted from this is the Ligand name. The data collected is added to a variable 
“rowHtml2” with HTML code which creates a table with the ligand data within it. The code shown in 
row 5 of Table 5.2 is used to add it to the ligand_table div on the page with the “TABLE TAG” being 
set to “#ligand_table”. 
5.3.4 Docking 3D Viewer 
The 3D viewer on the docking viewer page is the same as the 3D viewers on the protein and ligand 
viewer pages. The only difference being how the protein and conformations are loaded into the 
viewer within the “viewer.js” JavaScript file. The basic structure is the same compared to the 
“pViewer.js” and “lViewer.js” JavaScript files, but as there are multiple conformations that can be 
loaded into the 3D viewer, the new code has been developed to accommodate this.  
Protein PDB upload 
Like the protein viewer page, a function called “load3Dprotein” is used to load the protein into the 
viewer. The ID of the protein involved in the selected docking was extracted previously within the 
“tableData” function, described earlier, which is used in this function to get the location of the PDB 
file. This is pushed to the “get_database_data.php” file as the svalue variable with the variable table 
equalling “Proteins” by using AJAX. This extracts the record associated with the ID pushed within the 
Proteins table and encode it in JSON and return it to the JavaScript function. This is decoded and 
inputted into a loop which then only extracts the data from the column’s protein name and the 
location of the PDB. After this data has been extracted the protein ID is used again and pushed to 
the “pdb_proxy2.php” file which runs DSSP on the PDB to add secondary structure data using the 
code shown in row 13 in table 5.2. The PDB file is read, and the contents are pushed back to the 
function within the JavaScript file. The contents of that PDB file are added to the variable 
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“thisProteinText”, and the protein name and ID are set as the variables “thisProtName” and 
“thisIndex”. These are added to a dictionary called “proteinStackData” which stores all the data as 
shown in table 5.19. Finally, the function “drawSingleProt” is started which initialises and loads the 
protein PDB to the 3D viewer on screen.  
Table 5.19: Variables set to for the data stored within the protein PDB – shown are what part of the protein PDB are set to 
within the “pdb_proxy2.php” file. 
Ligand PDB upload 
This is where the code differs compared to the ligand viewer page as there are up to 10 
conformations that will be able to be displayed on the 3D viewer with the protein involved. This all 
starts a JavaScript function called “load3Ddocking”. Within this function, the conformation file is 
opened, and each conformation is split into its entity which makes it possible for the user to select 
what conformation to view on the screen.  
The Docking ID that was pushed to the docking viewer page is used to gather the information about 
the location of the conformation file for the selected docking. AJAX is used to extract this 
information from the database. A PHP file called “get_ligand_models2.php” is used to extract this 
data by using the variables shown in table 5.20, which are pushed to it from the JavaScript function. 
Table 5.20: Variables set to extract ligand conformation file location – shown are the variable set within the 
get_ligand_models2.php file which would allow the location of the specific conformation file for the selected docking pair to 
be extracted from the MySQL database 
Variable Name Variable 
pdb Docking ID 
Table Docking_Table 
Numofres 1 
 
The first thing is for these to be set as different variables within the PHP file, so the PDB variable is 
set as pdb2, and a filename, the table as $opt_table, and the Numofres is set as Numoflig. By using 
these variables, the first thing the PHP file does is to extract the selected docking record from the 
Docking_Table by using the following code shown in figure 5.6. When the record has been extracted 
Variable Name Variable 
struct: thisProtein the calculated molecules for the viewer 
text: thisProteinText the contents of the protein PDB file 
name: thisProtName Name of the protein 
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from the table, within a while loop the “results_file” column is extracted and set as the variable 
“filename2”. Once the conformation file location has been extracted, there is a need to unzip the 
file. The way the file system is set up each protein has its zip file which will contain all the ligand 
conformation file that had been calculated for that protein. The file is zipped to save hard drive 
space on the system. Shellcode is used to extract the files stored in the zip file, which allows access 
to the conformation data required.  
An IF statement is used to check firstly that the file that is required exists and that it is readable. If 
both statements are true, Using OBABEL  the conformation file is converted to the correct PDB file 
format . The conformation files are in a MOL2 format which is the output given by the docking 
algorithms. OBABEL also splits all the ligand conformations stored within the file into their own 
entity. Once the MOL2 file has been converted and split is to access each of those separate 
conformations and extract the contents and add them to an array which is encoded using JSON and 
pushed back to the JavaScript function “load3Ddocking”. These are decoded, and a for loop is used 
to extract each conformation data separately. For each of the conformations within the array, they 
are added to a dictionary called “ligandStackData”. Shown in table 5.21 are the variables which will 
store the data for each of the conformations. 
Table 5.21: Variables set for the data stored within the ligand conformation PDB – shown are what part of the ligand 
conformation PDB are set to within the  file. 
Variable Name Variable 
Struct: thisStruct the calculated molecules for the viewer 
text: thisLig the contents of the ligand PDB file 
i: LigandID Ligand ID number 
j:j Conformation number within the file 
 
Once all the conformations have been added to the dictionary, the function “drawLigands” is 
launched which displays the conformations within the 3D viewer. Within this function, it is 
mysqli_select_db($connection, '3DProteomeDatabase'); 
$result=mysqli_query($connection, " 
 SELECT * 
 FROM $opt_table 
 WHERE Docking_ID = '$RunID' 
 "); 
 
Figure 5.6: code that establishes a connection with the MySQL  - the 
shown code is used to extract the specific docking record from the 
Docking_Table within the MySQL database by setting the $opt_table 
and $RunID variables. 
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determined what conformation is displayed within the 3D viewer. The user can choose which 
conformation 1 to 10 or all at the same time by selecting one of the radio buttons on the screen. On 
page load, the top conformation is displayed automatically. The “drawLigands” function first sets the 
“drawType” to “drawTypeL” which is for functions that control how the ligand conformation will 
look in the 3D viewer. An IF statement is opened which first checks that the “ligandStackData” 
dictionary is not empty because if it was that means there are no conformations to display. If the 
dictionary does contain conformation information, the function enters another for loop which 
extracts the conformations required. The code shown in figure 5.7 is used to upload the required 
conformation(s) to the 3D viewer. The variable “thisLig” is where the number of the conformation 
which is required to be shown is set. The variable “conf” is set by the radio button which is selected 
by the user on the screen. In this case, only the top conformation is shown in the viewer, so the 
“conf” variable is set to 0. This will extract the top conformation from the “ligandStackData” 
dictionary. There are different options of how the conformation looks on screen, the default being 
sticks. This displays the top conformation with the selected protein within the 3D viewer in its 
calculated docking coordinates.  
Docking conformation results table 
Finally, on the screen is the table which displays all the calculated scores for the conformations that 
have been selected to be displayed within the 3D viewer. The user is able to view the scores of 
individual conformations 1 to 10 or view them all at once. To display the requested conformation 
data, a JavaScript function called “dockingResults” is used. First thing this function does is to collect 
all the Scores associated with the selected docking. Within this function, the docking ID of the page 
is used and set as the variable “thisRID”. The function is used to extract all the scores that are stored 
for (j in usedLigandPoses){ 
var thisLig=usedLigandPoses[conf]; 
 var ligName='ligand'; 
 switch (drawType){ 
  case ("sticks"): 
   var thisLigStruct=viewer.ballsAndSticks(ligName, thisLig['struct']); 
   break; 
  case ("lines"): 
   var thisLigStruct=viewer.lines(ligName, thisLig['struct']); 
   break; 
  case ("spheres"): 
   var thisLigStuct=viewer.spheres(ligName, thisLig['struct']); 
   break; 
  case ("dots"): 
   var thisLigStruct=viewer.customMesh(ligName); 
   ligCenters.addSphere(thisLig['struct'].center(),0.5,{color:'#0000FF'}); 
   viewer.requestRedraw(); 
   break; 
  } 
 
Figure 5.7: Switch function which will change view type of the 3D ligand within the 3D viewer – shown is the code used 
that will allow the user to change the view type of the ligand within the 3D viewer. 
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in the database table “Scores” which are linked to this ID. To extract this data an AJAX call is used to 
send and receive data to the PHP file “get_dockdata.php” which extracts the data from the 
database. The variables set within the PHP file are shown in table 5.22. 
 Table 5.22: Variable set within the get_database_data.php file to extract docking scoring data from the Scores table - the 
table shows the three variables that are set within the get_dockdata.php to extract docking score information data from 
the Scores table within the MySQL database. 
 
The query shown in row 17 of Table 5.2 is used to extract the data from the Scores table, which links 
to the Docking ID of the selected docking. For all the scores extracted an array is created to store all 
the data. A WHILE loop is used to split up the data so that all scores associated with one 
conformation and is added to a dictionary within the array so that all scores linked to one 
conformation are put together under one entry. When the creation of the array has been 
completed, it is encoded using JSON and pushed back to the JavaScript function.  
The JSON array is decoded and read by the function. For extracting the data from the array, there 
are two options which are decided by the user. One being if the user would like to view all the 
conformations data and scores at once or to view each conformation individually. This requires an IF 
statement which determines what data is uploaded to the page. The variable “confdata” will 
determine what the IF statement will do. When the page is loaded “confdata” automatically set to 0 
which is the top result of all the conformations. The two options, one being if “confdata” is set as 
“allposes”, and an ELSE statement if it is not set to it. For this case, “confdata” is not set to “allposes” 
so the ELSE statement would be used. Within this statement, many variable values are set, which are 
Variable Name Variable 
$selectvalue selected docking ID 
$opt_table Scores (table within the database) 
$idcolname Docking_ID (column within the Scores table) 
var Dock_affinity= obj[confdata].Dock_Affinity; 
var Dock_van_der_Waals = obj[confdata].Dock_van_der_Waals; 
var Dock_Electrostatics = obj[confdata].Dock_Electrostatics; 
var Dock_Internal_energy = obj[confdata].Dock_Internal_energy; 
var GBSA_Affinity = obj[confdata].GBSA_Affinity; 
var GBSA_van_der_Waals = obj[confdata].GBSA_van_der_Waals; 
var GBSA_Electrostatics = obj[confdata].GBSA_Electrostatics; 
var GBSA_Born_solvation = obj[confdata].GBSA_Born_solvation; 
var GBSA_Solvent_accessible_surface_area = 
obj[confdata].GBSA_Solvent_accessible_surface_area; 
var Vina_Affinity = obj[confdata].Vina_Affinity; 
var Vina_Repulsion = obj[confdata].Vina_Repulsion; 
var Vina_H_bond = obj[confdata].Vina_H_bond; 
var Vina_Hydrophobic = obj[confdata].Vina_Hydrophobic; 
var DSX_Atom_distance = obj[confdata].DSX_Atom_distance; 
var DSX_Contact_count = obj[confdata].DSX_Contact_count; 
var DSX_Per_contact = obj[confdata].DSX_Per_contact; 
 
Figure 5.8: Scoring function variables for the docking data table – shown are all the 
variables that are set for all the scoring functions extracted from “confdata”. 
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shown in figure 5.8 so that a table can be created on the webpage. The important variable is the 
“confdata” variable which is used to extract the correct scores associated with that conformation ID. 
The code shown above are the variables that are created for all the scores associated with the 
conformation number. The “obj[confdata]” code is telling which conformation dictionary to extract 
the data from, for example, the dictionary with ID 0. The name of the column is used to extract the 
score associated with it. The results are added to a variable called “rowHtml3” with some HTML 
code which will create a table when added to the Docking viewer page. This is uploaded to the 
docking viewer page by using the code shown in row 5 of table 5.2 with the “TABLE TAG” set to 
“Dockres” to load the table to the DIV tag “Dockres” which is hardcoded into the main docking 
viewer page. 
After the docking viewer page has loaded, the user is able to change which conformation data is 
shown on screen by using the radio buttons provided. These radio buttons are linked to a click 
function within the “viewer.js” file that when selected will change the data within the docking 
results table automatically. This is done by using If and ELSE IF statements. Within each option, two 
variables are given values depending on what conformation is selected. Shown in table 5.23 are the 
variables used within the ELSE IF statement. 
Table 5.23: Variables set within the IF ELSE statements within the viewr.js file – shown are the variables set within the IF 
ELSE statement which will allow the user to select which conformation they would like to view within the 3D viewer. 
Variable Name Variable 
conf the number of the conformation selected for 
what conformation to display in the 3D viewer 
confdata the number of the conformation selected for 
what data to display in the docking results table 
 
Within each of the IF and ELSE IF statements the functions “drawLigands” (to draw the conformation 
within the 3D viewer) and “dockingResults” (to display the associated results in the docking results 
table) are launched. This makes viewing the results for the user interactive.  
5.3.5 Database Page HTML 
The visual page is a PHP file but consists of mainly HTML code. This is where the content is inputted. 
This page consists of a “head” tag and a “body” tag. The “head” tag has within its things such as links 
to external libraries and JavaScript files and is linked to CSS files to the page. Within the “body” tag is 
where all the content is inputted into.  
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Firstly, within the “body” tags, DIV tags are added which have ids and classes associated with them. 
The created JavaScript file can send content to these tags which position the content needed and 
links with CSS which tells where and how the content should look on the screen. There are DIV’s 
used to identify different areas of the page so that the CSS can position the tables to the desired 
area. The database page has three different DIV’s for the locations of the tables. The protein table 
DIV is the top left of the page; the ligand table is the top right of the page in line with the proteins 
table, which is shown in figure 5.3. These will take up 47% of the screen width each. The DIV for the 
docking table is below both other tables and be set for 95.6% of the screen length. CSS is used to tell 
the web browsers where these DIV’s should be placed on the screen. The following CSS is used for 
these 3 DIV’s shown in figure 5.9. 
For designing the tables, a JQuery plug-in is used called DataTables (http://datatables.net). 
DataTables is a library of CSS and JavaScript files that have been created explicitly for displaying and 
giving enhanced functions to any HTML table. To design how the table looks, Bootstrap 
(http://getbootstrap.com/) is used. The DataTables code is within the main JavaScript file for the 
main page, which initializes the DataTable functions once the data has been generated to display. 
To prepare the database page for the data that is generated by the JavaScript file, a component 
needs to be added to the HTML code so that the JavaScript functions can be coded to interact with 
them. The Protein and Ligand table sections have two radio buttons and three submission buttons 
respectively. The two radio buttons are for two options for the user either to view all the 
proteins/ligands in the system or to look at a saved list that the user may have created. There is an 
Update button which when clicked displays the number of proteins available from the list that has 
been selected. The next button within the Protein and ligand table panels is for adding a database 
filter. This is how the user will be able to filter down the results they are looking at to their specific 
search. JavaScript is used to interact with this button which adds the option, which will be explained 
further on in the chapter. The final button within these panels is an update query button. When 
clicked this will start a function that extracts the data that matches the criteria of the search and 
Protein and Ligand DIV’s 
.col-md-6 { 
Width: 47%; 
}  
Docking DIV 
.col-md-11 { 
Width: 95.6% 
} 
Figure 5.9: CSS used for page containers – the code shown is 
used to set columns within the webpage which will then be 
used to help set locations for tables and the 3D viewers 
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output it into the panel using DataTables. To create the radio buttons for the panels, the “input” tag 
is used within the HTML with the option “type=’radio’” set. Both radio buttons are given the same 
name so that the JavaScript file can identify the two different options which can be linked with a 
single function. The only difference is the “value” variable given to each radio button. To create the 
submission buttons on the page, the HTML tag “button” is used with the option “type=’button’” set. 
Each of these buttons is given a different ID which associates with a function within the JavaScript 
file when clicked. The only difference between the Protein and ligand panels and the docking panel 
are that there’s one extra radio button that can be selected within the docking panel. The user can 
select multiple proteins and ligands from the protein and ligand panel. The extra radio button option 
is so when selected; the docking table only displays dockings involving those selected on the page. 
Finally, on the database page is the three main DIV with the ID’s of “protein_table”, “ligand_table”, 
and “docking_table”. These are used to output the results generated for the protein, ligand, and 
docking tables.  
Search filtering 
As mentioned before having temp tables that store all the ID’s of the proteins/ligands/dockings to 
extract and display in the tables will enable them to be filtered down according to  the decisions 
made by the user. The user is able to add filters that they can search so that it narrows down the 
number of proteins/ligands/dockings that are displayed. This helps the user to find the desired 
results from a large amount of data that is stored in the system. The user is able to add these filters 
by using a button on the table panel. The user is able to add as many filters as they want, but for 
every filter added a new temp table is created as will now be explained. By using JavaScript, every 
time a filter is added and executed a new temp table will be created in the MySQL database which 
stores all the ID’s that are matched with the search criteria inputted by the user. Figure 5.10 shows 
the design of the proteins table of the main page, which includes the database filter button. When 
all the filters have been added the user then clicks the button “Update Table” which then updates 
and loads all the data that equals all the database filters set. This set up is a similar design to the 
Ligand and Docking table on the database page but set up for Ligand table data and docking table 
data respectively. 
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5.4 GUI Implementation 
This section is how the graphical user interface has been implemented and how a user can use it for 
protein, ligand, and protein interaction investigations. 
5.4.1 Login page 
The login page is the first page that the user will view after typing in the URL for the website. Shown 
in figure 5.11 shows the created login page. The created logo for the site is displayed in the middle of 
the page. When the user clicks the logo, a form will open where they can log in to the database or 
sign-up. If the user has not got an account, there is a hyperlink on the form which will allow them to 
sign-up to use the database. By clicking the hyperlink, it takes the user to a form shown in figure 
 
All Proteins           Saved Lists  
  
Number of Proteins selected 
Add Database Filter Update Table 
  
Protein Table Results 
Update 
Figure 5.10: Protein table filter design – shown is the design of the protein table panel of the 
database page. 
Figure 5.11:  login page – shown is the login page which the user views. The user clicks the logo shown in the left 
photo which will open the login form. The login form has a username and password inputs with a login button 
and sign up (registration) button. 
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5.12. There are four input boxes on the form. The top one is for the user to create a username to use 
to log in. The second input box is for the user to give their email address.  
Finally, the last two input boxes are for the user to set a password. There are two boxes which are 
used to verify that the password meets the credentials needed for it to be accepted by the system 
and to verify that the users have typed the correct password they would like to use. When the user 
has completed the form, they then proceed by clicking the register button. If all the information is 
correct, then the user will then be taken back to the login page so that they can proceed to log in. In 
figure 5.11, when the user has login credentials, they input the username into the first input box 
followed by the password in the second input box. When completed the final step is to click the login 
button to gain entry to the database.  
Figure 5.12: registration form – shown is the registration form which allows the user to create an account for 
the system which will grant them access to the docking database. 
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5.4.2 Database page 
If all login credentials were correct, this then allows the user to access the central database page. 
The database page is where the user will be able to select proteins, ligands, and docking pairs to 
view in the system. The database page viewed is shown in figure 5.13. Three forms are visible, one 
for protein selection, ligand selection, and docking selection.  
Figure 5.13: database page - shown is the database page which the user views after login. The page displays a proteins 
selection panel (top left), Ligand selection panel (top right), and a docking selection panel (bottom).   
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Protein selection table 
The protein selection table displays the proteins that are stored in the database which is shown in 
figure 5.14. The first options for the user involve deciding whether they would like to view all the 
stored proteins in the database or look at  a saved list of specific proteins. The saved list selection 
will display all saved lists for that specific user if they have previously saved a group of proteins. 
After a list or the “All Protein” option has been selected the user clicks the “Update” button to load 
in those proteins. Shown in figure 5.15 shows how many proteins are within the user’s selected set. 
When the loaded proteins have been selected, the user will have options to use other filters to 
narrow down the loaded protein set to find the specific protein of interest.  
Figure 5.15: filter option panel within the proteins selection panel – shown is an option panel where 
the user can select either to search all proteins which are stored in the database or a saved list they 
may have created in a previous session. 
Figure 5.14: Protein selection panel – shown is the Protein selection panel were the user can select the protein of interest 
which are stored in the database. The user can add filters and view a list of proteins in table form. 
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Protein table filter options 
Shown in figure 5.16 is an example of a filter that can be selected by the user to narrow down the 
results of the loaded proteins. The user can add a filter by clicking the “Add database Filter” button 
shown in the red box in figure 5.16. Shown in figure 5.17 are the different columns that the user can 
apply a filter too. The user has the option to either select columns of stored data within the 
database or can search using a string. Once the user has selected the options or search term desired, 
the “Update” button shown in figure 5.16 within the green box is the clicked. The system will then 
gather all the proteins that meet the selected criteria. Shown in the blue square in figure 5.16 is the 
number of proteins that are within the filtered set. The user can remove any the filter by clicking the 
remove button shown in the purple box in figure 5.16.  
Protein results table 
With the selected protein chosen, the user would then click the “Update Query” button which will 
load the data for that selected protein into a table. Figure 5.18 shows the full table after the “Update 
Query” button had been clicked. The full table shows the Protein Index, Gene Name, UniProt ID, 
Protein Name, Variant, Model Type, and the Date Created.Within the red box shown in figure, 5.18, 
the user can select the number of data rows are shown on each page of the data table. The options 
that are selected for the number of results displayed on each page are 10, 25, 50 and 100. The blue 
box shown in figure 5.18 is where the user can search the full table for specific strings such as a 
protein name or date created. The user has the option to save the loaded protein results as a 
personal list. Instead of searching for those selected proteins every time the user logs in, they will be 
able to pre-load the saved list with those proteins of interest. The green box shown in figure 5.18 
shows the “Save all as list” button which will save the loaded proteins as a list. To view further data 
Figure 5.17: filter column options 
for the protein table – shown are 
the different columns whichare 
able to be searched using the 
search filter in the protein panel. 
Figure 5.16: shows the view of the protein filtering options available to the 
user: Shown in the green box is the “Update” button to set the filter. Shown in 
the blue box is an indicator of how many proteins meet that criteria. Shown in 
the purple box is a “Remove” button which deletes the filter. Shown in the red 
box is how a user can add a filter another filter to the query. 
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and a 3D model of any of the loaded proteins in the protein table, the results row is clicked opening 
a dedicated page for that protein.  
Ligand selection table 
The ligand selection table is the same as the protein selection table discussed previously. The screen 
view of the ligand selection table is shown in figure 5.19. Like the protein selection table, the first 
option to choose is to either view all of the ligands that are stored within the database or load up a 
saved list. This selection is shown in the green box in figure 5.19. Once either option has been 
selected, the “Update” button should be clicked which will load up the selected proteins from the 
database.  
Ligand table filter options 
Like the filter options discussed for the protein selection table, by clicking the “Add database filter” 
button, the user has the option to add a filter to the currently loaded ligands. Figure 5.20 shows how 
this function will look on the screen. The columns can have filters to the Ligand Name, PubChem ID, 
DrugBank ID, and Date created columns. 
Either a string can search within the selected column or options can be selected from a list of stored 
data in the selected column. After a search string or data filters have been selected, the “Update” 
Figure 5.18: Protein results table view - Shown is the table that is loaded with protein data for the proteins for the selected 
protein. shown in the blue box is a search bar that can be used to search the proteins within the table. Shown in the red box 
are option of how many results to show on one page. Shown in the green box is the “Save all as list” which saves a private 
list of all the proteins within the table. 
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button is then clicked which will apply the filter. The number of ligands that meet the selected 
criteria of the filter is shown in the red box in figure 5.20. To remove any filter, click the Remove 
Figure 5.19: Database page for Ligand selection panel - shown in the green box are options to view all ligands in the 
database or a saved list. Shown in the blue box is an “Update” button which will load the selected protein data. 
 
Figure 5.20: The database page’s protein selection panel filters - shown is the view 
of the ligand filtering: shown in the blue box is an “Update” button that will apply 
the filter. Shown in the red box are the number of ligands that meet the criteria of 
the filter. Shown in the yellow box is the “Update Query” button which will update 
the main ligand data table. Shown in the green box is the “Remove” button which 
the user clicks to remove the added filter. 
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button shown in the green box in figure 5.20. After all filters have been applied, clicking the “Update 
Query” button loads all the ligands that meet the selected criteria.  
Ligand results table 
Like the proteins results table, the ligand results will be loaded into a table, as shown in figure 5.21. 
The data shown for the ligands within the ligand results table are the Ligand Index, Ligand Name, 
PubChem ID, DrugBank ID, and the Date Created.  The number of results shown on each page can be 
selected by a drop-down list shown by the red box in figure 5.21. The options being to show 10, 25, 
50, and 100 on a single page. The data in the table can also be searched using the search bar shown 
in the green box in figure 5.21. The blue box shown in figure 5.21 shows the “Save all as list” button 
which will save the loaded ligands as a list. To view further data and a 3D model of any of the loaded 
ligands in the ligand table, The results row is clicked opening a dedicated page for that ligand. 
Docking selection table 
The docking selection table will display the docking data that is stored in the database. Figure 5.22 
shows the docking selection table as it is viewed on the webpage. Like both the proteins selection 
table and the ligand selection table, there are two options to either load all the stored docking data 
Figure 5.21: Example table of ligand panel results on the database page -  Shows the table that is loaded with ligand 
data for the selected ligand: shown in the green box is a search bar that can be used to search the ligands within the 
table. Shown in the red box are option of how many results to show on one page. Shown in the blue box is the “Save 
all as list” which saves a private list of all the ligands within the table 
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within the database or load up a previously saved list. When one of these options is selected, the 
“Update” button is clicked which loads the docking results into the form. 
Docking table filter options 
Like previous tables, filters can be added to the loaded docking data, as shown in figure 5.23. When 
a search string or data criteria has been selected, the “Update” button shown in the blue box in 
figure 5.23 is then clicked which will then load only the data that meets that criteria. Any of the 
filters can be removed by the “Remove” button shown in the red box in figure 5.23.  
Docking results table 
Like both the protein and ligands selection tables, the selected docking results are loaded into a 
table, as shown in figure 5.24 when the “Update Query” button is clicked. The “Update Query” 
button is shown in the red box in figure 5.24. The docking data loaded into the table are the Docking 
ID, Protein Name, Gene Name, UniProt Code, Variant, Model Type, Ligand Name, and the PubChem 
ID. The number of results shown on each page can be selected in the blue box shown in figure 5.24. 
The options being to show 10, 25, 50, and 100. The docking data loaded into the table can be 
searched by using the search bar shown in the green box in figure 5.24. The filtered docking results 
table can be saved as a personal list. This can be done by clicking the “Save all as list” button shown 
in the yellow box in figure 5.24.  
Figure 5.22: Database page docking selection panel – Shows the docking selection panel where can search for specific 
docking pairs. 
Figure 5.23: Database page’s dockings selection panel filters - shown is the view of the 
ligand filtering: shown in the blue box is an “Update” button that will apply the filter. Shown 
in the green box is the “Update Query” button which will update the main ligand data table. 
Shown in the red box is the “Remove” button which the user clicks to remove the added 
filter. 
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5.4.3 Protein viewer page 
When a user clicks one of the proteins from the protein selection table, a dedicated window opens 
for the selected protein. Shown in figure 5.25 is an example of a dedicated protein viewer page for 
Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1).  
Protein information panel 
Shown on the left side of the screen in figure 5.25 is the protein information table. The table will 
display information about the selected protein. With the information for UniProt, the user is able to 
interact by clicking on the ID numbers, which will then open a new window with the UniProt 
database webpage linked to the selected protein.  
Figure 5.24: Database page’s docking selection results table – Shown is the table that is loaded with docking data for 
the selected proteins and ligands. shown in the green box is a search bar that can be used to search the dockings 
within the table. Shown in the blue box are option of how many results to show on one page. Shown in the yellow box 
is the “Save all as list” which saves a private list of all the dockings within the table 
Figure 5.25: Protein view page – shown is an image of a view of the protein viewer page for the protein 
Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1). 
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3D viewer panel 
In the centre of the screen shown in figure 5.25 is the 3D viewer. This viewer is used to show the 
predicted 3D model of the selected docking. Shown in figure 5.26 is a closeup of the 3D viewer for 
the protein Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated  
Figure 5.26: Close view of the 3D viewer in the protein viewer page for the protein Serine/threonine-protein kinase Sgk1 (EC 
2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) – shown is an image of the 3D viewer which will be displayed within the 
protein view page 
kinase 1). The user can change the angle at which they view the protein. Shown in table 5.24 are the 
controls for using the 3D Viewer. The user will also be able to change how the protein looks in the 
3D viewer by using option buttons which are on the top right on the page. 
Table 5.24: Controls for the 3D viewer – shown are the controls which allow the user to change the view of the object within 
the 3D viewer. 
 
 
Action Control 
Rotate Click and drag with the left mouse button. 
Shift sideways Click and drag with the middle button (often 
found by pressing down the scroll wheel). 
Zoom Use scroll wheel, up for zoom, down for zoom 
in. 
Re-centre double click with the left button on a residue or 
atom. The view will centre on and rotate 
around the selected location. 
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Shown in figure 5.27 are the view option buttons for the 3D viewer. Each of these buttons is linked 
to a type of visual style that can be applied to the protein. Shown in figure 5.28 are the different 
protein views that can be chosen. Both “Ribbon – colour by structure” and “Ribbon – colour by 
position” would be selected if the user is interested in viewing the alpha-helix and beta sheets of the 
structure of a protein. The “Tube” option would be selected if the user would like to view the 
backbone structure of the protein. The “Lines” option will be selected if the user is interested in 
viewing the proteins atoms and their bonds. The “Spheres” option would be selected if the user was 
interested in viewing the protein surface.  
Figure 5.27: option buttons to change the view style of the 3D viewer – shown are the different options available to the user 
to change the display type of the protein. 
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Figure 5.28: 3D Viewer protein display types – shown are Images of the different types of protein views that are available in 
the Graphical User Interface. the protein views that are shown are Ribbon – colour position, Tube, Lines, Spheres, Points, 
and Ribbon – Colour by structure. 
Docking results selection panel 
The last part of the protein viewer page is the docking results selection form. Shown in figure 5.29 is 
an image of the docking results selection that will be viewable on the protein view webpage. The 
table will show a list of all drug that has had a docking predicted with the selected protein. The user 
is  
Ribbon – colour position Tube 
Lines Spheres 
Points Ribbon – Colour by 
structure 
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Figure 5.29: Protein view docking selection panel – shown is an image of the docking results selection displayed on the 
protein view webpage. 
also, able to search this list using the search bar shown in the green box of figure 5.29. The user can 
select the drug of interest from the list, which will then open another window which will display the 
selected drugs conformations with the protein of interest.  
5.4.4 Ligand viewer page 
When a user has clicked on a ligand of interest from the loaded list within the ligand selection form 
on the database page, this action would then open a new window with a dedicated page. Shown in 
figure 5.30 is an image of the dedicated page that would be viewed by the user.  
Figure 5.30: Ligand view page – shown is an image of the dedicated page for the ligand Tadalafil when selected from the 
ligand selection panel on the database page. 
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The ligand shown in figure 5.30 is Tadalafil. The Ligand viewer page has an identical setup to the 
protein viewer page. There are four panels that are a part of the dedicated ligand viewer page, these 
being the Ligand Information panel, the 3D viewer panel, Ligand style panel, and Docking results 
selection panel.  
Ligand information panel 
The ligand information panel will display all known information about the ligand that is stored in the 
database. The ligand information that’s shown will be the PubChem ID, Ligand Name, DrugBank ID, 
Reactome ID’s, and KEGG ID’s. With the information for PubChem and DrugBank, the user is able to 
interact by clicking on the ID numbers which will then open a new window with the PubChem or 
DrugBank database webpage linked to the selected ligand. 
Ligand 3D Viewer panel 
The 3D viewer is the same as the one shown for the protein viewer page. Shown in figure 5.31 is an 
image of the ligand Tadalafil being shown in the 3D viewer. The only difference is that there are 
fewer options for the way the ligand is displayed. The options available are Ball & Sticks, Lines, and 
Sphere views. Shown in figure 5.32 are images of how the ligand will display in the 3D viewer for 
each view option. Like the 3D viewer on the protein viewer page, the 3D image of the ligand can be 
turned, zoomed, and the centre point of view can be changed. These functions can be done by using 
the same control instruction discussed for the protein viewer page’s 3D Viewer.  
Figure 5.31: Ligand view page 3D viewer – shown is an image of the ligand Tadalafil being shown in the 3D viewer. 
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Figure 5.32: 3D Viewer ligand display types – Shown are images of how the ligand can be displayed in the 3D viewer for 
each display option available. The options are Ball & Sticks, Lines, and Spheres. 
Ligand Docking results selection panel 
Like the protein viewer page, but instead of ligands, the docking results selection panel will display a 
list of every protein within the database that has had a conformation predicted with the ligand of 
interest. Shown in figure 5.33 is an image of the docking results selection panel with a list of proteins  
Figure 5.33: Ligand view docking selection panel – shown is an image of the docking results selection displayed on the 
Ligand view webpage for Tadalafil. 
 
Ball & Sticks Lines 
Spheres 
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that have had conformations predicted for Tadalafil. The user can search for specific proteins within 
the list using the search bar shown in the green box in figure 5.33. The user can click one of the 
proteins in the list, which will then open a new window with the selected protein with the 
conformation of the ligand of interest.  
5.4.5 Docking Viewer Page 
The docking viewer page is where the user will be able to view 3D docking conformations between a 
protein and a ligand. Shown in figure 5.34 is an image of the docking viewer page for the docking 
pair of Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) 
and Tadalafil. There are 5 panels that are on the docking viewer page, these being the Protein 
Information panel, 3D Viewer panel, Ligand Information, Protein style panel, Ligand style panel, and 
the Conformation scores panel. 
Protein Information Panel 
Like in the protein viewer page, the protein information panel will display all stored information 
about the protein within a table. The data shown in the panel are the Protein UniProt ID, Protein 
Name, Other Names, Gene Names, Protein Model type, Variant, Protein sequence length, Protein 
sequence, and the Date run. 
Figure 5.34: Docking view page – shown is an image of the docking viewer page for the docking pair of Serine/threonine-
protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) and Tadalafil. 
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3D Viewer panel 
The 3D viewer panel will display the 3D conformations of the selected protein and ligand docking 
pair.  Shown in figure 5.35 is an image of the top-ranked conformation between Serine/threonine-
protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) and Tadalafil in the 3D 
viewer. Like the 3D viewer used in the protein viewer page, which is discussed in section 5.4.3, it will 
show the generated 3D model for the protein which is a part of the selected docking pair. The 
difference being that also loaded in the 3D viewer will be the top-ranked predicted conformation for 
the ligand which is a part of the selected docking pair. The same controls are used as discussed in 
section 5.4.3 as to how to manipulate the view of the conformation shown in the 3D viewer. 
However, the 3D viewer on the docking viewer page has two extra features. The first extra feature is 
if the user hovers the mouse over any of the protein or the drug atoms within the 3D viewer, the 
text will appear below the viewer identifying residue. Shown in figure 5.36 is an image of the 3D 
viewer with an atom of the protein highlighted and it is identified by text shown in the red box.  
The second extra feature is the ability for the user to measure distances between two atoms. To 
measure a distance between two atoms, firstly by using the mouse, click the first atom of interest 
within the 3D viewer. Secondly, click on the second atom of interest within the 3D viewer. When 
both atoms have been selected, the distance is calculated and displayed within the viewer. 
Angstroms is the unit of measurement for all distances. This feature can be handy for the user as 
they are able to find the closest interacting atoms with the bound ligand. With both additional 
features, it allows the user to do an essential analysis of the docking pair conformations.  
Figure 5.35:Docking page 3D Viewer – shown is an image of the top-ranked conformation between Serine/threonine-
protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) (Ribbon – colour by position protein view)  and 
Tadalafil (Ball & stick ligand view) in the 3D viewer. 
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Figure 5.36: Docking page 3D viewer amino acid Identifier – shown is an image of the 3D viewer with a protein atom 
highlighted which is being identified by an atom identifier by text shown in the red box. 
Protein Style Panel 
Like the protein style panel on the protein viewer page, the protein style panel is used to change the 
view type of the protein that is visualised in the 3D viewer. Shown in figure 5.27 are the options 
available and shown in figure 5.28 are how the different view options are displayed. 
Ligand Style Panel 
Like the ligand style panel on the ligand viewer page, this panel is used to change the view type of 
the ligand that is visualised in the 3D viewer. Shown in figure 5.32 are how the different types of 
view that are available are displayed. 
Ligand Information Panel 
Like the ligand viewer page, the ligand information panel displays all stored information about the 
drug within the selected docking pair. The information that is displayed is the PubChem ID, 
DrugBank ID, Ligand Name, KEGG ID’s, Reactome ID’s, and the Date Uploaded. 
Conformation Options panel 
Below the Ligand style panel are options for displaying different conformations. The docking 
program predicts the 10 best conformations and ranks them from 1 to 10. These options give the 
user the ability to examine all top 10 conformations that were predicted by the docking. programs 
from 1 to 10. 
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Shown in figure 5.37 is an image of the different conformation options that can be selected. When a 
radio button is selected, the similar conformation will then be displayed on the 3D viewer at the 
same time. Shown in figure 5.38 is an image of all 10 predicted conformations for the docking pair of 
Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) and 
Tadalafil displayed in the 3D viewer. This view can show the user all the areas of the protein that the 
docking programs found possible docking “pockets” to dock a ligand. The other with the selected 
protein. One of the options is to display every generated conformation for the docking pair within 
the 3D  options shown in figure 5.37 and to also label the ligands displayed in the 3D viewer. Shown 
in figure 5.38 is an image of the Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) 
(Serum/glucocorticoid-regulated kinase 1) and Tadalafil docking with the label “Tadalafil” attached 
to the ligand. These labels will help the user to identify which conformations are being displayed, 
and where, on the 3D viewer. 
Figure 5.37:Docking view page conformation selector – shown is an image of the conformation options that are available to 
display on the 3D viewer within the docking viewer page. 
Figure 5.38: docking view page 3D viewer with all 10 conformations – shown is an image of all 10 predicted conformations 
for the docking pair of Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated kinase 1) and 
Tadalafil displayed in the 3D viewer. 
Conformation scores panel 
The conformation scores panel is used to display all stored scores related to the selected docking 
pair. Shown in figure 5.39 is an image of conformation scores for the top-ranked conformation for 
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the docking pair of Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-
regulated kinase 1) and Tadalafil. The conformation scores panel is also linked to the conformation 
options panel. Whichever conformation that has been selected to be viewed on in the 3D viewer, 
only those scores related to that conformation will be displayed. The user can see all conformations 
scores at once by selecting to view all poses in the conformation options panel shown in figure 5.37, 
all 10 scores will be displayed within the conformation scores panel.  
Figure 5.39: Docking view page conformation scores table – shown is an image of conformation scores for the top-ranked 
conformation for the docking pair of Serine/threonine-protein kinase Sgk1 (EC 2.7.11.1) (Serum/glucocorticoid-regulated 
kinase 1) and Tadalafil. 
5.5 Conclusion 
The graphical user interface implemented has made it possible to visualise any of the stored 
structures and dockings in the extensive database of protein-ligands dockings. It would be an 
onerous task for an individual to go through and search for particular dockings within these huge set, 
but this intuitive graphical user interface has made it possible for any protein-ligand docking pair to 
be searched for and have the results shown in a user-friendly graphical format.  
The big advantage of the developed system is the great flexibility of options provided to the user. If a 
user requires information about a protein of interest, the system provides detailed information 
about the protein in isolation (one protein to many ligands). This is illustrated in figure 5.25. Another 
user might require information about a specific drug of interest, and in this case the system would 
provide detailed information about the drug (one ligand to many proteins). This is illustrated in 
figure 5.30. In a more complex application, the user might be interested in an interaction between 
any protein in a group of proteins, considering all the potential drugs of interest. The system 
provides detailed information about the predicted dockings with options to analyse the interactions 
further to effectively “mine” for new leads.  
This compares very favourably with the situation beforehand, where if a user wanted to investigate 
a protein-ligand docking pair of interest manually, they would first have to find the docking pair 
conformation in the vast array of folders that store the results and then to display them by export to 
a program like UCSF Chimera (Pettersen et al., 2004). If they wished to examine the predicted scores 
and outcome for that docking pair, they would have to explore a vast data file which in turn contains 
different ranked conformation for each docking pair, which can be impeding. This kind of search 
would take a long time to do, particularly for most programmes of work, which need to consider 
194 
 
multiple protein-ligand pairs. The current Graphical User Interface linked with the developed system 
architecture has created a seamless, easy to use system that can enable users to investigate a vast 
array of valuable data in a fraction of the time spent with manual analysis. 
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6 Discussion 
6.1 Overview 
This study has incorporated the use of supercomputing, database and web development 
technologies, and in silico docking approaches to develop a vast database of 3D models of the 
human proteome with predicted binding conformation data against the 20 top-selling drugs in the 
UK, which are all able to be visualised on a graphical user interface for the purpose of aiding 
research in drug discovery. The intention of this research was to address the need for a 
comprehensive interactive resource which would aid the development and repurposing of drugs. 
There was no such resource in existence that addressed this need. The system gives access to a vast 
source of docking data that can be interrogated by users in order to answer specific questions about 
drug interactions. The aim was to develop a system which is readily adaptable to various areas of 
research within the drug development field. This involved developing a system architecture which 
answers these specific needs. The system had to efficiently handle a vast amount of data generated 
from protein modelling and molecular docking. The system has proven to be a useful and broadly 
accurate tool with the development of a new docking analysis methodology which gives an overall 
accuracy of 72.05%, which is encouraging for further development.  
With the development of NGS and the cost of screening individual genome steadily decreasing, the 
advancement of personalised medicine is at the forefront of research. Personalised medicine has the 
potential to transform healthcare including reducing the number of patients being prescribed less 
suitable drugs for them that could result in non-response or  cause side effects (Mathur and Sutton, 
2017). The system that has been developed here can help with first steps of identifying possible 
protein target variants which modify how drugs are metabolised and identify potential off-target 
interactions which could cause adverse drug events and patient illness. With the accuracy that was 
achieved by the combinational forecasting approach developed, the system can reduce the time and 
costs involved in identifying these instances. The developed database and system prototype have 
the potential to change the way drugs are developed in the drug discovery sector by facilitating rapid 
investigation, classification and comparison of predicted protein-ligand interactions across the whole 
human proteome.The system is a powerful tool which can be used to determine if a ligand has scope 
for specific interaction with a protein of interest before deciding to further investigate in the 
laboratory. With all of the available docking data and 3D viewer to display and enable the user to 
analyse the protein, ligand and conformations, the system has the potential to identify new leads or 
establish opportunities for repurposing existing drugs. Drug development is a risky and costly affair 
(Mohs and Greig, 2017) which this system has the ability to reduce by the vast amount of data and 
analysis available, to systematically narrow down potential targets to investigate. The system can 
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contribute towards the advancement of personalised medicine with incorporation of further 
knowledge of protein interactions and the impacts of protein variation.  
The cost of developing a new drug is very expensive, which has led to an increase in drug 
repurposing (repositioning). Pharmaceutical companies turn to this as it is a means of appropriating 
drugs faster for clinical use. Drug developers are increasingly looking into the use of computational 
techniques which can help aid them in the process (Xue et al., 2018). The developed system 
reported in this thesis is a tool which can be applied to both the repurposing case and discovery of 
new targets for existing drugs currently in the healthcare system. It has the ability to help identify 
ligands that can be linked with the treatment of another illness or disease by virtue of a predicted 
interaction with a protein of interest. The system can help pharmaceutical researchers expedite the 
repurposing process even further by the vast scale visualisation and analysis of stored 
conformations.  
6.2 Applications for the system 
The system can be used to help answer questions such as Investigate protein structures, 
Investigation of drugs for repurposing, Investigating drug “off-target” hits, The potential for 
investigating the interactions of “new” ligands.  
6.3 Limitations of this study 
The main practical limitation of this study was the sporadic availability of HPC computational 
resources. Due to HPC Wales having more than 500 users, at peak usage times there would be long 
queues which hampered the progression rate for homology modelling, protein threading and 
docking. There were also issues with HPC Wales occasionally going offline altogether which affected 
progress. This mainly affected the protein threading as this is the longest process to complete. 
Depending on the length of the sequence that has been inputted to be modelled, it can take up to 
60 hours to complete a single 3D model.  
The docking algorithms used do not allow for proteins movement, which in turn can affect docking 
results. This is due to that protein movement can change the shape of the proteins pockets which 
can alter how a ligand interacts. Updates in the future might include the incorporation of docking 
algorithms which allow for side-chain flexibility. As computer hardware gets faster, eventually it 
could be possible to apply molecular dynamics simulations in the same high-throughput way as we 
currently apply docking. 
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6.4 Future Work 
6.4.1 System architecture 
The future work that will be carried out on the system architecture is to incorporate the meta-score 
from the developed combinational forecasting model within the database so that it can give users an 
initial idea as to whether the docking has been classed as a possible interaction or a non-interaction. 
This will be undertaken by introducing another table called “Data_analysis” which would store data 
on each docking pair as either a possible interaction or a non-interaction. This would be linked to the 
docking table via the docking ID. An example of how the new database structure would look is 
shown in figure 6.1. There would be another column which would have either “TRUE” or “FALSE” 
within it, if it is true it means that the docking is a potential interaction and if false it is a non-
interaction. By having this added it would make it possible to display the results on the screen to the 
user at the point of when they have first selected a protein-ligand docking pair to view. This 
database structure could help users to determine earlier if it might be worth investigating a specific 
interaction further.  
Figure 6.1: Entity relationship diagram for future improvements of the database structure – shown is an ERD diagram 
which displays the future improvement of the database by the addition of the Data_analysis table to store 
combinational forecasting results. 
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Another addition to the database structure will be to add another table, linked to the proteins table, 
that ranks the quality/structural coverage of the 3D protein model. The quality of a model structure 
would be reported by the structure coverage script described in the protein modelling and molecular 
docking chapter. The model structure quality will be ranked as 80%+ - GOLD, between 50% and 80% 
- Silver, and between 1% and 50% - Bronze. As there will be a mixture of homology models and 
threaded protein models, this would let the user know beforehand whether the resulting docking is 
more likely to be of good accuracy rather than following up on a low-quality model. 
6.4.2 Protein Modelling 
The protein modelling reported in the thesis was to some extent complicated by having to apply 
both homology modelling and protein threading. A potential way of moving the research forward is 
to attempt to combine homology modelling and protein threading in one modelling methodology. 
Homology modelling can generate a model if the sequence has 30% or more homologue coverage. 
Protein threading can generate a model with a sequence with as low as 15%. Combining the two 
methods holds some potential for “filling in the gaps” of homology modelling in terms of cross-
proteome and intra-protein coverage. This may not be easily done due to the two modelling 
pipelines using different methods but is an idea to investigate. 
6.4.3 Protein-Ligand Molecular Docking 
The molecular docking analysis gave a good accuracy of 72.05%, but this can be further improved. A 
method can be applied to the protein models before the docking process which could utilise 
biological data to better define the search space explored by the docking algorithms. The method 
could help reduce the number of false-positive docking results where a ligand is predicted to interact 
in a location which is not biologically feasible in life and increase the number of correctly predicted 
dockings in known active sites in proteins for which some functional data is known.  
6.4.4 Graphical User Interface 
There is also a need to improve the way that users are able to save search results and lists for use in 
future sessions. A modification can be added to the database; an indicator applied to the docking 
view page which can clearly display to the user if the system deems the selected conformation a 
potential interaction. The indicator would provide the scope to save time in the search for new leads 
from the vast amount of data stored. 
6.4.5 Database Expansion 
The next stage of development will be the addition of the protein-ligand dockings of variant forms of 
proteins against the 20 top-selling drugs in the UK. This has the potential of the addition of 
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16,000,000 new data points and could be of use in assessing the potential for adverse drug events 
across populations due to polymorphic variation.  
Another likely addition will be to incorporate the full FDA approved drug set with additional dockings 
with the proteins stored within the database, which will provide great potential for pursuing 
investigations of repurposing opportunities. 
6.5 Concluding remarks 
No other system has been developed that can be used to visualise and analyse such an extensive 
database of hundreds of thousands of protein-ligand interactions in such a comprehensive, user-
friendly way. The developed system has the potential to easily increase the data stored to include 
more drugs such as FDA approved to also have the potential to analyse newly developed drugs. This 
will be an important part of its future development.  
The work carried out in this project has contributed towards the development of a comprehensive in 
silico platform, Human3DProteome (human.3dproteome.swan.ac.uk), that utilises the system 
architecture, methodologies, data and methods of data analysis advanced in this project. 
The system is freely available at: http://proteins.swan.ac.uk/hpdd 
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8 Appendix 
Table 8.1: Results of the "hit" results for the known target predictions for the new homology model set (2017) using Shipyard 1.5 – shown is the original table of results used to create the graph 
shown in figure 4.8 
Ligand Protein 
DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX 
Atom 
distances 
SD 
DSX 
Atom 
distances 
hit 
Meta-
score 
hit 
Ezetimibe P15144_AMPN_HUMAN -1.071 FALSE -1.509 FALSE -1.835 FALSE -0.604 FALSE FALSE 
Solifenacin P08172_ACM2_HUMAN -0.414 FALSE -0.004 FALSE 0.682 FALSE -1.744 FALSE FALSE 
Solifenacin P08173_ACM4_HUMAN -0.062 FALSE -0.257 FALSE -0.225 FALSE 0.069 FALSE FALSE 
Lenalidomide P35354_PGH2_HUMAN -1.500 FALSE -2.085 TRUE -1.328 FALSE -0.767 FALSE TRUE 
Lenalidomide Q96SW2_CRBN_HUMAN 0.200 FALSE 0.104 FALSE -0.275 FALSE 0.174 FALSE FALSE 
Tiotropium P08172_ACM2_HUMAN -0.921 FALSE -1.228 FALSE 0.052 FALSE -0.780 FALSE FALSE 
Formoterol P07550_ADRB2_HUMAN -1.195 FALSE -1.486 FALSE 0.363 FALSE -1.407 FALSE FALSE 
Gabapentin P30542_AA1R_HUMAN 0.610 FALSE 0.036 FALSE -0.069 FALSE 0.015 FALSE FALSE 
Fluticasone 
Propionate P47712_PA24A_HUMAN -2.218 TRUE -2.283 TRUE -2.697 TRUE -0.346 FALSE 
TRUE 
Aripiprazole P08172_ACM2_HUMAN 0.008 FALSE 0.814 FALSE 0.286 FALSE 0.052 FALSE FALSE 
Aripiprazole P08173_ACM4_HUMAN -0.058 FALSE -0.459 FALSE 0.385 FALSE -1.731 FALSE FALSE 
Aripiprazole P08908_5HT1A_HUMAN -0.170 FALSE -0.142 FALSE -0.103 FALSE -0.301 FALSE FALSE 
Aripiprazole P08913_ADA2A_HUMAN -0.069 FALSE -1.449 FALSE 0.379 FALSE -1.561 FALSE FALSE 
Aripiprazole P14416_DRD2_HUMAN -1.006 FALSE 0.026 FALSE -1.188 FALSE 0.378 FALSE FALSE 
Aripiprazole P18089_ADA2B_HUMAN -0.567 FALSE -1.843 FALSE -0.533 FALSE -1.217 FALSE FALSE 
Aripiprazole P18825_ADA2C_HUMAN -0.863 FALSE -0.566 FALSE -0.412 FALSE -0.501 FALSE FALSE 
Aripiprazole P21917_DRD4_HUMAN -0.472 FALSE -0.481 FALSE -1.181 FALSE -0.259 FALSE FALSE 
Aripiprazole P28221_5HT1D_HUMAN -1.454 FALSE -2.217 TRUE -1.500 FALSE -0.499 FALSE TRUE 
Aripiprazole P28222_5HT1B_HUMAN 0.151 FALSE -0.753 FALSE -0.316 FALSE 0.021 FALSE FALSE 
Aripiprazole P28335_5HT2C_HUMAN -1.096 FALSE -0.072 FALSE -0.908 FALSE 0.801 FALSE FALSE 
Aripiprazole P28566_5HT1E_HUMAN -0.774 FALSE -0.462 FALSE -0.975 FALSE -0.224 FALSE FALSE 
Aripiprazole P35367_HRH1_HUMAN -2.086 TRUE -1.599 FALSE -1.790 FALSE -1.058 FALSE TRUE 
Aripiprazole P35462_DRD3_HUMAN 0.293 FALSE -0.064 FALSE -0.541 FALSE 0.277 FALSE FALSE 
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Table 8.2: Results of the "med" results for the known target predictions for the new homology model set (2017) using Shipyard 1.5 - shown is the original table of results used to create the 
graph shown in figure 4.9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligand Protein 
DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity 
SD 
Vina 
Affinity 
med 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
med 
DSX 
Atom 
distances 
SD 
DSX 
Atom 
distances 
med 
Meta-
score 
med 
Ezetimibe P15144_AMPN_HUMAN -1.071 TRUE -1.509 TRUE -1.835 TRUE -0.604 FALSE TRUE 
Solifenacin P08172_ACM2_HUMAN -0.414 FALSE -0.004 FALSE 0.682 FALSE -1.744 TRUE TRUE 
Solifenacin P08173_ACM4_HUMAN 
-
0.0622 
FALSE 
-0.257 
FALSE 
-0.225 
FALSE 
0.069 
FALSE FALSE 
Lenalidomide P35354_PGH2_HUMAN -1.500 TRUE -2.085 FALSE -1.328 TRUE -0.767 FALSE TRUE 
Lenalidomide Q96SW2_CRBN_HUMAN 0.200 FALSE 0.104 FALSE -0.275 FALSE 0.174 FALSE FALSE 
Tiotropium P08172_ACM2_HUMAN -0.921 FALSE -1.228 TRUE 0.052 FALSE -0.780 FALSE TRUE 
Formoterol P07550_ADRB2_HUMAN -1.195 TRUE -1.486 TRUE 0.363 FALSE -1.407 TRUE TRUE 
Gabapentin P30542_AA1R_HUMAN 0.610 FALSE 0.036 FALSE -0.069 FALSE 0.015 FALSE FALSE 
Fluticasone 
Propionate P47712_PA24A_HUMAN -2.218 
FALSE 
-2.283 
FALSE 
-2.697 
FALSE 
-0.346 
FALSE FALSE 
Aripiprazole P08172_ACM2_HUMAN 0.008 FALSE 0.814 FALSE 0.286 FALSE 0.052 FALSE FALSE 
Aripiprazole P08173_ACM4_HUMAN -0.058 FALSE -0.459 FALSE 0.385 FALSE -1.731 TRUE TRUE 
Aripiprazole P08908_5HT1A_HUMAN -0.170 FALSE -0.142 FALSE -0.103 FALSE -0.301 FALSE FALSE 
Aripiprazole P08913_ADA2A_HUMAN -0.069 FALSE -1.449 TRUE 0.379 FALSE -1.561 TRUE TRUE 
Aripiprazole P14416_DRD2_HUMAN -1.006 TRUE 0.026 FALSE -1.188 TRUE 0.378 FALSE TRUE 
Aripiprazole P18089_ADA2B_HUMAN -0.567 FALSE -1.843 TRUE -0.533 FALSE -1.217 TRUE TRUE 
Aripiprazole P18825_ADA2C_HUMAN -0.863 FALSE -0.566 FALSE -0.412 FALSE -0.501 FALSE FALSE 
Aripiprazole P21917_DRD4_HUMAN -0.472 FALSE -0.481 FALSE -1.181 TRUE -0.259 FALSE TRUE 
Aripiprazole P28221_5HT1D_HUMAN -1.454 TRUE -2.217 FALSE -1.500 TRUE -0.499 FALSE TRUE 
Aripiprazole P28222_5HT1B_HUMAN 0.151 FALSE -0.753 FALSE -0.316 FALSE 0.021 FALSE FALSE 
Aripiprazole P28335_5HT2C_HUMAN -1.096 TRUE -0.072 FALSE -0.908 FALSE 0.801 FALSE TRUE 
Aripiprazole P28566_5HT1E_HUMAN -0.774 FALSE -0.462 FALSE -0.975 FALSE -0.224 FALSE FALSE 
Aripiprazole P35367_HRH1_HUMAN -2.086 FALSE -1.599 TRUE -1.790 TRUE -1.058 TRUE TRUE 
Aripiprazole P35462_DRD3_HUMAN 0.293 FALSE -0.064 FALSE -0.541 FALSE 0.277 FALSE FALSE 
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Table 8.3: Results of the "hit" results for the known non-interactions predictions for the new homology model set (2017) using Shipyard 1.5 - shown is the original table of results used to create 
the graph shown in figure 4.10 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX 
Atom 
distances 
SD 
DSX 
Atom 
distances 
hit 
Meta-
score 
Tadalafil P19838_NFKB1_HUMAN -0.298 FALSE 0.688 FALSE -0.201 FALSE -0.329 FALSE FALSE 
Abiraterone P19838_NFKB1_HUMAN 0.46 FALSE -0.274 FALSE 1.235 FALSE -0.240 FALSE FALSE 
Lenalidomide P19838_NFKB1_HUMAN -1.992 FALSE -2.078 TRUE -2.309 TRUE -2.197 TRUE TRUE 
Formoterol P19838_NFKB1_HUMAN -1.742 FALSE -1.229 FALSE -0.829 FALSE -1.378 FALSE FALSE 
Imatinib P19838_NFKB1_HUMAN -2.004 TRUE -2.163 TRUE -0.821 FALSE -1.877 FALSE TRUE 
Levothyroxine P01137_TGFB1_HUMAN -0.413 FALSE 0.575 FALSE 0.757 FALSE -2.172 TRUE TRUE 
Levothyroxine P19838_NFKB1_HUMAN -1.211 FALSE -0.18 FALSE -1.163 FALSE 0.103 FALSE FALSE 
Levothyroxine P22415_USF1_HUMAN -0.51 FALSE -0.047 FALSE 0.533 FALSE -0.383 FALSE FALSE 
Aripiprazole P19838_NFKB1_HUMAN -1.292 FALSE -0.99 FALSE -1.217 FALSE -1.373 FALSE FALSE 
 
Table 8.4: Results of the "med" results for the known non-interactions predictions for the new homology model set (2017) using Shipyard 1.5 - shown is the original table of results used to 
create the graph shown in figure 4.11 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity 
SD 
Vina 
Affinity 
med 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
med 
DSX 
Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta-
score-med 
Tadalafil P19838_NFKB1_HUMAN -0.298 FALSE 0.688 FALSE -0.201 FALSE -0.329 FALSE FALSE 
Abiraterone P19838_NFKB1_HUMAN 0.46 FALSE -0.274 FALSE 1.235 FALSE -0.240 FALSE FALSE 
Lenalidomide P19838_NFKB1_HUMAN -1.992 TRUE -2.078 FALSE -2.309 FALSE -2.197 FALSE TRUE 
Formoterol P19838_NFKB1_HUMAN -1.742 TRUE -1.229 TRUE -0.829 FALSE -1.378 TRUE TRUE 
Imatinib P19838_NFKB1_HUMAN -2.004 FALSE -2.163 FALSE -0.821 FALSE -1.877 TRUE TRUE 
Levothyroxine P01137_TGFB1_HUMAN -0.413 FALSE 0.575 FALSE 0.757 FALSE -2.172 FALSE FALSE 
Levothyroxine P19838_NFKB1_HUMAN -1.211 TRUE -0.18 FALSE -1.163 TRUE 0.103 FALSE TRUE 
Levothyroxine P22415_USF1_HUMAN -0.51 FALSE -0.047 FALSE 0.533 FALSE -0.383 FALSE FALSE 
Aripiprazole P19838_NFKB1_HUMAN -1.292 TRUE -0.99 FALSE -1.217 TRUE -1.373 TRUE TRUE 
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Table 8.5: Results of the "hit" results for the known targets predictions for the new homology model set with 80%+ structural coverage after docking site analysis script - shown is the original 
table of results used to create the graph shown in figure 4.14 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX 
Atom 
distances 
SD 
DSX 
Atom 
distances 
hit 
Meta-
score 
Ezetimibe sp_P15144_AMPN_HUMAN -1.062 FALSE -1.496 FALSE -1.819 FALSE -0.607 FALSE FALSE 
Solifenacin sp_P08172_ACM2_ HUMAN -0.410 FALSE 0.000 FALSE 0.677 FALSE -1.774 FALSE FALSE 
Solifenacin sp_P08173_ACM4_ HUMAN -0.061 FALSE -0.251 FALSE -0.222 FALSE 0.061 FALSE FALSE 
Lenalidomide sp_P35354_PGH2_ HUMAN  -1.489 FALSE -2.067 TRUE -1.320 FALSE -0.769 FALSE TRUE 
Lenalidomide sp_Q96W2_CRBN_ HUMAN 0.203 FALSE 0.110 FALSE -0.270 FALSE 0.169 FALSE FALSE 
Tiotropium sp_P08172_ACM2_ HUMAN -0.918 FALSE -1.216 FALSE 0.055 FALSE -0.783 FALSE FALSE 
Formoterol sp_P07550_ADRB2_ HUMAN -1.184 FALSE -1.471 FALSE 0.364 FALSE -1.407 FALSE TRUE 
Gabapentin sp_P30542_AA1R_ HUMAN 0.611 FALSE 0.040 FALSE -0.065 FALSE 0.011 FALSE FALSE 
Fluticasone 
Propionate 
sp_P47712_PA24A_ HUMAN -2.197 TRUE -2.265 TRUE -2.677 TRUE -0.352 FALSE TRUE 
Aripiprazole sp_P08172_ACM2_ HUMAN 0.007 FALSE 0.809 FALSE 0.284 FALSE 0.038 FALSE FALSE 
Aripiprazole sp_P08173_ACM4_ HUMAN -0.058 FALSE -0.453 FALSE 0.382 FALSE -1.742 FALSE FALSE 
Aripiprazole sp_P08908_5HT10A_ HUMAN -0.170 FALSE -0.139 FALSE -0.102 FALSE -0.314 FALSE FALSE 
Aripiprazole sp_P08913_ADA2A_ HUMAN -0.069 FALSE -1.435 FALSE 0.376 FALSE -1.572 FALSE FALSE 
Aripiprazole sp_P14416_DRD2_ HUMAN -0.999 FALSE 0.028 FALSE -1.180 FALSE 0.363 FALSE FALSE 
Aripiprazole sp_P18825_ADA2C_ HUMAN -0.858 FALSE -0.559 FALSE -0.410 FALSE -0.514 FALSE FALSE 
Aripiprazole sp_P21917_DRD4_ HUMAN -0.469 FALSE -0.475 FALSE -1.173 FALSE -0.272 FALSE FALSE 
Aripiprazole sp_P28221_5HT1D_ HUMAN -1.443 FALSE -2.197 TRUE -1.490 FALSE -0.513 FALSE TRUE 
Aripiprazole sp_P28335_5HT2C_ HUMAN -1.088 FALSE -0.070 FALSE -0.903 FALSE 0.785 FALSE FALSE 
Aripiprazole sp_P28566_5HT1E_ HUMAN -0.769 FALSE -0.456 FALSE -0.968 FALSE -0.237 FALSE FALSE 
Aripiprazole sp_P35367_HRH1_ HUMAN -2.070 TRUE -1.584 FALSE -1.779 TRUE -1.070 FALSE TRUE 
Aripiprazole sp_P35462_DRD3_HUMAN 0.290 FALSE -0.062 FALSE -0.538 FALSE 0.262 FALSE FALSE 
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Table 8.6: Results of the "med" results for the known targets predictions for the new homology model set with 80%+ structural coverage using Shipyard 1.5 after docking site analysis script -  
shown is the original table of results used to create the graph shown in figure 4.15 
 
 
 
 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity 
SD 
Vina 
Affinity 
med 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
med 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta-
score- 
med 
Ezetimibe sp_P15144_AMPN_HUMAN -1.062 TRUE -1.496  TRUE -1.819 TRUE -0.607 FALSE TRUE 
Solifenacin sp_P08172_ACM2_ HUMAN -0.410 FALSE 0.000 FALSE 0.677 FALSE -1.774 TRUE TRUE 
Solifenacin sp_P08173_ACM4_ HUMAN -0.061 FALSE -0.251 FALSE -0.222 FALSE 0.061 FALSE FALSE 
Lenalidomide sp_P35354_PGH2_ HUMAN  -1.489  TRUE -2.067 FALSE -1.320 TRUE -0.769 FALSE TRUE 
Lenalidomide sp_Q96W2_CRBN_ HUMAN 0.203 FALSE 0.110 FALSE -0.270 FALSE 0.169 FALSE FALSE 
Tiotropium sp_P08172_ACM2_ HUMAN -0.918 FALSE -1.216  TRUE 0.055 FALSE -0.783 FALSE TRUE 
Formoterol sp_P07550_ADRB2_ HUMAN -1.184  TRUE -1.471 TRUE 0.364 FALSE -1.407 TRUE TRUE 
Gabapentin sp_P30542_AA1R_ HUMAN 0.611 FALSE 0.040 FALSE -0.065 FALSE 0.011 FALSE FALSE 
Fluticasone 
Propionate 
sp_P47712_PA24A_ HUMAN -2.197 FALSE -2.265 FALSE -2.677 FALSE -0.352 FALSE FALSE 
Aripiprazole sp_P08172_ACM2_ HUMAN 0.007 FALSE 0.809 FALSE 0.284 FALSE 0.038 FALSE FALSE 
Aripiprazole sp_P08173_ACM4_ HUMAN -0.058 FALSE -0.453 FALSE 0.382 FALSE -1.742 TRUE TRUE 
Aripiprazole sp_P08908_5HT10A_ HUMAN -0.170 FALSE -0.139 FALSE -0.102 FALSE -0.314 FALSE FALSE 
Aripiprazole sp_P08913_ADA2A_ HUMAN -0.069 FALSE -1.435 TRUE 0.376 FALSE -1.572 TRUE TRUE 
Aripiprazole sp_P14416_DRD2_ HUMAN -0.999 FALSE 0.028 FALSE -1.180 TRUE 0.363 FALSE TRUE 
Aripiprazole sp_P18825_ADA2C_ HUMAN -0.858 FALSE -0.559 FALSE -0.410 FALSE -0.514 FALSE FALSE 
Aripiprazole sp_P21917_DRD4_ HUMAN -0.469 FALSE -0.475 FALSE -1.173 TRUE -0.272 FALSE TRUE 
Aripiprazole sp_P28221_5HT1D_ HUMAN -1.443  TRUE -2.197 FALSE -1.490 TRUE -0.513 FALSE TRUE 
Aripiprazole sp_P28335_5HT2C_ HUMAN -1.088  TRUE -0.070 FALSE -0.903 FALSE 0.785 FALSE TRUE 
Aripiprazole sp_P28566_5HT1E_ HUMAN -0.769 FALSE -0.456 FALSE -0.968 FALSE -0.237 FALSE FALSE 
Aripiprazole sp_P35367_HRH1_ HUMAN -2.070 FALSE -1.584 TRUE -1.779 TRUE -1.070 TRUE TRUE 
Aripiprazole sp_P35462_DRD3_HUMAN 0.290 FALSE -0.062 FALSE -0.538 FALSE 0.262 FALSE FALSE 
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Table 8.7: Results of the "hit" columns for the known targets predictions for the new protein threaded model set with 80%+ structural coverage using Shipyard 1.5 -   shown is the original table 
of results used to create the graph shown in figure 4.17 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity hit 
Vina 
Affinity SD 
Vina Affinity 
hit 
GBSA 
Affinity SD 
GBSA 
Affinity hit 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
hit 
Meta score 
Abiraterone P05093 
CP17A 
HUMAN 
-1.272 FALSE -1.605 FALSE -2.401 TRUE -1.713 FALSE TRUE 
Ezetimibe P15144 
AMPN 
HUMAN 
-0.921 FALSE -1.736 FALSE -0.786 FALSE -0.687 FALSE FALSE 
Solifenacin P08172 
ACM2 
HUMAN 
-0.178 FALSE -0.928 FALSE 0.231 FALSE -0.063 FALSE FALSE 
Solifenacin P08173 
ACM4 
HUMAN 
-0.536 FALSE -1.640 FALSE -0.682 FALSE 0.200 FALSE FALSE 
Solifenacin P08912 
ACM5 
HUMAN 
-1.082 FALSE -0.460 FALSE -1.025 FALSE -1.236 FALSE FALSE 
Solifenacin P11229 
ACM1 
HUMAN 
-0.130 FALSE -1.053 FALSE 0.817 FALSE -0.156 FALSE FALSE 
Solifenacin P20309 
ACM3 
HUMAN 
-0.665 FALSE -0.678 FALSE -0.152 FALSE -0.350 FALSE FALSE 
  
Lenalidomide 
Q14788 
TNF11 
HUMAN 
-1.377 FALSE -2.276 TRUE -1.661 FALSE -1.143 FALSE TRUE 
  
Lenalidomide 
P35354 
PGH2 
HUMAN 
-1.837 FALSE -1.326 FALSE 0.042 FALSE -1.367 FALSE FALSE 
  
Lenalidomide 
Q96SW2 
CRBN 
HUMAN 
-1.105 FALSE 0.626 FALSE -1.208 FALSE -1.179 FALSE FALSE 
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Table 8.8: Continuation of table 8.7 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
hit 
Meta 
score 
Tiotropium P08172 ACM2 
HUMAN 
-0.821 FALSE -1.093 FALSE -0.018 FALSE -0.384 FALSE FALSE 
Tiotropium P11229 ACM1 
HUMAN 
-0.501 FALSE -1.159 FALSE -0.051 FALSE 0.192 FALSE FALSE 
Tiotropium P20309 ACM3 
HUMA 
-1.126 FALSE 0.004 FALSE -0.116 FALSE 0.233 FALSE FALSE 
Gabapentin P30542 AA1R 
HUMAN 
-0.213 FALSE -0.374 FALSE -0.585 FALSE 0.322 FALSE FALSE 
Sitagliptin P27487 DPP4 
HUMAN 
-1.554 FALSE -0.915 FALSE -0.093 FALSE -0.892 FALSE FALSE 
Levitiracetam Q7L013 SV2A 
HUMAN 
-1.558 FALSE -2.106 TRUE -0.607 FALSE -0.123 FALSE TRUE 
Fluticasone 
propionate 
P47712 
PA24A 
HUMAN 
-1.773 FALSE -1.774 FALSE -2.119 TRUE -2.436 TRUE TRUE 
Levothyroxine P10828 THB 
HUMAN 
-0.801 FALSE -1.102 FALSE -0.924 FALSE -0.545 FALSE FALSE 
Aripiprazole P08172 ACM2 
HUMAN 
-0.544 FALSE -0.365 FALSE -0.742 FALSE 0.243 FALSE FALSE 
Aripiprazole P08173 ACM4 
HUMAN 
0.599 FALSE -0.270 FALSE -0.778 FALSE -0.415 FALSE FALSE 
Aripiprazole P08908 
5HT1A 
HUMAN 
-1.239 FALSE -1.409 FALSE -1.888 FALSE -0.686 FALSE FALSE 
Aripiprazole P08912 ACM5 
HUMAN 
0.601 FALSE 0.194 FALSE -0.667 FALSE 0.086 FALSE FALSE 
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Table 8.9: Continuation of table 8.7 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity hit 
Vina Affinity 
SD 
Vina 
Affinity hit 
GBSA 
Affinity SD 
GBSA 
Affinity hit 
DSX Atom 
distances SD 
DSX Atom 
distances hit 
Meta 
score 
Aripiprazole P11229 ACM1 
HUMAN 
0.396 FALSE -0.476 FALSE -0.577 FALSE -0.051 FALSE FALSE 
Aripiprazole P14416 DRD2 
HUMAN 
-0.251 FALSE -0.664 FALSE -0.170 FALSE -0.692 FALSE FALSE 
Aripiprazole P18825 ADA2C 
HUMAN 
-0.710 FALSE -1.997 FALSE -0.502 FALSE -0.609 FALSE FALSE 
Aripiprazole P20309 ACM3 
HUMAN 
-0.571 FALSE -0.931 FALSE -0.742 FALSE 0.307 FALSE FALSE 
Aripiprazole P21728 DRD1 
HUMAN 
-.0.966 FALSE -0.633 FALSE -0.621 FALSE -0.282 FALSE FALSE 
Aripiprazole P21917 DRD4 
HUMAN 
0.323 FALSE -0.813 FALSE -0.382 FALSE -0.608 FALSE FALSE 
Aripiprazole P28223 5HT2A 
HUMAN 
-0.523 FALSE -1.273 FALSE -0.534 FALSE -1.679 FALSE FALSE 
Aripiprazole P28335 5HT2C 
HUMAN 
0.187 FALSE -1.784 FALSE -0.673 FALSE -0.218 FALSE FALSE 
Aripiprazole P34969 5HT7R 
HUMAN 
-0.178 FALSE -0.187 FALSE -0.621 FALSE -0.900 FALSE FALSE 
Aripiprazole P35367 HRH1 
HUMAN 
-2.260 TRUE -1.831 FALSE -2.115 TRUE -1.233 FALSE TRUE 
Aripiprazole P27487 DPP4 
HUMAN 
-2.304 TRUE -1.548 FALSE -1.428 FALSE -1.290 FALSE TRUE 
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Table 8.10 Results of the "med" rule for the known targets predictions for the new protein threaded model set with 80%+ structural coverage using Shipyard 1.5 - shown is the original table of 
results used to create the graph shown in figure 4.18 
Ligand Protein DOCK 
Affinity SD 
DOCK 
Affinity 
med 
Vina 
Affinity SD 
Vina 
Affinity 
med 
GBSA 
Affinity SD 
GBSA 
Affinity 
med 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta score 
med 
Abiraterone P05093 
CP17A 
HUMAN 
-1.272 TRUE -1.605 TRUE -2.401 FALSE -1.713 TRUE TRUE 
Ezetimibe P15144 
AMPN 
HUMAN 
-0.921 FALSE -1.736 TRUE -0.786 FALSE -0.687 FALSE TRUE 
Solifenacin P08172 
ACM2 
HUMAN 
-0.178 FALSE -0.928 FALSE 0.231 FALSE -0.063 FALSE FALSE 
Solifenacin P08173 
ACM4 
HUMAN 
-0.536 FALSE -1.640 TRUE -0.682 FALSE 0.200 FALSE TRUE 
Solifenacin P08912 
ACM5 
HUMAN 
-1.082 TRUE -0.460 FALSE -1.025 TRUE -1.236 TRUE TRUE 
Solifenacin P11229 
ACM1 
HUMAN 
-0.130 FALSE -1.053 TRUE 0.817 FALSE -0.156 FALSE TRUE 
Solifenacin P20309 
ACM3 
HUMAN 
-0.665 FALSE -0.678 TRUE -0.152 FALSE -0.350 FALSE FALSE 
  
Lenalidomide 
Q14788 
TNF11 
HUMAN 
-1.377 TRUE -2.276 TRUE -1.661 TRUE -1.143 TRUE TRUE 
  
Lenalidomide 
P35354 
PGH2 
HUMAN 
-1.837 TRUE -1.326 TRUE 0.042 FALSE -1.367 TRUE TRUE 
  
Lenalidomide 
Q96SW2 
CRBN 
HUMAN 
-1.105 TRUE 0.626 FALSE -1.208 TRUE -1.179 TRUE TRUE 
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Table 8.11: Continuation of table 8.10 
Ligand Protein DOCK 
Affinity SD 
DOCK 
Affinity med 
Vina Affinity 
SD 
Vina Affinity 
med 
GBSA 
Affinity SD 
GBSA 
Affinity med 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta 
score med 
Tiotropium P08172 ACM2 
HUMAN 
-0.821 FALSE -1.093 TRUE -0.018 FALSE -0.384 FALSE TRUE 
Tiotropium P11229 ACM1 
HUMAN 
-0.501 FALSE -1.159 TRUE -0.051 FALSE 0.192 FALSE TRUE 
Tiotropium P20309 ACM3 
HUMA 
-1.126 TRUE 0.004 FALSE -0.116 FALSE 0.233 FALSE TRUE 
Gabapentin P30542 AA1R 
HUMAN 
-0.213 FALSE -0.374 FALSE -0.585 FALSE 0.322 FALSE FALSE 
Sitagliptin P27487 DPP4 
HUMAN 
-1.554 TRUE -0.915 FALSE -0.093 FALSE -0.892 FALSE TRUE 
Levitiracetam Q7L013 SV2A 
HUMAN 
-1.558 TRUE -2.106 FALSE -0.607 FALSE -0.123 FALSE TRUE 
Fluticasone 
propionate 
P47712 PA24A 
HUMAN 
-1.773 TRUE -1.774 TRUE -2.119 FALSE -2.436 FALSE TRUE 
Levothyroxine P10828 THB 
HUMAN 
-0.801 FALSE -1.102 TRUE -0.924 FALSE -0.545 FALSE TRUE 
Aripiprazole P08172 ACM2 
HUMAN 
-0.544 FALSE -0.365 FALSE -0.742 FALSE 0.243 FALSE FALSE 
Aripiprazole P08173 ACM4 
HUMAN 
0.599 FALSE -0.270 FALSE -0.778 FALSE -0.415 FALSE FALSE 
Aripiprazole P08908 5HT1A 
HUMAN 
-1.239 TRUE -1.409 TRUE -1.888 TRUE -0.686 FALSE TRUE 
Aripiprazole P08912 ACM5 
HUMAN 
0.601 FALSE 0.194 FALSE -0.667 FALSE 0.086 FALSE FALSE 
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Table 8.12: continuation of table 8.10 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity SD 
Vina 
Affinity 
med 
GBSA 
Affinity SD 
GBSA 
Affinity 
med 
DSX Atom 
distances SD 
DSX Atom 
distances 
med 
Meta score 
med 
Aripiprazole P11229 ACM1 
HUMAN 
0.396 FALSE -0.476 FALSE -0.577 FALSE -0.051 FALSE FALSE 
Aripiprazole P14416 DRD2 
HUMAN 
-0.251 FALSE -0.664 FALSE -0.170 FALSE -0.692 FALSE FALSE 
Aripiprazole P18825 
ADA2C 
HUMAN 
-0.710 FALSE -1.997 TRUE -0.502 FALSE -0.609 FALSE TRUE 
Aripiprazole P20309 ACM3 
HUMAN 
-0.571 FALSE -0.931 FALSE -0.742 FALSE 0.307 FALSE FALSE 
Aripiprazole P21728 DRD1 
HUMAN 
-.0.966 FALSE -0.633 FALSE -0.621 FALSE -0.282 FALSE FALSE 
Aripiprazole P21917 DRD4 
HUMAN 
0.323 FALSE -0.813 FALSE -0.382 FALSE -0.608 FALSE FALSE 
Aripiprazole P28223 
5HT2A 
HUMAN 
-0.523 FALSE -1.273 TRUE -0.534 FALSE -1.679 TRUE TRUE 
Aripiprazole P28335 
5HT2C 
HUMAN 
0.187 FALSE -1.784 TRUE -0.673 FALSE -0.218 FALSE TRUE 
Aripiprazole P34969 
5HT7R 
HUMAN 
-0.178 FALSE -0.187 FALSE -0.621 FALSE -0.900 FALSE FALSE 
Aripiprazole P35367 HRH1 
HUMAN 
-2.260 FALSE -1.831 TRUE -2.115 FALSE -1.233 TRUE TRUE 
Aripiprazole P27487 DPP4 
HUMAN 
-2.304 FALSE -1.548 TRUE -1.428 TRUE -1.290 TRUE TRUE 
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Table 8.13: Results of the "hit" columns for the known non-interactions predictions for the new protein threaded model set with 80%+ structural coverage -   shown is the original table of 
results used to create the graph shown in figure 4.19 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
hit 
Meta 
score 
Tadalafil P04637_P53_HUMAN -0.593 FALSE -0.771 FALSE 1.097 FALSE -0.271 FALSE FALSE 
Tadalafil P11511 CP19A HUMAN -1.479 FALSE -1.103 FALSE 0.432 FALSE -1.896 FALSE FALSE 
Tadalafil P37231 PPARG HUMAN -1.616 FALSE -1.243 FALSE -0.259 FALSE -2.276 TRUE TRUE 
Tadalafil Q16236 NF2L2 HUMAN 0.307 FALSE -0.227 FALSE 1.315 FALSE -1.117 FALSE FALSE 
Abiraterone P04637 P53 HUMAN -1.398 FALSE -0.908 FALSE -0.275 FALSE -0.503 FALSE FALSE 
Abiraterone P11511 CP19A HUMAN -0.987 FALSE -0.880 FALSE -1.316 FALSE -0.975 FALSE FALSE 
Lenalidomide P04637 P53 HUMAN -0.018 FALSE 0.350 FALSE 1.593 FALSE 0.663 FALSE FALSE 
Lenalidomide P11511 CP19A HUMAN 0.242 FALSE -0.129 FALSE -0.861 FALSE -0.523 FALSE FALSE 
Lenalidomide P37231 PPARG HUMAN -0.899 FALSE -0.716 FALSE -0.462 FALSE -0.909 FALSE FALSE 
Lenalidomide Q16236 NF2L2 HUMAN 0.411 FALSE 0.237 FALSE 0.765 FALSE -0.132 FALSE FALSE 
Formoterol P04637 P53 HUMAN -0.548 FALSE -0.132 FALSE -0.230 FALSE -0.099 FALSE FALSE 
Formoterol P11511 CP19A HUMAN -1.102 FALSE -0.748 FALSE -1.139 FALSE -0.626 FALSE FALSE 
Formoterol P37231 PPARG HUMAN -2.416 TRUE -1.499 FALSE -1.213 FALSE -1.088 FALSE TRUE 
Formoterol Q16236 NF2L2 HUMAN 0.696 FALSE 1.647 FALSE 1.145 FALSE 0.667 FALSE FALSE 
Budesonide O43524 FOXO3 HUMAN 0.020 FALSE 0.496 FALSE 2.421 FALSE 0.028 FALSE FALSE 
Budesonide P01106 MYC HUMAN -0.278 FALSE -1.002 FALSE 0.476 FALSE -0.879 FALSE FALSE 
Budesonide P10276 RARA HUMAN -1.793 FALSE -2.038 TRUE -2.138 TRUE -1.659 FALSE TRUE 
Budesonide P10826 RARB HUMAN 0.032 FALSE 0.967 FALSE -0.024 FALSE 0.404 FALSE FALSE 
Budesonide P11474 ERR1 HUMAN -1.194 FALSE -0.426 FALSE 0.773 FALSE -1.481 FALSE FALSE 
Budesonide P11511 CP19A HUMAN -1.316 FALSE -1.105 FALSE -1.532 FALSE -1.306 FALSE FALSE 
Budesonide P13631 RARG HUMAN 0.449 FALSE -0.422 FALSE 2.086 FALSE 0.001 FALSE FALSE 
Budesonide P15976 GATA1 HUMAN 0.355 FALSE 0.320 FALSE 0.281 FALSE -1.420 FALSE FALSE 
Budesonide P19793 RXRA HUMAN -0.077 FALSE -0.339 FALSE -0.364 FALSE 0.020 FALSE FALSE 
Budesonide P26367 PAX6 HUMAN -0.594 FALSE -0.695 FALSE -0.604 FALSE -0.353 FALSE FALSE 
Budesonide P28702 RXRB HUMAN 0.219 FALSE -0.013 FALSE -0.650 FALSE 0.013 FALSE FALSE 
Budesonide P35398 RORA HUMAN -0.438 FALSE -1.105 FALSE -0.318 FALSE -1.206 FALSE FALSE 
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Table 8.14: Continuation of Table 8.13 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
hit 
Meta 
score 
Budesonide P37231 PPARG HUMAN 0.305 FALSE 0.154 FALSE 0.775 FALSE 0.700 FALSE FALSE 
Budesonide P40763 STAT3 HUMAN 0.896 FALSE 0.059 FALSE 2.356 FALSE -1.885 FALSE FALSE 
Budesonide P41235 HNF4A HUMAN 0.837 FALSE -0.494 FALSE 2.899 FALSE 0.881 FALSE FALSE 
Budesonide Q01094 E2F1 HUMAN 1.237 FALSE 1.510 FALSE 0.664 FALSE -0.811 FALSE FALSE 
Budesonide Q14994 NR1I3 HUMAN -0.646 FALSE -0.761 FALSE -0.659 FALSE -0.811 FALSE FALSE 
Budesonide Q15797 SMAD1 HUMAN -0.065 FALSE -1.134 FALSE 1.405 FALSE -1.115 FALSE FALSE 
Budesonide Q7Z6R9 AP2D HUMAN 0.303 FALSE 0.083 FALSE -0.180 FALSE -0.900 FALSE FALSE 
Budesonide Q92481 AP2B HUMAN -0.336 FALSE -1.083 FALSE -1.145 FALSE -1.067 FALSE FALSE 
Budesonide Q92753 RORB HUMAN -0.212 FALSE -3.885 TRUE -1.163 FALSE -3.588 TRUE TRUE 
Budesonide Q9UBC0 HNF6 HUMAN -1.388 FALSE -1.204 FALSE -1.861 FALSE -0.679 FALSE FALSE 
Budesonide P04637 P53 HUMAN -1.138 FALSE -0.714 FALSE -1.312 FALSE 0.047 FALSE FALSE 
Imatinib P37231 PPARG HUMAN -0.340 FALSE -1.108 FALSE -0.399 FALSE -0.967 FALSE FALSE 
Imatinib Q16236 NF2L2 HUMAN 1.812 FALSE 0.975 FALSE 3.197 FALSE 1.559 FALSE FALSE 
Imatinib P04637 P53 HUMAN -0.018 FALSE -0.245 FALSE -0.538 FALSE 0.147 FALSE FALSE 
Pregabalin P11511 CP19A HUMAN -1.845 FALSE -1.483 FALSE -1.920 FALSE -1.370 FALSE FALSE 
Pregabalin P37231 PPARG HUMAN 0.148 FALSE -0.315 FALSE -0.437 FALSE -0.037 FALSE FALSE 
Pregabalin O43524 FOXO3 HUMAN -0.105 FALSE 0.090 FALSE -0.843 FALSE -0.041 FALSE FALSE 
Levothyroxine P01106 MYC HUMAN -1.110 FALSE -1.488 FALSE -1.369 FALSE -2.042 TRUE TRUE 
Levothyroxine P01137 TGFB1 HUMAN -0.698 FALSE 0.258 FALSE 0.475 FALSE -2.465 TRUE TRUE 
Levothyroxine P10276 RARA HUMAN -0.841 FALSE -0.233 FALSE -0.947 FALSE -1.795 FALSE FALSE 
Levothyroxine P10826 RARB HUMAN 0.244 FALSE 0.090 FALSE 0.861 FALSE 0.359 FALSE FALSE 
Levothyroxine P10914 IRF1 HUMAN -3.013 TRUE -1.117 FALSE -1.369 FALSE -0.739 FALSE TRUE 
Levothyroxine P11474 ERR1 HUMAN -0.853 FALSE 0.036 FALSE 0.919 FALSE 0.214 FALSE FALSE 
Levothyroxine P11511 CP19A HUMAN -2.137 TRUE -0.831 FALSE -2.115 FALSE -0.448 FALSE TRUE 
Levothyroxine P13631 RARG HUMAN 0.366 FALSE 0.375 FALSE 1.067 TRUE 1.008 FALSE FALSE 
Levothyroxine P14921 ETS1 HUMAN -0.917 FALSE 0.203 FALSE -0.064 FALSE 0.261 FALSE FALSE 
Levothyroxine P15976 GATA1 HUMAN -0.154 FALSE 0.985 FALSE -0.809 FALSE -1.005 FALSE FALSE 
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Table 8.15: continuation of Table 8.13. 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
hit 
Vina 
Affinity 
SD 
Vina 
Affinity 
hit 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
hit 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
hit 
Meta 
score 
Levothyroxine P19793 RXRA HUMAN -0.449 FALSE -1.550 FALSE -0.644 FALSE -1.148 FALSE FALSE 
Levothyroxine P22415 USF1 HUMAN -1.012 FALSE -1.015 FALSE 0.113 FALSE -0.959 FALSE FALSE 
Levothyroxine P26367 PAX6 HUMAN -0.258 FALSE -0.642 FALSE 0.723 FALSE -0.466 FALSE FALSE 
Levothyroxine P40763 STAT3 HUMAN 0.617 FALSE 0.935 FALSE 0.633 FALSE 1.035 FALSE FALSE 
Levothyroxine P41235 HNF4A HUMAN -2.050 TRUE -1.423 FALSE -1.608 FALSE -1.357 FALSE TRUE 
Levothyroxine P55055 NR1H2 HUMAN -0.750 FALSE -0.749 FALSE -1.223 FALSE 2.030 FALSE FALSE 
Levothyroxine Q01094 E2F1 HUMAN 0.557 FALSE 1.099 FALSE 0.588 FALSE -0.226 FALSE FALSE 
Levothyroxine Q13133 NR1H3 HUMAN -0.883 FALSE -0.120 FALSE -0.730 FALSE -0.641 FALSE FALSE 
Levothyroxine Q15797 SMAD1 HUMAN 1.619 FALSE 1.721 FALSE 1.617 FALSE 3.324 FALSE FALSE 
Levothyroxine Q7Z6R9 AP2D AP2D HUMAN -0.127 FALSE -0.991 FALSE 0.377 FALSE 0.129 FALSE FALSE 
Levothyroxine Q92481 AP2B HUMAN -0.513 FALSE -0.559 FALSE 0.032 FALSE -0.796 FALSE FALSE 
Levothyroxine Q9UBC0 HNF6 HUMAN -1.225 FALSE -1.298 FALSE -1.285 FALSE -0.651 FALSE FALSE 
Aripiprazole Q9UJU2 LEF1 HUMAN 0.230 FALSE 0.816 FALSE 0.170 FALSE 0.587 FALSE FALSE 
Emtricitabine Q9Y261 FOXA2 HUMAN -0.059 FALSE 0.566 FALSE 0.457 FALSE -3.172 TRUE TRUE 
Emtricitabine P11511 CP19A HUMAN -1.279 FALSE -1.224 FALSE -0.678 FALSE -0.534 FALSE FALSE 
Emtricitabine P04637 P53 HUMAN -0.402 FALSE -0.612 FALSE -0.203 FALSE -0.908 FALSE FALSE 
Emtricitabine P11511 CP19A HUMAN -0.321 FALSE -0.528 FALSE 0.559 FALSE -1.251 FALSE FALSE 
Emtricitabine P37231 PPARG  -0.417 FALSE -0.590 FALSE -0.443 FALSE -0.761 FALSE FALSE 
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Table 8.16: Results of the "med" rule for the known non-interactions predictions for the new protein threaded model set with 80%+ structural coverage- shown is the original table of results 
used to create the graph shown in figure 4.20 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity 
SD 
Vina 
Affinity 
med 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
med 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta 
score 
med 
Tadalafil P04637_P53_HUMAN -0.593 FALSE -0.771 TRUE 1.097 FALSE -0.271 FALSE TRUE 
Tadalafil P11511 CP19A HUMAN -1.479 TRUE -1.103 TRUE 0.432 FALSE -1.896 TRUE TRUE 
Tadalafil P37231 PPARG HUMAN -1.616 TRUE -1.243 FALSE -0.259 FALSE -2.276 FALSE TRUE 
Tadalafil Q16236 NF2L2 HUMAN 0.307 FALSE -0.227 FALSE 1.315 FALSE -1.117 TRUE TRUE 
Abiraterone P04637 P53 HUMAN -1.398 TRUE -0.908 FALSE -0.275 FALSE -0.503 FALSE TRUE 
Abiraterone P11511 CP19A HUMAN -0.987 FALSE -0.880 FALSE -1.316 TRUE -0.975 FALSE FALSE 
Lenalidomide P04637 P53 HUMAN -0.018 FALSE 0.350 FALSE 1.593 FALSE 0.663 FALSE FALSE 
Lenalidomide P11511 CP19A HUMAN 0.242 FALSE -0.129 FALSE -0.861 FALSE -0.523 FALSE FALSE 
Lenalidomide P37231 PPARG HUMAN -0.899 FALSE -0.716 FALSE -0.462 FALSE -0.909 FALSE FALSE 
Lenalidomide Q16236 NF2L2 HUMAN 0.411 FALSE 0.237 FALSE 0.765 FALSE -0.132 FALSE FALSE 
Formoterol P04637 P53 HUMAN -0.548 FALSE -0.132 FALSE -0.230 FALSE -0.099 FALSE FALSE 
Formoterol P11511 CP19A HUMAN -1.102 TRUE -0.748 FALSE -1.139 TRUE -0.626 FALSE TRUE 
Formoterol P37231 PPARG HUMAN -2.416 FALSE -1.499 TRUE -1.213 TRUE -1.088 TRUE TRUE 
Formoterol Q16236 NF2L2 HUMAN 0.696 FALSE 1.647 FALSE 1.145 FALSE 0.667 FALSE FALSE 
Budesonide O43524 FOXO3 HUMAN 0.020 FALSE 0.496 FALSE 2.421 FALSE 0.028 FALSE FALSE 
Budesonide P01106 MYC HUMAN -0.278 FALSE -1.002 TRUE 0.476 FALSE -0.879 FALSE TRUE 
Budesonide P10276 RARA HUMAN -1.793 TRUE -2.038 FALSE -2.138 FALSE -1.659 TRUE TRUE 
Budesonide P10826 RARB HUMAN 0.032 FALSE 0.967 FALSE -0.024 FALSE 0.404 FALSE FALSE 
Budesonide P11474 ERR1 HUMAN -1.194 TRUE -0.426 FALSE 0.773 FALSE -1.481 TRUE TRUE 
Budesonide P11511 CP19A HUMAN -1.316 TRUE -1.105 TRUE -1.532 TRUE -1.306 TRUE TRUE 
Budesonide P13631 RARG HUMAN 0.449 FALSE -0.422 FALSE 2.086 FALSE 0.001 FALSE FALSE 
Budesonide P15976 GATA1 HUMAN 0.355 FALSE 0.320 FALSE 0.281 FALSE -1.420 FALSE FALSE 
Budesonide P19793 RXRA HUMAN -0.077 FALSE -0.339 FALSE -0.364 FALSE 0.020 TRUE TRUE 
Budesonide P26367 PAX6 HUMAN -0.594 FALSE -0.695 FALSE -0.604 FALSE -0.353 FALSE FALSE 
Budesonide P28702 RXRB HUMAN 0.219 FALSE -0.013 FALSE -0.650 FALSE 0.013 FALSE FALSE 
Budesonide P35398 RORA HUMAN -0.438 FALSE -1.105 TRUE -0.318 FALSE -1.206 FALSE TRUE 
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Table 8.17: continuation of Table 8.16. 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity 
SD 
Vina 
Affinity 
med 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
med 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta 
score 
med 
Budesonide P37231 PPARG HUMAN 0.305 FALSE 0.154 FALSE 0.775 FALSE 0.700 TRUE TRUE 
Budesonide P40763 STAT3 HUMAN 0.896 FALSE 0.059 FALSE 2.356 FALSE -1.885 FALSE FALSE 
Budesonide P41235 HNF4A HUMAN 0.837 FALSE -0.494 FALSE 2.899 FALSE 0.881 TRUE TRUE 
Budesonide Q01094 E2F1 HUMAN 1.237 FALSE 1.510 FALSE 0.664 FALSE -0.811 FALSE FALSE 
Budesonide Q14994 NR1I3 HUMAN -0.646 FALSE -0.761 FALSE -0.659 FALSE -0.811 FALSE FALSE 
Budesonide Q15797 SMAD1 HUMAN -0.065 FALSE -1.134 TRUE 1.405 FALSE -1.115 TRUE TRUE 
Budesonide Q7Z6R9 AP2D HUMAN 0.303 FALSE 0.083 FALSE -0.180 FALSE -0.900 FALSE FALSE 
Budesonide Q92481 AP2B HUMAN -0.336 FALSE -1.083 TRUE -1.145 TRUE -1.067 TRUE TRUE 
Budesonide Q92753 RORB HUMAN -0.212 FALSE -3.885 FALSE -1.163 TRUE -3.588 FALSE TRUE 
Budesonide Q9UBC0 HNF6 HUMAN -1.388 FALSE -1.204 TRUE -1.861 TRUE -0.679 FALSE TRUE 
Budesonide P04637 P53 HUMAN -1.138 TRUE -0.714 FALSE -1.312 TRUE 0.047 FALSE TRUE 
Imatinib P37231 PPARG HUMAN -0.340 TRUE -1.108 TRUE -0.399 FALSE -0.967 FALSE TRUE 
Imatinib Q16236 NF2L2 HUMAN 1.812 FALSE 0.975 FALSE 3.197 FALSE 1.559 FALSE FALSE 
Imatinib P04637 P53 HUMAN -0.018 FALSE -0.245 FALSE -0.538 FALSE 0.147 FALSE FALSE 
Pregabalin P11511 CP19A HUMAN -1.845 FALSE -1.483 TRUE -1.920 TRUE -1.370 TRUE TRUE 
Pregabalin P37231 PPARG HUMAN 0.148 TRUE -0.315 FALSE -0.437 FALSE -0.037 FALSE FALSE 
Pregabalin O43524 FOXO3 HUMAN -0.105 FALSE 0.090 FALSE -0.843 FALSE -0.041 FALSE FALSE 
Levothyroxine P01106 MYC HUMAN -1.110 FALSE -1.488 TRUE -1.369 TRUE -2.042 FALSE TRUE 
Levothyroxine P01137 TGFB1 HUMAN -0.698 TRUE 0.258 FALSE 0.475 FALSE -2.465 FALSE FALSE 
Levothyroxine P10276 RARA HUMAN -0.841 FALSE -0.233 FALSE -0.947 FALSE -1.795 TRUE TRUE 
Levothyroxine P10826 RARB HUMAN 0.244 FALSE 0.090 FALSE 0.861 FALSE 0.359 FALSE FALSE 
Levothyroxine P10914 IRF1 HUMAN -3.013 FALSE -1.117 TRUE -1.369 TRUE -0.739 FALSE TRUE 
Levothyroxine P11474 ERR1 HUMAN -0.853 FALSE 0.036 FALSE 0.919 FALSE 0.214 FALSE FALSE 
Levothyroxine P11511 CP19A HUMAN -2.137 FALSE -0.831 FALSE -2.115 FALSE -0.448 FALSE FALSE 
Levothyroxine P13631 RARG HUMAN 0.366 FALSE 0.375 FALSE 1.067 FALSE 1.008 FALSE FALSE 
Levothyroxine P14921 ETS1 HUMAN -0.917 FALSE 0.203 FALSE -0.064 FALSE 0.261 FALSE FALSE 
Levothyroxine P15976 GATA1 HUMAN -0.154 FALSE 0.985 FALSE -0.809 FALSE -1.005 TRUE TRUE 
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Table 8.18: Continuation of Table 8.16. 
Ligand Protein DOCK 
Affinity 
SD 
DOCK 
Affinity 
med 
Vina 
Affinity 
SD 
Vina 
Affinity 
med 
GBSA 
Affinity 
SD 
GBSA 
Affinity 
med 
DSX Atom 
distances 
SD 
DSX Atom 
distances 
med 
Meta 
score 
med 
Levothyroxine P19793 RXRA HUMAN -0.449 FALSE -1.550 TRUE -0.644 FALSE -1.148 TRUE TRUE 
Levothyroxine P22415 USF1 HUMAN -1.012 TRUE -1.015 TRUE 0.113 FALSE -0.959 FALSE TRUE 
Levothyroxine P26367 PAX6 HUMAN -0.258 FALSE -0.642 FALSE 0.723 FALSE -0.466 FALSE FALSE 
Levothyroxine P40763 STAT3 HUMAN 0.617 FALSE 0.935 FALSE 0.633 FALSE 1.035 FALSE FALSE 
Levothyroxine P41235 HNF4A HUMAN -2.050 FALSE -1.423 TRUE -1.608 TRUE -1.357 TRUE TRUE 
Levothyroxine P55055 NR1H2 HUMAN -0.750 FALSE -0.749 FALSE -1.223 TRUE 2.030 FALSE TRUE 
Levothyroxine Q01094 E2F1 HUMAN 0.557 FALSE 1.099 FALSE 0.588 FALSE -0.226 FALSE FALSE 
Levothyroxine Q13133 NR1H3 HUMAN -0.883 FALSE -0.120 FALSE -0.730 FALSE -0.641 FALSE FALSE 
Levothyroxine Q15797 SMAD1 HUMAN 1.619 FALSE 1.721 FALSE 1.617 FALSE 3.324 FALSE FALSE 
Levothyroxine Q7Z6R9 AP2D AP2D HUMAN -0.127 FALSE -0.991 FALSE 0.377 FALSE 0.129 FALSE FALSE 
Levothyroxine Q92481 AP2B HUMAN -0.513 FALSE -0.559 FALSE 0.032 FALSE -0.796 FALSE FALSE 
Levothyroxine Q9UBC0 HNF6 HUMAN -1.225 TRUE -1.298 TRUE -1.285 TRUE -0.651 FALSE TRUE 
Aripiprazole Q9UJU2 LEF1 HUMAN 0.230 FALSE 0.816 FALSE 0.170 FALSE 0.587 FALSE FALSE 
Emtricitabine Q9Y261 FOXA2 HUMAN -0.059 FALSE 0.566 FALSE 0.457 FALSE -3.172 FALSE FALSE 
Emtricitabine P11511 CP19A HUMAN -1.279 FALSE -1.224 TRUE -0.678 FALSE -0.534 FALSE TRUE 
Emtricitabine P04637 P53 HUMAN -0.402 FALSE -0.612 FALSE -0.203 FALSE -0.908 FALSE FALSE 
Emtricitabine P11511 CP19A HUMAN -0.321 FALSE -0.528 FALSE 0.559 FALSE -1.251 TRUE TRUE 
Emtricitabine P37231 PPARG  -0.417 FALSE -0.590 FALSE -0.443 FALSE -0.761 FALSE FALSE 
 
